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General inTroducTion
General introduction 13
1Thyroid FuncTion
The thyroid gland synthetizes and secretes thyroid hormones T4 (3, 5, 3’, 5’-tet-
raiodothyronine, also known as thyroxine) and T3 (3, 5, 3’-triiodothyronine).1 Thy-
roid hormones are produced in response to the thyroid–stimulating hormone (TSH). 
TSH is secreted from the anterior pituitary gland in response to the thyrotropin-
releasing hormone (TRH), which is secreted from the hypothalamus (Figure 1). The 
production of TSH and TRH is downregulated by thyroid hormones (Figure 1).2 T3, 
which is mainly derived from the local metabolism of circulating T4, inhibits the 
synthesis and secretion of TRH and TSH, via binding to the thyroid hormone recep-
tors in the hypothalamus and pituitary.2 This negative feedback mechanism ensures 
the stability of circulating thyroid hormone levels, which is crucial for the biological 
functioning of all organs.
Thyroid
Pituitary
Hypothalamus
TRH (+)
TSH (+)
T4, T3 (‐)
T4, T3 (‐)
Figure 1. The hypothalamic-pituitary-thyroid axis.
Abbreviations: T4, thyroxine; T3, triiodothyronine, TSH, thyroid–
stimulating hormone, TRH, thyrotropin-releasing hormone.
Thyroid function is clinically defined by the measurements of TSH and free thyroxine 
(FT4) levels. Clinical hypothyroidism is characterized by TSH above the reference 
range and FT4 levels below the reference range, whereas clinical hyperthyroidism is 
characterized by TSH below the reference range and FT4 levels above the reference 
range. Subclinical hypothyroidism is defined by FT4 within the reference range com-
bined with elevated TSH levels. Subclinical hyperthyroidism is defined by FT4 within 
the reference range combined with reduced TSH levels. In the adult population, the 
prevalence of clinical and subclinical hypothyroidism ranges from 0.2 to 5.3% and 
from 4 to 15%, respectively.3-9 The prevalence of overt and subclinical hyperthyroid-
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ism ranges from 0.8 to 1.3% and from 0.6 to 12.4%, respectively.5,10-17 This variability 
may be explained by the different characteristics of the studied populations (eg, 
different iodine status) and the different assays of thyroid function used.
TSH levels needed to achieve the same thyroid hormone levels vary significantly 
among individuals,18 indicating that each individual has a unique pituitary-thyroid 
set point. Several genetic loci have been linked to the pituitary-thyroid set point, sug-
gesting that the set point is to some extent, genetically determined.19,20 In addition, 
the relationship between TSH and FT4 concentrations can be modulated throughout 
ageing.21 Several studies have suggested that increasing age can reduce the sensitiv-
ity of the pituitary gland to thyroid hormones.22-24 As a result, TSH levels needed to 
maintain the same FT4 levels are different in younger and older adults.24
The reference ranges of TSH and FT4 levels provide the basis for the diagnosis 
and treatment of thyroid disease. At present, the reference ranges of thyroid func-
tion are determined by a statistical approach, which is based on the 2.5th and 97.5th 
percentiles of the TSH and FT4 distributions in an apparently healthy population. 
That is, TSH (or FT4) levels above the 2.5th and below the 97.5th percentiles are con-
sidered as normal, whereas TSH (or FT4) levels below the 2.5th and above the 97.5th 
percentiles are considered as abnormal. However, many studies have reported that 
the clinical consequences of abnormal thyroid function are extended even within 
the current reference ranges of TSH and FT4,25-28 thus indicating that the statisti-
cally defined reference ranges do not properly reflect the risk of developing clinical 
outcomes. Therefore, over the past years, there has been an ongoing debate on 
whether the reference ranges of TSH and FT4 should be reevaluated. While some 
researchers support a reevaluation of TSH and FT4 reference ranges, suggested 
measures are inconsistent varying from a lowering of the upper TSH reference limit 
(eg, from approximately 4 to 2.5 mIU/L) to an increase of the upper TSH reference 
limit or a downward shift of the FT4 reference limit.25,29-31 Others do not support a 
reevaluation, suggesting that more robust evidence needs to illustrate the risk of 
clinical outcomes within the reference ranges of TSH and FT4.32-35
The role oF Thyroid FuncTion on cardiomeTabolic healTh
Thyroid hormones play a critical role in maintaining cardiometabolic homeostasis, 
via regulating cardiac and vascular physiology, as well as lipid, glucose and pro-
tein metabolism.36 Besides, thyroid hormones influence energy expenditure by 
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1accelerating basal metabolic rate, mitochondrial oxygen consumption and ther-
mogenesis.37 In the heart, thyroid hormones exert genomic effects via binding to 
the thyroid hormone receptors that are located in the nucleus of cardiomyocytes, 
further promoting the expression of target genes.38 Thyroid hormones also exert 
non-genomic effects on various ion channels in the membranes of cardiomyocytes.38 
These genomic and non-genomic effects are translated into inotropic, chronotropic 
and bathmotropic cardiac effects of thyroid hormones.38 Previous studies have ex-
tensively explored the association of thyroid function with various cardiometabolic 
conditions, including atrial fibrillation (AF), coronary heart disease (CHD), stroke, 
heart failure, hypertension, diabetes mellitus, dyslipidemia, and obesity.25,28,32,39-48 
Interestingly, even minimal fluctuations in TSH and FT4 concentrations have been 
associated with remarkable alterations in cardiometabolic health.27,49-53
Atrial fibrillation: High and high-normal thyroid function constitute an increased 
risk of AF. An individual participant data (IPD) meta-analysis from the Thyroid Stud-
ies Collaboration showed that subclinical hyperthyroidism is associated with a 1.68 
times higher risk of AF compared with euthyroidism.39 Prospective studies focusing 
on the normal range of thyroid function have also consistently reported an associa-
tion between high-normal thyroid function and increased AF risk.28,40
Coronary heart disease: Three large IPD meta-analyses from the Thyroid Studies 
Collaboration have focused on the risk of CHD and CHD mortality in subclinical 
hypothyroidism, subclinical hyperthyroidism and euthyroidism, respectively.32,39,41 
The first reported that subclinical hypothyroidism with TSH levels above 10 mIU/L is 
associated with a 1.89 and 1.58 times higher risk of CHD events and CHD mortality 
than euthyroidism, respectively.41 The second reported that subclinical hyperthy-
roidism is associated with a 1.21 and 1.29 times higher risk of CHD events and CHD 
mortality than euthyroidism, respectively.39 The third IPD meta-analysis, performed 
among euthyroid subjects, showed no association between thyroid function within 
the reference range and CHD risk.32
Stroke: The association of thyroid function with stroke has been investigated in two 
IPD meta-analyses from the Thyroid Studies Collaboration.43 One of them found no 
overall effect of subclinical hypothyroidism on the risk of stroke events or fatal stroke.43 
However, age-stratified analyses (younger versus older than 65 years) revealed that in 
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younger participants, subclinical hypothyroidism was associated with a higher risk of 
stroke than euthyroidism. The other IPD meta-analysis, which included only euthyroid 
participants, showed that low-normal TSH levels and high-normal FT4 levels are associ-
ated with an increased risk of stroke.42
Hypertension: Overt and subclinical hyperthyroidism often lead to systolic hyper-
tension via increasing cardiac output.45,54 Overt and subclinical hypothyroidism, on 
the other hand, promote diastolic hypertension via increasing systemic vascular 
resistance.55,56 Even in euthyroid subjects, higher TSH levels have been associated 
with both systolic and diastolic hypertension.51,52
Heart failure: In an IPD meta-analysis from the Thyroid Studies Collaboration, 
both higher and lower TSH levels showed a significant trend for an increased risk 
of heart failure.44 Participants with TSH levels ≥10 and <0.1 mIU/L had a 1.86 and 
1.94 times higher risk of heart failure than euthyroid participants, respectively. 
Several mechanisms can explain the role of thyroid function on heart failure. Sub-
clinical thyroid dysfunction can increase the risk of CHD, which is a common cause 
of heart failure. Moreover, alterations in thyroid function affect heart rate, cardiac 
contractility, cardiac output and vascular resistance, that can all contribute to the 
development of heart failure.57 On the other hand, a potential influence of heart 
failure on the metabolism of thyroid hormones is also likely. Heart failure-related 
hypoxia increases the gene expression of type 3 deiodinase, which promotes the 
degradation of thyroid hormone, eventually reducing the local availability of T3 in 
cardiomyocytes.58,59 Low levels of T3 further contribute to a progressive deteriora-
tion of cardiac function in heart failure and have been proposed as an independent 
predictor of New York Heart Association functional class.60
Diabetes mellitus: Hypothyroidism is associated with an increased risk of diabetes, 
most likely due to a decreased insulin sensitivity and glucose tolerance.46,61 Accord-
ingly, restauration of euthyroidism after treatment of hypothyroidism has been 
shown to improve insulin sensitivity.62,63 These negative consequences of hypothy-
roidism on glucose metabolism can also be extended within the reference range of 
thyroid function. In a large prospective population-based cohort study, even low-
normal thyroid function was associated with an increased risk of type 2 diabetes and 
progression from prediabetes to diabetes.27
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1Dyslipidemia:  Overt hypothyroidism commonly leads to hypercholesterolemia 
and hypertriglyceridemia,36 via decreasing the expression of hepatic LDL receptors, 
reducing cholesterol clearance and modulating fatty acid metabolism.47 The role of 
subclinical hypothyroidism on dyslipidemia is less clear. Some studies have suggested 
that thyroid hormone replacement may improve the lipid parameters.64-66 This, how-
ever, was not confirmed in a meta-analysis of randomized clinical trials, that showed 
no overall effects of thyroid hormone replacement in the lipid profiles of patients 
with subclinical hypothyroidism.67 Levothyroxine treatment did not result in a re-
duction of total cholesterol, HDL cholesterol, triglycerides, apolipoprotein A and B, 
and lipoprotein A, though there was a trend towards reducing LDL cholesterol >155 
mg/dl.67
Obesity: In some,48,53,68 but not all69 population-based studies, high and high-normal 
TSH levels have been associated with an increased body weight. The association 
between thyroid function and body weight is likely bidirectional. On one hand, 
low thyroid function is typically characterized by decreased energy expenditure and 
low metabolic rate, resulting in weight gain.70 On the other hand, adipose tissue 
has been recognized as an endocrine organ because it secretes leptin,70-72 which is 
known to stimulate TSH release.70
The PleioTroPic eFFecTS oF Thyroid hormoneS
Thyroid hormones have complex pleiotropic effects in nearly all tissues and or-
gans.73,74 Clinical, epidemiological and experimental evidence suggests that even 
subtle changes in circulating thyroid hormone levels can adversely affect cardio-
vascular, musculoskeletal and neurocognitive functioning.26,28,73,74 The effects of 
thyroid hormones vary in character, some being stimulatory and others inhibitory. 
This is illustrated by several prospective studies, showing that circulating thyroid 
hormones are negatively associated with the risk of diabetes or dyslipidemia27,49 and 
are positively associated with the risk of cognitive decline or atrial fibrillation.26,28 
The effects of thyroid hormones also vary in magnitude, depending on the targeted 
tissues and organs. For example, in middle-aged and older adults, increasing FT4 
levels have been prospectively associated with an increased risk of dementia, and 
even higher risk of AF.26,28
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aimS oF ThiS TheSiS
This thesis has two main aims. The first aim is to extend the current knowledge 
on the specific effects of thyroid function on cardiometabolic health. In view of 
the inconsistent results of previous studies,32,42,75-78 we investigate the association 
of thyroid function with cardiometabolic diseases, such as nonalcoholic fatty liver 
disease, fibrotic disease, and atherosclerosis. Furthermore, we focus on the asso-
ciation of thyroid function with some aspects of cardiometabolic health that have 
been studied less extensively so far, such as coagulation and epicardial adipose 
tissue. To provide some mechanistic evidence, we also investigate whether and to 
what extent coagulation factors and epicardial adipose tissue can explain certain 
cardiovascular effects of thyroid hormones. The second aim is to yield novel in-
sights about the qualitative and quantitative impact of thyroid function on general 
health. We thus adopt a broader perspective, using multidimensional measures 
Figure 2. Implications of thyroid function among middle-aged and older adults: Focused ver-
sus broader perspective.
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1that can reflect the pleiotropic effects of thyroid hormones, such as frailty index, 
global gait, and measurements of life expectancy with and without diseases. The 
conceptual framework of this thesis is presented in Figure 2.
raTionale oF ThiS TheSiS
beyond thyroid status categories
The classification of thyroid status in categories of euthyroidism, clinical and sub-
clinical hypothyroidism, clinical and subclinical hyperthyroidism, is useful in clinical 
decision making. However, thyroid status categories are based on arbitrary cutoffs of 
TSH and FT4 levels. As a result, cohort studies exclusively investigating thyroid status 
categories or arbitrary cutoffs of thyroid function may not properly account for po-
tential nonlinear effects of thyroid function. Hypothetically, variations throughout 
the full spectrum of TSH and FT4 levels may be associated with the risk of adverse 
outcomes. Therefore, our investigations were mainly focused on the risk of adverse 
outcomes throughout the continuous range of TSH and FT4 levels, beyond the above 
described thyroid status categories.
Thyroid function, a potential risk factor for cardiometabolic conditions
The burden of diseases that affect cardiometabolic health can be reduced by iden-
tifying and modifying their determinants. High thyroid function, for example, is a 
well-established risk factor for AF, and thyroid function measurements are routinely 
performed in patients diagnosed with newly-onset AF.79 Yet, the association of thyroid 
function with some other aspects of cardiometabolic health is less established. Previous 
studies focusing on the role of thyroid function on fatty liver, fibrosis or atherosclerosis 
have yielded inconsistent results.32,42,75-78 Moreover, current data on the role of thyroid 
function on coagulation or epicardial adipose tissue are scarce. Therefore, we aimed to 
extend the current knowledge about the role of thyroid function on several aspects of 
cardiometabolic health, including fatty liver, fibrosis, atherosclerosis, coagulation, and 
epicardial adipose tissue.
Potential mediators linking thyroid function to cardiovascular disease
The influence of thyroid function on cardiovascular events, such as AF, CHD, and 
stroke, seems to be independent of hypertension, dyslipidemia, obesity, and dia-
betes.25 This suggests that alternative factors beyond traditional cardiovascular risk 
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factors can mediate the effects of thyroid function on the cardiovascular system. 
The elucidation of these mediators is important, not only for a better pathophysi-
ological understanding of cardiovascular diseases, but also for establishing novel 
preventive and treatment strategies. Therefore, we hypothesized that coagulation 
factors and epicardial adipose tissue can partially explain the effects of thyroid func-
tion on cardiovascular disease and AF, respectively.
The need for a broader health perspective
Thyroid hormones have stimulatory or inhibitory, major or minor effects, depend-
ing on the targeted tissues and organs. The resultant of all the specific effects of 
thyroid hormones is likely reflected in general health. However, the role of thyroid 
hormones on general health remains unclear. This information could help improve 
the prevention and possible prediction of health deterioration, and would also be 
relevant in view of the ongoing debate on the optimal reference ranges of thyroid 
function. Therefore, we sought to provide novel insights regarding the qualitative 
and quantitative impact of thyroid function on general health. Given that a “golden 
standard” measure of general health is lacking, we used several multidimensional 
measures that can reflect the pleiotropic effects of thyroid hormones, such as frailty 
index (measure of general health and frailty), global gait (measure of general health 
and functional mobility), and measurements of life expectancy with and without 
diseases.
SeTTinG
The study presented in Chapter 2.2 is a systematic review of the literature. Two 
reviewers independently screened the titles and abstracts, further selecting the 
eligible studies. The Newcastle-Ottawa Scale for non-randomized studies was used 
to assess the quality of the included studies based on 3 predefined domains, namely 
selection of participants, comparability of study groups, and ascertainment of the 
outcomes of interest.
The other studies presented in Chapters 2 and 3 of this thesis were performed 
within the framework of the Rotterdam Study. The Rotterdam Study is an ongo-
ing prospective population-based cohort study that investigates the determinants, 
occurrence, and progression of chronic diseases among middle-aged and older 
adults.80 In 1989, the Rotterdam Study enrolled participants into its first cohort (RS 
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1cohort I), which was further extended in 2000 (RS cohort II) and 2006 (RS cohort III). 
Study participants are followed-up for the occurrence of chronic diseases. Extensive 
medical examinations are performed every 3 to 5 years. Thyroid function tests were 
measured in the three Rotterdam Study cohorts using the same method and assay.
ouTline oF ThiS TheSiS
Chapter 1 provides a general background on the pleiotropic effects of thyroid hor-
mones, with a particular focus on cardiometabolic health. The objectives, rationale 
and outline of the thesis are further described.
Chapter 2 aims to extend the knowledge on the association of thyroid function 
with specific aspects of cardiometabolic health, including fatty liver, fibrosis, and 
atherosclerosis. Most studies examining the role of thyroid function on fatty liver 
are characterized by inconsistent results, that can be explained by cross-sectional 
designs and small sample sizes.75,76 Therefore, Chapter 2.1 prospectively investigates 
the association of thyroid function with the risk of nonalcoholic fatty liver disease, 
in a large population-based cohort.
Furthermore, it has been suggested that variations in thyroid function may affect 
the occurrence and progression of fibrosis, but the data are fragmented and in-
conclusive.77,78,81,82 In this context, Chapter 2.2 systematically appraises the evidence 
regarding the role of thyroid function on fibrosis of the liver, lung, and heart.
Thyroid hormones have been linked to both proatherogenic83,84 and antiath-
erogenic36 processes, but the role of thyroid function on the different stages of 
atherosclerosis progression has not been investigated. The cohort study presented 
in Chapter 2.3 examines the association of thyroid function with different stages 
of atherosclerosis, from subclinical atherosclerosis to atherosclerotic cardiovascular 
events to atherosclerotic cardiovascular mortality.
The effects of thyroid hormones on the cardiovascular system seem to be 
independent of traditional cardiovascular risk factors, such as hypertension or 
dyslipidemia.25 In Chapters 2.4 and 2.5, we aim to identify potential mediators link-
ing thyroid function to cardiovascular events. In Chapter 2.4, we hypothesize that 
blood coagulation can be one of the underlying mechanisms through which thyroid 
hormones affect cardiovascular health. Using a four-way decomposition approach, 
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Chapter 2.5 explores whether epicardial adipose tissue mediates the association of 
thyroid function with atrial fibrillation.
Thyroid hormones exert specific effects on nearly all tissues and organs, the resultant 
of which can be reflected in general health. In Chapter 3, we aim to provide novel 
insights on the qualitative and quantitative impact of thyroid function on general 
health. We therefore evaluate conditions that can reflect the pleiotropic effects 
of thyroid hormones, including general health, vulnerability to adverse outcomes, 
functional mobility, and life expectancy. In Chapter 3.1, we cross-sectionally and 
longitudinally investigate the association of thyroid function with frailty index, a 
well-established measure of frailty and general health. Chapter 3.2 seeks to identify 
the spatiotemporal gait aspects that are related to thyroid function. Comprehensive 
measurements of gait patterns, including global gait, rhythm, variability, phases, 
pace, base of support, tandem, turning, and velocity, are used. In view of the cur-
rent debate on the reference ranges of TSH and FT4 levels, Chapters 3.3 and 3.4 
investigate whether there are meaningful differences in total life expectancy and 
disease-specific life expectancy within the reference range of thyroid function. 
Given the important role of thyroid hormones on cardiovascular health, Chapter 
3.3 focuses on the association between thyroid function within the reference range 
and life expectancy with and without cardiovascular disease. Meanwhile, Chapter 
3.4 provides a broader perspective by investigating the association between thyroid 
function within the reference range and life expectancy with and without non-
communicable diseases.
Chapter 4 summarizes the principal findings of this thesis, elaborates on the main 
methodological considerations, and further discusses the clinical implications and 
potential directions for future research.
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abSTracT
background Although thyroid function is associated with several risk factors of 
nonalcoholic fatty liver disease (NAFLD), its role in NAFLD development remains 
unclear. We therefore aimed to prospectively investigate the association between 
variations in thyroid function and NAFLD, in a large population-based, prospective 
cohort study.
methods Participants from the Rotterdam Study with thyroid function measure-
ments at baseline and NAFLD data (ie, at baseline fatty liver index, at follow-up 
ultrasound) were eligible. Transient elastography was performed to assess the pres-
ence of fibrosis in patients with NAFLD, using the liver stiffness measurements ≥8 
kilopascals as cutoff for clinically relevant fibrosis. The association between thyroid 
parameters and incident NAFLD was explored by using logistic regression models.
results A total of 9419 participants (mean age, 64.75 years) were included. The 
median follow-up time was 10.04 years (interquartile range, 5.70 to 10.88 years). 
After adjusting for age, sex, cohort, follow-up time, use of lipid-lowering medica-
tions, and cardiovascular risk factors, higher free thyroxine levels were associated 
with a decreased risk of NAFLD (odds ratio [OR], 0.42; 95% confidence interval [95% 
CI], 0.28 to 0.63). In line, higher thyroid-stimulating hormone levels were associated 
with an increased risk of having clinically relevant fibrosis in NAFLD (OR, 1.49; 95% 
CI, 1.04 to 2.15). Compared to euthyroidism, hypothyroidism was associated with a 
1.24 times higher NAFLD risk (95% CI, 1.01 to 1.53). Moreover, NAFLD risk decreased 
gradually from hypothyroidism to hyperthyroidism (P for trend, 0.003).
conclusions Lower thyroid function is associated with an increased NAFLD risk. These 
findings may lead to new avenues regarding NAFLD prevention and treatment.
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inTroducTion
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver condi-
tion worldwide.1 It comprises a broad spectrum ranging from simple steatosis to 
nonalcoholic steatohepatitis with fibrosis, which can eventually progress to cirrhosis 
and hepatocellular carcinoma.2,3 Nonalcoholic steatohepatitis-related cirrhosis is 
anticipated to become the leading indication for liver transplantation by 2030.4 
Moreover, accumulating evidence has shown that NAFLD, either independently or 
in combination with other metabolic risk factors, is associated with extrahepatic 
complications such as cardiovascular disease, type 2 diabetes, chronic kidney dis-
ease, malignancy, and all-cause mortality.5 Despite improved understanding and 
treatment of its risk factors (eg, diabetes mellitus and dyslipidemia), prevalence of 
NAFLD has rapidly increased.6 Hence, investigation of additional modifiable risk 
factors is urgently needed.
Thyroid hormone is the major regulator of metabolic rate. Although hypothy-
roidism has been implicated in the etiology of NAFLD,7 prior studies regarding the 
association between thyroid function and NAFLD risk have yielded controversial 
results, varying from a strong 8,9 to no association.10,11 Studies confined to euthyroid 
subjects have been inconsistent as well, reporting that free thyroxine (FT4) alone,12 
thyroid-stimulating hormone (TSH) alone,13 both,8 or neither of them14 are linked 
with NAFLD. These discrepancies are mainly due to small sample sizes and cross-
sectional design of previous studies.
The only prospective study to date focused exclusively on the risk of NAFLD in 
subclinical hypothyroidism.15 As a consequence, the risk of NAFLD has not been 
explored prospectively in the remaining categories of thyroid function, other than 
subclinical hypothyroidism. A recent review has also highlighted the need for pro-
spective research on the association between normal thyroid function and NAFLD 
risk.16 Moreover, it remains unclear whether and to what extent thyroid function 
affects fibrosis risk in NAFLD patients. Therefore, we prospectively investigated the 
association between variations in thyroid function and NAFLD spectrum, in a large 
population-based cohort study.
36 Chapter 2.1
meThodS
Study population
The Rotterdam Study (RS) is a large, prospective, population-based cohort study, 
conducted among middle-aged and elderly inhabitants of the Ommoord district in 
Rotterdam, the Netherlands. The complete rationale and study design have been 
described in detail previously.17 In brief, all residents of Ommoord aged 55 years or 
older were invited to participate. Firstly, 7983 participants were enrolled between 
1990 and 1993 (RS I). In 2000, the study was extended with a second cohort of 3011 
subjects (RS II). In 2006, a third cohort of 3932 subjects aged 45 years and over was 
added (RS III), and thereafter the study population comprised a total of 14926 sub-
jects.
Participants from study cohorts RS I visit 3 (RS I.3), RS II visit 1 (RS II.1) and RS III 
visit 1 (RS III.1) were eligible for the study if they had thyroid function measure-
ments and data available on ultrasound-diagnosed NAFLD at follow-up or fatty liver 
index (FLI) at baseline. We considered the date of baseline laboratory testing, which 
comprised the assessment of thyroid function and FLI components, the start date 
of follow-up. The end date of follow-up was considered the date of the ultrasound 
measurement (Supplemental Figure 1).
The Medical Ethics Committee of the Erasmus University and the Ministry 
of Health, Welfare and Sport of the Netherlands approved the study protocols, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rot-
terdam Study)”. All included participants provided a written informed consent in 
accordance with the Declaration of Helsinki to participate in the study and to obtain 
information from their family physicians.
assessment of thyroid function
We performed thyroid function tests in the 3 independent Rotterdam Study cohorts 
using the same method and assay. Thyroid function assessment was performed for 
TSH, FT4, and thyroid peroxidase antibodies (TPOAbs) in baseline serum samples 
stored at -80°C (The electrochemiluminescence immunoassay ECLIA, Roche). We de-
termined the reference range of TSH (0.4 to 4.0 mIU/L) and FT4 (0.85 to 1.95 ng/dL [to 
convert to picomoles per liter, multiply by 12.871]), according to national guidelines 
and previous reports from the Rotterdam Study.18 Thyroid function was defined as 
euthyroid if serum TSH was within the reference range. Subclinical hypothyroidism 
was defined as serum TSH >4.0 mIU/L and FT4 levels within the reference range. 
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Overt hypothyroidism was defined as serum TSH >4.0 mIU/L and FT4 levels <0.85 
ng/dL. Subclinical hyperthyroidism was defined as serum TSH <0.4 mIU/L and FT4 
levels within the reference range. Overt hyperthyroidism was defined as serum TSH 
<0.4 mIU/L and FT4 levels >1.95 ng/dL. Levels of TPOAb >35 kU/ml were regarded as 
positive, as recommended by the assay manufacturer.
assessment of naFld
Assessment of NAFLD comprised abdominal ultrasonographies at follow-up and FLI 
measurements at baseline. To assess incident NAFLD during follow-up, abdominal 
ultrasonography was performed by a single trained technician and subsequently 
images were reevaluated by an experienced hepatologist.17 NAFLD was defined by 
the presence of liver steatosis on abdominal ultrasound, in the absence of secondary 
causes as excessive alcohol consumption (>14 alcoholic beverages weekly), hepatitis 
B surface antigen, and/or hepatitis C virus positivity, and use of fatty liver inducing 
pharmacological agents (ie, amiodarone, tamoxifen, corticosteroids, and metho-
trexate).
At baseline, ultrasound measurements were not available and instead, we 
utilized FLI measurements. FLI, an algorithm based on levels of triglycerides, 
gamma-glutamyl transferase, body mass index (BMI) and waist circumference, was 
calculated by the formula previously described by Bedogni et al.19 The accuracy of 
FLI in the detection of NAFLD has been demonstrated in various studies, including 
the Rotterdam Study.20-22 FLI ≥60 has a probability of 82.3% to identify the presence 
of NAFLD.22 Therefore, we used a cutoff of 60 to classify participants into low and 
high probability of NAFLD, after primarily excluding subjects with a secondary cause 
of hepatic steatosis.
Liver stiffness (LS) was examined using transient elastography (Fibroscan; Echo-
sens). LS measurements were performed by a single operator, on the right lobe 
of the liver, through the intercostal spaces, with the participant lying flat on his 
back with the right arm laying in maximal abduction. Either M- or XL-probe was 
applied, based on the manufacturer’s instructions. Reliability of LS measurements 
was defined according to the criteria by Boursier et al.23 LS measurements were con-
sidered poorly reliable if interquartile range /median LS >0.30 with median LS ≥7.1 
kilopascals (kPa). A total of 48 participants with NAFLD diagnosis had unreliable 
LS measurements and were therefore excluded from the analyses involving LS. LS 
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≥8.0 kPa was used as a cutoff suggesting clinically relevant fibrosis. A high positive 
predictive value of this cutoff has been previously reported.24,25
additional measurements
Information was obtained from each participant through a home questionnaire 
concerning demographics, medical history, alcohol intake, tobacco smoking, and 
medication use. Blood lipids, glucose, gamma-glutamyl transferase, were mea-
sured using automatic enzymatic procedures (Roche Diagnostics GmbH). BMI was 
calculated as weight in kilograms divided by height in meters squared. Waist cir-
cumference was measured in centimeters, at the level midway between the lower 
rib margin and the iliac crest with participants in standing position without heavy 
outer garments and with emptied pockets, breathing out gently.  Blood pressure 
was calculated as the average of two consecutive measurements, realized in the 
sitting position at the right upper arm with a random-zero-sphygmomanometer. 
Hypertension was defined as a systolic blood pressure ≥140 mmHg or a diastolic 
blood pressure ≥90 mmHg or the use of blood pressure-lowering drugs prescribed 
for hypertension. Diabetes mellitus was defined as fasting plasma glucose level ≥7 
mmol/L, non-fasting plasma glucose level ≥11.1 mmol/L (when fasting samples were 
absent) or the use of antidiabetic medications.
Statistical analysis
We prospectively assessed the association between thyroid parameters (TSH, FT4, 
and TPOAb) and incident NAFLD, by using logistic regression models. Subsequently, 
we restricted the analyses to those with baseline FLI values <60, to minimize the 
possibility of misclassification of cases with incident NAFLD.
We explored differences in the risk of NAFLD throughout tertiles of FT4, taking 
the highest tertile as reference. After our primary analyses, we performed sensitiv-
ity analyses, restricting to subjects with TSH and FT4 within the reference ranges, 
excluding thyroid medication users and participants with previous thyroid surgery.
Next, we evaluated the risk of NAFLD throughout thyroid status categories of 
participants, taking euthyroid subjects as reference group. After excluding thyroid 
medication users and participants with previous thyroid surgery, we investigated 
the association between thyroid function/status and the risk of having a combina-
tion of NAFLD and LS ≥8.0 kPa.
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After excluding thyroid medication users and participants with previous thyroid 
surgery, we cross-sectionally assessed the association between thyroid function and 
NAFLD, performing logistic regression analysis. Here, NAFLD was defined on basis of 
categorized FLI, in the absence of secondary causes of hepatic steatosis.
In longitudinal analyses, we first adjusted for age, sex, cohort, alcohol intake, 
smoking, and follow-up time (Model 1). Further adjustments were made for the use 
of lipid-lowering medications, total cholesterol, triglycerides, BMI, hypertension, 
and diabetes mellitus (Model 2). Lipids, BMI, hypertension, and diabetes mellitus 
could act as confounders as well as possible mediators depending on the presumed 
pathway through which thyroid function is related to NAFLD and therefore in-
cluded in the multivariable model (Model 2). In mediation analyses, we calculated 
the percentage of excess risk mediated ((odds ratio [OR]con adj − ORcon + med adj)/(ORcon 
adj − 1)) × 100%, where ORcon adj is the confounder-adjusted OR and ORcon + med adj is the 
confounder and mediator–adjusted OR.
In cross-sectional analyses, we adjusted for the aforementioned covariates, 
excluding lipids and BMI, as these variables are used to calculate FLI. High-density 
lipoprotein cholesterol and waist circumference were not included as covariates 
in the multivariable model to avoid multicollinearity. TSH was naturally log trans-
formed in the continuous analyses in order to approximate a normal distribution. 
We checked for risk modification by adding an interaction term of the exposure 
(TSH or FT4) with covariates of the multivariable model, but none of the interac-
tion terms were significant. There was no departure from linearity for the TSH and 
FT4 analyses, assessed by adding quadratic terms of covariates in the multivariable 
model. Multiple imputations were performed in case of missing covariates (<2% for 
all covariates). Statistical analyses were conducted using IBM SPSS version 21 (IBM 
Corp) and R statistical software (R-project, Institute for Statistics and Mathematics, R 
Core Team [2013], version 3.0.2). Reporting is done according to the Strengthening 
of the Reporting of Observational Studies in Epidemiology Statement.
reSulTS
We included a total of 9419 eligible participants with thyroid function measure-
ments at baseline and data available on ultrasound-diagnosed NAFLD at follow-up 
or FLI at baseline.
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Table 1 and Supplemental Table 1 summarize the baseline characteristics of in-
cluded participants. The mean age was 64.7 years and 56.5% were females. Amongst 
5324 participants in whom follow-up data were available, we documented 1763 
cases of incident hepatic steatosis, of which 1217 cases of incident NAFLD (median 
follow-up time, 10.0 years; interquartile range, 5.7 to 10.9 years). A total of 546 
subjects with hepatic steatosis had secondary causes, comprising 460 subjects with 
excessive alcohol consumption, 54 subjects with known steatosis-inducing drugs, 15 
subjects with viral hepatitis, and 17 with combinations of the above. After excluding 
thyroid medication users and participants with previous thyroid surgery, reliable 
LS measurements were available in 805 participants with ultrasound-diagnosed 
NAFLD, of which 69 (8.6%) had LS ≥8.0 kPa.
Table 1. Baseline characteristics of 9419 participants*
Age, years 64.7 (9.7)
Women, n (%) 5321 (56.5)
Smoking, n (%)
Current 1989 (21.1)
Past 4490 (47.7)
Never 2940 (31.2)
Use of lipid-lowering medications, n (%) 1508 (16.0)
Use of thyroid medication, n (%) 296 (3.1)
Total cholesterol, mmol/l 5.7 (1.0)
High-density lipoprotein cholesterol, mmol/l 1.4 (0.4)
Triglycerides, mmol/l 1.5 (0.8)
Body mass index, kg/m2 27.2 (4.2)
Waist circumference, cm 93.7 (12.1)
Hypertension, n (%) 5881 (62.4)
Diabetes mellitus, n (%) 1073 (11.4)
TSH, mIU/L, median (IQR) 1.9 (1.3-2.8)
FT4, ng/dL 1.2 (0.1)
TPOAb positive, n (%) 1240 (13.2)
*Data are mean (standard deviation), unless otherwise specified. Abbreviations: TSH, thyroid-stimulating hormone; 
IQR, interquartile range; FT4, free thyroxine; TPOAb, thyroid peroxidase antibodies.
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Thyroid function and the risk of naFld
The risk of NAFLD decreased gradually with higher FT4 levels (OR, 0.33; 95% confi-
dence interval [95% CI], 0.22 to 0.48 per 1ng/dL) (Table 2). These results remained 
similar after further adjustments for cardiovascular risk factors (OR, 0.42; 95% CI, 0.28 
to 0.63), and also after restricting the analyses to participants with baseline FLI <60 
(OR, 0.42; 95% CI, 0.24 to 0.74). In the multivariable-adjusted model, participants in 
the lowest FT4 tertile had a 1.31 times higher risk of NAFLD, compared with those in 
the highest tertile (95% CI, 1.11 to 1.56; Supplemental Table 2). There was a positive 
linear association between TSH levels and NAFLD risk (OR, 1.09; 95% CI, 1.01 to 1.19 
per 1 logTSH), which was attenuated after additional adjustment for cardiovascular 
risk factors (OR, 1.07; 95% CI, 0.98 to 1.17; Table 2). After separate and simultaneous 
additions of cardiovascular risk factors to Model 1, BMI and triglycerides were held 
accountable for the attenuation (Supplemental Table 3). The percentage of excess 
risk mediated by BMI and triglycerides was 22.2% in the association of TSH with 
Table 2. Longitudinal association between thyroid function and NAFLD risk
events/Tn
or (95% ci)  
model 1
or (95% ci)  
model 2
All participants
TSH 1216/5321 1.09 (1.01; 1.19) 1.07 (0.98; 1.17)
FT4 1217/5320 0.33 (0.22; 0.48) 0.42 (0.28; 0.63)
Baseline FLI < 60
TSH 553/3379 1.13 (1.00; 1.27) 1.08 (0.95; 1.23)
FT4 553/3376 0.42 (0.24; 0.74) 0.52 (0.29; 0.92)
Model 1: age, sex, cohort, alcohol intake, smoking, and follow-up time. Model 2: Model 1, use of lipid-lowering medi-
cations, total cholesterol, triglycerides, body mass index, hypertension, and diabetes mellitus. ORs of TSH are denoted 
per 1 unit increase of natural log transformed TSH (mIU/L). ORs of FT4 are denoted per 1 unit increase in FT4 (ng/dL). 
Abbreviations: NAFLD, nonalcoholic fatty liver disease; TN, total number; OR, odds ratio; CI, confidence interval; TSH, 
thyroid-stimulating hormone; FT4, free thyroxine; FLI, fatty liver index.
Table 3. Longitudinal association of thyroid status with NAFLD risk
events/Tn
or (95% ci)  
model 1
or (95% ci)  
model 2
Hypothyroidism* 155/536 1.32 (1.08; 1.62) 1.24 (1.01; 1.53)
Euthyroidism 1035/4664 1 (Reference) 1 (Reference)
Hyperthyroidism* 26/121 0.88 (0.56; 1.36) 0.88 (0.54; 1.37)
Model 1: age, sex, cohort, alcohol intake, smoking, and follow-up time. Model 2: Model 1, use of lipid-lowering medi-
cations, total cholesterol, triglycerides, body mass index, hypertension, and diabetes mellitus. * includes subclinical and 
clinical range. Abbreviations: NAFLD, nonalcoholic fatty liver disease; TN, total number; OR, odds ratio; CI, confidence 
interval.
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NAFLD and 13.4% in the association of FT4 with NAFLD; that is 22.2% and 13.4% of 
the respective associated effect size of TSH and FT4 on NAFLD is explained by BMI 
and triglycerides. No significant association was observed for TPOAb and NAFLD risk 
(OR, 1.09; 95% CI, 0.89 to 1.32; Supplemental Table 2).
There was a significant trend (P for trend, 0.003) in the decrease of NAFLD risk, 
across categories of thyroid function from clinical hypothyroidism to clinical hyper-
thyroidism (OR from 2.08 to 0.54; Figure 1, Supplemental Table 4). Compared to 
euthyroidism, hypothyroidism was associated with a 1.24 times higher risk of NAFLD 
(95% CI, 1.01 to 1.53; Table 3).
Figure 1. Longitudinal association between thyroid status and NAFLD.
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Point estimates for NAFLD (nonalcoholic fatty liver disease) were plotted against thyroid status of participants, taking 
euthyroid subjects as reference, after adjusting for age, sex, cohort, alcohol intake, smoking, follow-up time. Euthy-
roidism was defined as TSH (thyroid-stimulating hormone) within reference range (0.4 to 4.0 mIU/L); overt hypothy-
roidism as TSH >4.0 mU/L and FT4 (free thyroxine) <0.85 ng/dL; subclinical hypothyroidism as TSH >4.0 mU/L and FT4 
0.85 to 1.95 ng/dL; overt hyperthyroidism as TSH <0.4 mU/L and FT4 >1.95 ng/dL; subclinical hyperthyroidism as TSH 
<0.4 mU/L and FT4 0.85 to 1.95 ng/dL. Dashed lines represent confidence intervals. Within brackets: NAFLD events/
Total number.
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Cross-sectional analyses, based on categorized FLI, demonstrated a significant 
association of TSH (OR, 1.11; 95% CI, 1.04 to 1.18) and FT4 (OR, 0.45; 95% CI, 0.34 
to 0.60) with NAFLD (Supplemental Table 5). We found similar results in sensitivity 
analyses conducted only among euthyroid subjects, after excluding thyroid medica-
tion users and participants with previous thyroid surgery (Supplemental Table 2 and 
Supplemental Table 5).
Thyroid function and the risk of having a combination of naFld and lS ≥8 kPa
There was a positive association between TSH levels and the risk of having a com-
bination of NAFLD and LS ≥8.0 kPa (OR, 1.55; 95% CI, 1.09 to 2.20). In line, higher 
FT4 levels were associated with a lower risk of having a combination of NAFLD and 
LS ≥8.0 kPa, but not significantly (OR, 0.41; 95% CI, 0.09 to 1.73) (Table 4). The 
risk of having a combination of NAFLD and LS ≥8.0 kPa decreased gradually from 
hypothyroidism to hyperthyroidism (P for trend, 0.002) (Table 4).
Compared with euthyroidism, subclinical hypothyroidism was associated with a 
2.30 times higher risk of having a combination of NAFLD and LS ≥8.0 kPa (95% 
CI, 1.12 to 4.31; Table 4). Results remained similar after further adjustments for 
Table 4. Longitudinal association of thyroid function and status with the risk of having a com-
bination of NAFLD and LS ≥8 kPa*†
naFld with lS
≥8.0 kPa/ Tn
or (95% ci)
model 1
or (95% ci)
model 2
Thyroid function and the risk of having combined NAFLD & LS ≥8.0 kPa
TSH 69/4762 1.55 (1.09; 2.20) 1.49 (1.04; 2.15)
FT4 69/4762 0.41 (0.09; 1.73) 0.59 (0.13; 2.59)
Thyroid status and the risk of having combined NAFLD & LS ≥8.0 kPa
Clinical hypothyroidism 2/31 5.93 (0.93; 20.85) 6.64 (1.04; 23.98)
Subclinical hypothyroidism 11/408 2.30 (1.12; 4.31) 2.14 (1.04; 4.07)
Euthyroidism 55/4240 1 [Reference] 1 [Reference]
Subclinical hyperthyroidism 1/81 0.87 (0.04; 4.11) 0.80 (0.04; 3.91)
Clinical hyperthyroidism NA NA NA
P value for trend 0.002 0.004
Model 1: age, sex, cohort, alcohol intake, smoking, and follow-up time. Model 2: Model 1, use of lipid-lowering 
medications, total cholesterol, triglycerides, body mass index, hypertension, and diabetes mellitus. *LS ≥8.0 kilopascals 
suggests clinically relevant fibrosis. †For this analysis, we excluded thyroid medication users and participants with pre-
vious thyroid surgery. ORs of TSH are denoted per 1 unit increase of natural log transformed TSH (mIU/L). ORs of FT4 
are denoted per 1 unit increase in FT4 (ng/dL). Abbreviations: NAFLD, nonalcoholic fatty liver disease; LS, liver stiffness; 
kPa, kilopascals, TN, total number; OR, odds ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; FT4, free 
thyroxine; NA, not applicable.
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cardiovascular risk factors (Table 4). In euthyroid subjects, higher TSH and lower FT4 
concentrations were associated with an increased risk of having a combination of 
NAFLD and LS ≥8.0 kPa, but not significantly (OR, 1.13; 95% CI, 0.63 to 2.03 for TSH; 
OR, 0.81; 95% CI, 0.11 to 5.75 for FT4).
diScuSSion
The current study is the first prospective population-based study to evaluate the 
relation between the whole spectrum of thyroid function and subsequent risk of 
NAFLD. We demonstrated a negative linear association between FT4 levels and 
incident NAFLD, even among euthyroid subjects, as well as a positive linear asso-
ciation for TSH levels. Moreover, the risk of NAFLD progressively decreased from a 
hypothyroid to a hyperthyroid state. Hypothyroidism was associated with a higher 
NAFLD risk compared to euthyroidism. Lower thyroid function was also associated 
with an increased risk of having NAFLD with fibrosis. We demonstrate for the first 
time that subclinical hypothyroidism is associated with an increased risk of having 
NAFLD with fibrosis in the general population.
There are various pathways via which the beneficial effects of thyroid hormone 
on NAFLD risk can be mediated. Thyroid dysfunction is related to several cardiovas-
cular risk factors that are in turn associated with an increased NAFLD risk (eg, higher 
BMI and dyslipidemia). When we add BMI and triglycerides into the model, the 
risk estimates of the association between thyroid function and NAFLD attenuate, 
indeed suggesting a mediating role of these factors.
Studies in rodents have demonstrated a regression of hepatic steatosis after 
treatment with liver-targeted thyroid hormone receptor agonists.26-28 Thyroid hor-
mone induces intrahepatic lipolysis through lipophagy, that involves the sequestra-
tion and degradation of lipid droplets within hepatic lysosomes.29 Moreover, thyroid 
hormone receptor-mediated lipophagy enhances fatty acid oxidation, which may 
accelerate the clearance of liver lipids and reduce hepatosteatosis.29
Conversely, the decreased activity of hepatic lipases that occurs under hypothy-
roid conditions can promote NAFLD via decreased triglyceride clearance and hepatic 
triglyceride accumulation.30 In addition, the insulin resistance state associated with 
hypothyroidism 31 can contribute to NAFLD by concomitantly inducing “de novo” 
lipogenesis and generating a flux of free fatty acids from adipose tissue to the 
liver.32 Furthermore, decreased thyroid hormones might affect circulating levels of 
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adipocytokines, such as tumor necrosis factor-α, leptin and adiponectin.32,33 Altered 
adipocytokines may then contribute to hepatic inflammation and fibrosis, by exert-
ing direct hepatotoxic effects or promoting oxygen radicals.34
A putative role of thyroid autoimmunity has also been suggested in NAFLD 
pathogenesis, because various autoantibodies such as antinuclear antibodies and 
antismooth muscle antibodies, have been reported in patients with NAFLD.35 
However, our findings do not support this hypothesis, as there was no association 
between TPOAb and NAFLD.
Our findings consistently demonstrate that low thyroid function is associated 
with an increased risk of developing NAFLD, as well as higher risk of having NAFLD 
with fibrosis. Therefore, it can be hypothesized that a hypothyroid state might 
accelerate the progression of liver steatosis to fibrosis. Alternatively, low thyroid 
function might contribute on the development of liver fibrosis, independently of 
steatosis. Additional prospective research is needed to address these underlying 
mechanisms and possible mediating role of cardiovascular risk factors.
The results of the present study confirm a negative linear association between 
FT4 levels and the risk of NAFLD. Based on the negative feedback regulation of 
hypothalamus-pituitary-thyroid axis, we would expect an analogous opposite as-
sociation for TSH. Although there was a positive linear relationship between TSH 
levels and NAFLD risk, it attenuated among euthyroid subjects and after adjustment 
for cardiovascular risk factors. Several comparable studies exploring the association 
between thyroid function and different clinical end points have shown that FT4, 
rather than TSH, is significantly related to the outcome risk,18,36,37 particularly within 
the euthyroid range.18,36 This may be ascribed to the distinct central and peripheral 
effects of thyroid hormone, as pituitary gland and liver differ in thyroid hormone 
transporters, receptors and deiodinases.38 Also, genetic determinants and ageing 
can modify the TSH-FT4 set point of the feedback mechanism, accounting for the 
weaker TSH-FT4 association predominantly among euthyroid subjects.39,40
Our study has several important strengths. To our knowledge, it represents the 
first population-based prospective study to assess the effect of the whole spectrum 
of thyroid function on NAFLD and presence of clinically relevant fibrosis. The large 
sample size allowed us to conduct multiple sensitivity analyses. Other strengths 
include the extensive data on potential confounding factors and the laboratory 
assessment of thyroid parameters. In addition, we minimized the possibility of mis-
classification of cases with incident NAFLD, by excluding individuals with baseline 
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FLI ≥60 (thus highest probability of already having NAFLD), which however did not 
affect our results.
One limitation of our study is that we could not restrict the analysis to partici-
pants with baseline FLI values <30, due to a large sample size reduction (over 70% of 
the total population and over 80% of the NAFLD cases). Moreover, the diagnosis of 
NAFLD was based on ultrasonographic examination, whereas liver biopsy is consid-
ered the gold standard for the detection of mild steatosis or liver fibrosis. However, 
liver biopsies are not conducted routinely in NAFLD diagnosis and are considered 
unethical in population-based studies, because of invasiveness and potential com-
plications. Also, abdominal ultrasonography has a sensitivity of 80-90% for detect-
ing liver steatosis compared with histology, and its accuracy for diagnosing steatosis 
meets other imaging modalities.41 In addition, transient elastography is considered 
reproducible and effective in liver fibrosis assessment.24,25 Thyroid parameters were 
tested only at baseline and we lacked information regarding their variations over 
time. However, this would generate an underestimation of the association strength, 
rather than a spurious finding. Serum triiodothyronine measurements were not 
available in our study. Nevertheless, thyroid function is clinically defined by the 
combined TSH and FT4 measurement. Furthermore, the generalizability of our find-
ings to non-Caucasian populations remains uncertain. Finally, we cannot dismiss the 
possibility of residual confounding in an observational study design, even though 
we accounted for a large number of covariates.
conclusions
Individuals with hypothyroidism are at increased risk of NAFLD compared with 
euthyroid subjects. The current study also reveals a negative linear association 
between FT4 levels and the subsequent risk of NAFLD, even within the euthyroid 
reference range. Lower thyroid function is associated with an increased risk of 
fibrosis in NAFLD patients. Our findings highlight the need for future investigations 
on preventive measures (eg, screening of thyroid function in NAFLD patients) and 
possible therapeutic interventions (eg, decision of treatment in subclinical thyroid 
dysfunction).
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Supplemental Figure 1. Assessment of thyroid function and NAFLD in the Rotterdam Study.
First cohort   
Second cohort 
Third cohort 
Follow-up
RS I.4 RS I.5 RS I.3 RS I.2 RS I.1 
RS II.1 RS II.2 RS II.3 
RS III.2 RS III.1 
Ultrasound  
(end of follow-up) 
Thyroid parameters 
and FLI components 
(baseline) 
Supplemental Table 1. Baseline characteristics of 9419 participants in three RS cohorts
rS i rS ii rS iii
Total number 3694 2355 3370
Age, years 72.2 (6.8) 64.3 (7.7) 56.8 (6.7)
Women, n (%) 2139 (57.9) 1281 (54.4) 1901 (56.4)
Smoking, n (%)
Current 628 (17.0) 468 (19.9) 893 (26.5)
Past 1849 (50.0) 1173 (49.8) 1468 (43.6)
Never 1217 (33.0) 714 (30.3) 1009 (29.9)
Use of lipid-lowering medications, n (%) 459 (12.4) 308 (13.1) 741 (22.0)
Use of thyroid medications, n (%) 104 (2.8) 70 (3.0) 122 (3.6)
Total cholesterol, mmol/l 5.8 (0.9) 5.7 (0.9) 5.5 (1.6)
HDL-C, mmol/l 1.4 (0.4) 1.4 (0.4) 1.4 (0.4)
Triglycerides, mmol/l 1.5 (0.7) 1.5 (0.8) 1.5 (0.9)
Body mass index, kg/m2 26.8 (3.9) 27.1 (3.9) 27.7 (4.5)
Waist circumference, cm 93.4 (11.4) 93.7 (11.8) 93.8 (12.9)
Hypertension, n (%) 2816 (76.2) 1423 (60.4) 1642 (48.7)
Diabetes mellitus, n (%) 532 (14.4) 265 (11.3) 276 (8.2)
TSH, mIU/L, median (IQR) 1.8 (1.2-2.7) 1.8 (1.2-2.7) 2.02 (1.4-2.8)
FT4, ng/dL 1.2 (0.1) 1.2 (0.1) 1.2 (0.1)
TPOAb positive, n (%) 473 (12.8) 326 (13.8) 441 (13.1)
*Data are mean (standard deviation), unless otherwise specified. Abbreviations: RS, Rotterdam Study; HDL-C, high 
density lipoprotein cholesterol; TSH, thyroid-stimulating hormone; IQR, interquartile range; FT4, free thyroxine; 
TPOAb, thyroid peroxidase antibodies.
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Supplemental Table 2. Longitudinal association of thyroid parameters with NAFLD risk
events/Tn
or (95% ci)
model 1
or (95% ci)
model 2
FT4 in tertiles and NAFLD risk
All participants
FT4 (ng/dL) tertiles
0.10-1.13 466/1774 1.47 (1.25; 1.73) 1.31 (1.11; 1.56)
1.14-1.27 420/1776 1.31 (1.12; 1.55) 1.27 (1.07; 1.51)
1.27-2.37 331/1770 1 [Reference] 1 [Reference]
P value for trend <0.001 0.003
Thyroid function within the reference ranges*
FT4 (ng/dL) tertiles
0.85-1.14 385/1503 1.54 (1.29; 1.84) 1.36 (1.12; 1.64)
1.14-1.27 339/1500 1.33 (1.11; 1.60) 1.25 (1.05; 1.53)
1.28-1.89 264/1501 1 [Reference] 1 [Reference]
P value for trend <0.001 0.003
Thyroid function within the reference ranges* and NAFLD risk
TSH 988/4504 0.97 (0.83; 1.13) 0.92 (0.78; 1.08)
FT4 988/4504 0.25 (0.15; 0.41) 0.37 (0.22; 0.63)
TPOAb and NAFLD risk
TPOAb 1217/5316 1.10 (0.91; 1.31) 1.09 (0.89; 1.32)†
Model 1: age, sex, cohort, alcohol intake, smoking, and follow-up time. Model 2: Model 1, use of lipid-lowering 
medications, total cholesterol, triglycerides, body mass index, hypertension, and diabetes mellitus. *Normal reference 
ranges of thyroid function were defined as serum TSH levels of 0.4 to 4.0 mIU/L and serum FT4 levels of 0.85 to 1.95 
ng/dL. For this analysis, we excluded thyroid medication users and participants with previous thyroid surgery. †Ad-
ditionally adjusted for lnTSH. ORs of TSH are denoted per 1 unit increase of natural log transformed TSH (mIU/L). ORs 
of FT4 are denoted per 1 unit increase in FT4 (ng/dL). Abbreviations: NAFLD, nonalcoholic fatty liver disease; TN, total 
number; OR, odds ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; FT4, free thyroxine; TPOAb, thyroid 
peroxidase antibodies.
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Supplemental Table 3. Longitudinal association of thyroid function with NAFLD risk
or (95% ci)
model 1
or (95% ci)
model 2a
or (95% ci)
model 2b
TSH 1.09 (1.01; 1.19) 1.09 (1.01; 1.19) 1.07 (0.98; 1.17)
FT4 0.33 (0.22; 0.48) 0.32 (0.22; 0.48) 0.42 (0.28; 0.63)
Model 1: age, sex, cohort, alcohol intake, smoking, and follow-up time. Model 2a: Model 1, use of lipid-lowering medi-
cations, total cholesterol, hypertension, and diabetes mellitus; Model 2b: Model 2a, triglycerides, and body mass index.
ORs of TSH are denoted per 1 unit increase of natural log transformed TSH (mIU/L). ORs of FT4 are denoted per 1 unit 
increase in FT4 (ng/dL). Abbreviations: NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confidence interval; 
TSH, thyroid-stimulating hormone; FT4, free thyroxine.
Supplemental Table 5. Cross-sectional association between thyroid function and NAFLD de-
fined by FLI*
Total number
or (95% ci)
model 1
or (95% ci)
model 2
All participants
TSH 8777 1.11 (1.05; 1.19) 1.11 (1.04; 1.18)
FT4 8779 0.45 (0.34; 0.59) 0.45 (0.34; 0.60)
Thyroid function within the reference ranges†
TSH 7668 1.12 (1.01; 1.24) 1.11 (0.99; 1.24)
FT4 7668 0.41 (0.29; 0.57) 0.41 (0.29; 0.58)
Model 1: age, sex, cohort, alcohol intake, and smoking. Model 2: Model 1, hypertension, and diabetes mellitus. *For 
this analysis, we excluded thyroid medication users and participants with previous thyroid surgery. NAFLD was based 
on categorized baseline FLI, with 60 as a cutoff, in the absence of secondary causes of hepatic steatosis (>14 alcoholic 
beverages weekly, viral hepatitis, use of fatty liver inducing pharmacological agents). †Normal reference ranges of thy-
roid function were defined as serum TSH levels of 0.4 to 4.0 mIU/L and serum FT4 levels of 0.85 to 1.95 ng/dL. ORs of TSH 
are denoted per 1 unit increase of natural log transformed TSH (mIU/L). ORs of FT4 are denoted per 1 unit increase in 
FT4 (ng/dL). Abbreviations: NAFLD, nonalcoholic fatty liver disease; FLI, fatty liver index; OR, odds ratio; CI, confidence 
interval; TSH, thyroid-stimulating hormone; FT4, free thyroxine.
Supplemental Table 4. Longitudinal association of thyroid status with NAFLD risk
naFld/Tn
median TSh
(iQr)
mean FT4
(extreme values) or (95% ci)
Clinical hypothyroidism 15/37 17.19 (8.54-40.75) 0.64 (0.10-0.84) 2.08 (1.05; 4.01)
Subclinical hypothyroidism 140/499 5.15 (4.44-6.43) 1.13 (0.86-1.67) 1.27 (1.03; 1.57)
Euthyroidism 1035/4664 1.86 (1.34-2.54) 1.21 (0.74-2.07) 1 [Reference]
Subclinical hyperthyroidism 25/114 0.17 (0.06-0.31) 1.36 (0.90-1.91) 0.91 (0.56; 1.41)
Clinical hyperthyroidism 1/7 0.10 (0.01-0.16) 2.09 (1.97-2.37) 0.54 (0.02; 3.24)
P for trend 0.003
Adjusted for age, sex, cohort, alcohol intake, smoking, and follow-up time. Abbreviations: NAFLD, nonalcoholic fatty 
liver disease; TN, total number; TSH, thyroid-stimulating hormone; IQR, interquartile range; FT4, free thyroxine; OR, 
odds ratio; CI, confidence interval.
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abSTracT
background Thyroid hormones have been linked with various proatherogenic and 
antiatherogenic processes. However, the relationship of thyroid function with mani-
festations of atherosclerosis remains unclear. We therefore aimed to investigate the 
association of thyroid function with atherosclerosis throughout its spectrum, from 
subclinical atherosclerosis to incident atherosclerotic cardiovascular (ASCV) events 
to ASCV mortality.
methods This population-based study was embedded within the Rotterdam Study. 
The risk of atherosclerosis was evaluated by measuring: (1) Presence of subclinical 
atherosclerosis, assessed by coronary artery calcification (CAC) score >100 AU; (2) 
ASCV events, defined as fatal and nonfatal myocardial infarction, other coronary 
heart disease mortality or stroke; (3) ASCV mortality, defined as death because 
of coronary heart disease, cerebrovascular or other atherosclerotic diseases. As-
sociations of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) with the 
outcomes were assessed through logistic regression and Cox proportional hazard 
models, adjusted for potential confounders including cardiovascular risk factors.
results A total of 9420 community-dwelling participants (mean age ± standard 
deviation, 64.8±9.7 years) were included. During a median follow-up of 8.8 (inter-
quartile range, 4.5 to 11.8) years, 934 incident ASCV events and 612 ASCV deaths 
occurred. FT4 levels were positively associated with high CAC score (odds ratio [OR], 
2.28; 95% confidence interval [95% CI], 1.30 to 4.02) and incident ASCV events 
(hazard ratio [HR], 1.87; 95% CI, 1.34 to 2.59). The risk of ASCV mortality increased 
in a linear manner with higher FT4 levels (HR, 2.41; 95% CI, 1.68 to 3.47 per 1 ng/dL) 
and lower TSH levels (HR, 0.92; 95% CI, 0.84 to 1.00 per 1 logTSH). Results remained 
similar or became stronger among euthyroid participants.
conclusions FT4 levels in middle-aged and elderly subjects were positively associ-
ated with atherosclerosis throughout the whole disease spectrum, independently of 
cardiovascular risk factors.
Thyroid function and atherosclerosis 79
2
inTroducTion
Atherosclerosis progresses insidiously from a subclinical condition to the clinical 
onset of vascular events to death.1 Despite advances in prevention and treatment, 
atherosclerotic disease remains a leading cause of death, with a considerable clinical 
and economic burden worldwide.2 Hence, the identification of additional modifi-
able risk factors for atherosclerosis is of major importance.
Thyroid function has a complex relation with various contributors to athero-
genesis. Higher thyroid hormone concentrations have commonly been linked with 
systolic hypertension3,4 and hypercoagulation,5 whereas lower levels of circulat-
ing thyroid hormones can instigate hyperlipidemia and inflammation.6 Although 
atherosclerosis is a continuous process, prospective epidemiological studies to date 
have mainly focused on the relation between specific ranges of thyroid function and 
distinct atherosclerotic events, such as coronary heart disease (CHD) or stroke.7-12 
Results have been inconsistent, including studies that find no association between 
thyroid function and atherosclerotic outcomes,8,12 as well as other studies reporting 
an increased risk of atherosclerotic outcomes with either lower7,10 or higher thy-
roid function.9,11,13 Differences in study designs, follow-up period, and age range 
of participants may partly explain the inconsistencies across studies. In addition, 
these inconsistencies can also stem from the heterogeneity in the assessment of 
atherosclerosis. To date, a comprehensive investigation exploring the link between 
the full range of thyroid function and atherosclerosis throughout its spectrum, 
from subclinical atherosclerosis to overt atherosclerosis to atherosclerotic mortality, 
within the same cohort is lacking.
Therefore, in a large population-based cohort study of middle-aged and elderly 
individuals, we examined the association of thyroid function with atherosclerosis 
throughout its spectrum, including coronary artery calcification (CAC: as a well-
documented marker of subclinical atherosclerosis),14 atherosclerotic cardiovascular 
(ASCV) events (as a measure of clinical atherosclerosis) and ASCV mortality.
meThodS
Study population
This study was embedded within the Rotterdam Study, a prospective population-
based cohort study that investigates the determinants, occurrence and progression 
of chronic diseases in the middle-aged and elderly. The objectives and study design 
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have been described in detail previously.15 The Rotterdam Study was initiated in 
1989, including 7983 participants aged 55 years or older (RS I) residing in Ommoord 
district of Rotterdam, the Netherlands. In 2000, the study was extended with a 
second cohort of 3011 subjects (RS II). In 2006, a third cohort of 3932 subjects aged 
45 years or older was added (RS III). Study participants undergo extensive follow-up 
medical examinations every 3 to 5 years.
Baseline measurements for our study were performed during the third visit of 
the first cohort (n=4797) and the first visit of the second (n=3011) and third (n=3932) 
cohorts of the Rotterdam Study. The original cohort during these three visits includ-
ed a total of 11740 participants, of which 10063 had available blood measurements. 
Thyroid function measurements were performed at baseline in a random sample of 
9683 participants of the Rotterdam Study, during the third visit of the first cohort 
and the first visit of the second and third cohorts. Of these, 9420 participants had 
complete information on prevalent ASCV disease status and complete follow-up 
data; and were considered eligible for the analysis (Supplemental Figure 1). Follow-
up started at the date of thyroid function assessment. In the analysis of incident 
ASCV events, the end date of follow-up was considered the date of incident ASCV 
event, the date of death or 1 January, 2012, whichever came first. In the analysis of 
ASCV mortality, the end date of follow-up was considered the date of death or 1 
January, 2012, whichever came first.
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus University and by the Ministry of Health, Welfare and Sport of the Neth-
erlands, implementing the Population Study Act Rotterdam Study. All participants 
have given written informed consent.
assessment of thyroid function
Thyroid function was assessed at baseline in 3 study cohorts using the same method 
and assay. Measurements of thyroid-stimulating hormone (TSH), free thyroxine 
(FT4), and thyroid peroxidase antibodies (TPOAb) were performed in baseline serum 
samples stored at -80°C using the electrochemiluminescence immunoassay ECLIA 
Roche. The reference ranges of serum TSH (0.40–4.0 mIU/L) and serum FT4 (0.86–1.94 
ng/dL; equivalent to 11–25 pmol/L) were determined based on national guidelines 
and our previous studies.16
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assessment of cac, aScv events, and aScv mortality
The risk of atherosclerosis was evaluated by measuring CAC, ASCV events and ASCV 
mortality. Hard outcomes were included to avoid misclassification bias.
CAC measurements were performed at baseline in a random sample of 1999 
participants, during the third visit of the first cohort and the first visit of the second 
cohort. CAC was measured by electron beam computed tomographic scans (C-150 
Imatron GE) of the coronary arteries.15 Calcification of the coronary arteries was 
quantified through AccuImage software (AccuImage Diagnostics Corp), displaying 
all pixels with a density >130 Hounsfield units and using the Agatston’s method.17 
CAC score of ≥100 Agatson units (AU) suggests clinically significant atherosclerotic 
plaque 2 and has been used in past consensus statements.18 Therefore, we grouped 
participants into CAC score <100 AU and CAC score ≥100 AU.
ASCV events were defined as fatal and nonfatal myocardial infarction, other CHD 
mortality, or stroke, as described previously.19 Prevalent ASCV disease was defined 
as history of myocardial infarction, stroke, and coronary or other arterial revascular-
ization.19,20 Prevalent ASCV disease at baseline was assessed through interview and 
verified in medical records.
ASCV mortality was defined as death because of CHD, cerebrovascular disease, or 
other atherosclerotic diseases, as described previously.19,21 Non-ASCV mortality was 
defined as death because of causes other than atherosclerotic disease. Ascertainment 
of ASCV mortality in the Rotterdam Study has been described in detail previously.21 
In short, information on ASCV mortality was obtained from municipality, general 
practitioners and reports of medical specialists. The underlying cause of death was 
ascertained independently by two research physicians and subsequently validated 
by a medical specialist. The completeness of follow-up for ASCV mortality was 99%.
additional measurements
Information on medical history and medication use was obtained from question-
naires in combination with medical records. Information on the history of thyroid 
disease, thyroid surgery and thyroid medication use was obtained from question-
naires in combination with pharmacy records. During the baseline home interview, 
participants provided information on smoking habits and the number of alcoholic 
beverages they consumed weekly. Smoking habits were categorized as current, 
former and never smoking. Serum glucose and lipid levels were measured by an 
automated enzymatic procedure (Mannheim System). Estimated glomerular filtra-
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tion rate (eGFR) was calculated according to the CKD Epidemiology Collaboration 
(CKD-EPI) formula.22 Physical activity was measured by questionnaires and expressed 
in metabolic equivalent hours (METh)/week. Body mass index (BMI) was calculated 
as weight in kilograms divided by height in meters squared. Blood pressure was 
measured in the sitting position on the right arm and calculated as the mean of two 
measurements using a random-zero sphygmomanometer. Diabetes mellitus was 
defined as fasting serum glucose level ≥7 mmol/L, non-fasting plasma glucose level 
≥11.1 mmol/L (when fasting samples were absent) or the use of antidiabetic medi-
cations.15 Atrial fibrillation (AF) cases were ascertained by two research physicians 
and a cardiologist utilizing: 1) electrocardiograms recorded at baseline and during 
follow-up; 2) additional medical information obtained from general practitioners 
files, from outpatient clinics and from a national registry of all hospital discharge 
diagnoses.15,16 Heart failure (HF) was defined as the presence of typical symptoms 
and signs (ie, breathlessness at rest or during exertion, ankle edema, and pulmonary 
crepitations), confirmed by the objective evidence of cardiac dysfunction (ie, chest 
X-ray, echocardiography) or a positive response to the initiated treatment.15 The ad-
judication of HF was performed in accordance with the guidelines of the European 
Society of Cardiology.23 Measurements of thyroid peroxidase antibodies (TPOAb) 
were performed in baseline serum samples stored at -80°C using the electrochemi-
luminescence immunoassay ECLIA Roche. Levels of TPOAb >35 kU/ml were regarded 
as positive, as recommended by the assay manufacturer.
Statistical analysis
The association of thyroid function with atherosclerosis spectrum was assessed by 
using logistic regression and Cox proportional hazard models. We used logistic 
regression models to investigate the cross-sectional association of thyroid function 
with the risk of having CAC score of ≥100 AU, among participants who were free 
of ASCV disease. The association of thyroid function with incident ASCV events was 
prospectively investigated through Cox proportional hazard models. The analysis 
on incident ASCV events comprised individuals who were free of any ASCV event at 
baseline and only first events during follow-up were analyzed. The association of 
thyroid function with ASCV mortality was also examined through Cox proportional-
hazard models. We further compared the hazard ratios (HR) of ASCV mortality with 
those of non-ASCV mortality. To account for multiple comparisons, the analyses 
investigating the association of TSH or FT4 with subclinical atherosclerosis, incident 
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ASCV events, and ASCV mortality were additionally corrected for the false discovery 
rate using the Benjamini and Hochberg method.24
Analyses were stratified by sex (men versus women) and age. The latter was 
grouped based on the cutoff of 65 years, which is closer to the mean and median 
age of our population.
Analyses were adjusted for potential confounders that were selected based on 
biological plausibility and previous literature. Model 1 was adjusted for age, sex and 
cohort. Model 2 was additionally adjusted for smoking status, alcohol intake, BMI, 
total cholesterol, triglycerides, systolic blood pressure, prevalent diabetes mellitus 
and use of antihypertensive and lipid-lowering medications. The analyses of ASCV 
mortality were additionally adjusted for presence of prevalent ASCV disease.
TSH was naturally log transformed, due to its skewed distribution. The propor-
tional hazards assumption was assessed by Schoenfeld test and plots. No violation 
of the proportional hazards assumption was observed. Potential departure from 
linearity was explored by adding quadratic and cubic terms of covariates in the mul-
tivariable model, but none of these terms were significant. We checked for effect 
modification by separately adding product interaction terms of the exposure (TSH 
or FT4 or TPOAb) with each of the covariates of the most adjusted model.
Multiple imputations were performed for missing data (<5% missings for all 
covariates). Schoenfeld test and plots were performed using R (survival package 
R project, Institute for Statistics and Mathematics, R Core Team, version 3.2.3). All 
other statistical analyses were performed using IBM SPSS version 21 (IBM Corp). 
Results of this study are reported according to the STROBE statement guidelines 
(Supplemental Material).25
Sensitivity analyses
We performed several sets of sensitivity analyses to explore the robustness of our 
findings: (1) We limited the study participants to only those with thyroid function 
within the reference range, without history of thyroid disease and not using thyroid 
medications; (2) Thyroid function-altering medications, physical activity and estimated 
glomerular filtration rate (eGFR) can influence the metabolism of thyroid hormones. 
Therefore, we excluded participants using thyroid function-altering medications, 
such as thyroid medications, analgesics (including nonsteroidal anti-inflammatory 
drugs, paracetamol and muscle relaxants), corticosteroids or amiodarone. Besides, 
we additionally adjusted our analyses for physical activity or estimated glomerular 
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filtration rate; (3) We restricted the analyses to participants without history of AF 
and censored the incident AF cases during follow-up; (4) We restricted the analyses 
to participants without history of HF at baseline and censored the incident HF cases 
during follow-up; (5) To account for possible reverse causation, we investigated 
the association of thyroid function with incident ASCV events and ASCV mortality, 
after excluding the events that occurred during the first 2 years of follow-up; (6) 
We investigated the association of thyroid function with CAC score as a continuous 
variable, among participants who were free of ASCV disease. Because of its skewed 
distribution, CAC score was log transformed after adding 1 (ln[CAC+1]); (7) To explore 
the role of thyroid autoimmunity on atherosclerotic outcomes, we investigated the 
association of TPOAb levels with the risk of incident ASCV events and ASCV deaths.
reSulTS
We included 9420 participants with a maximum follow-up time of 14.7 years and a 
median of 8.8 years (interquartile range, 4.5 to 11.8 years). Baseline characteristics 
are presented in Table 1. The mean age of participants was 64.8 (±9.7) years and 
56.7% were women (Table 1). A total of 934 incident ASCV events (incidence rate, 
12.6 per 1000 person-years) and 612 ASCV deaths (incidence rate, 7.9 per 1000 
person-years) occurred during follow-up. Results did not change substantially after 
primary and additional adjustments for potential confounders; therefore we further 
report the most adjusted model (Model 2).
The characteristics and determinants of thyroid function in the Rotterdam Study 
population have been described in detail previously.26 In brief, the main determi-
nants of FT4 in the Rotterdam Study population are age, BMI, sex, and TPOAb levels, 
whereas the main determinants of TSH are age, smoking, and TPOAb levels.
Thyroid function and cac score
Increasing FT4 levels were associated with higher odds of having CAC score ≥100 AU 
(odds ratio [OR], 2.28; 95% confidence interval [95% CI], 1.30 to 4.02 per 1 ng/dL; 
Table 2). The association remained statistically significant after controlling for the 
false discovery rate (false discovery rate-corrected P value, 0.008; Table 2). However, 
TSH levels were not associated with having a CAC score ≥100 AU (OR, 0.94; 95% CI, 
0.84 to 1.05 per 1 logTSH; Table 2). No evidence of nonlinearity was observed (P 
for nonlinearity for FT4 and TSH 0.8 and 0.6, respectively; Supplemental Figure 2). 
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Restricting the analyses to participants with thyroid function within the reference 
ranges resulted in similar or increased point estimates, with wider 95% CIs (OR, 2.43; 
95% CI, 1.14 to 5.16 per 1 ng/dL FT4; OR, 0.91; 95% CI, 0.72 to 1.16 per 1 logTSH; 
Table 2). Results were consistent in the analyses with CAC score as a continuous 
variable (β, 0.54; 95% CI, 0.01 to 1.08 per 1 ng/dL FT4; β, 0.01; 95% CI, -0.10 to 
0.12 per 1 log TSH; Supplemental Figure 2). Furthermore, we found no association 
of TPOAb with the odds of having CAC score ≥100 AU (OR, 0.85; 95% CI, 0.63 to 
1.15; Supplemental Table 1). In the analyses of CAC score, the interaction terms 
between the exposure (TSH or FT4) and each covariate in the most adjusted model 
were not statistically significant. In particular, there were no significant sex or age 
differences (P for interaction of TSH and FT4 with sex [men versus women], 0.96 and 
0.88, respectively; P for interaction of TSH and FT4 with age [<65 versus ≥65 years], 
0.88 and 0.67, respectively; Supplemental Table 4).
Table 1. Baseline characteristics of 9420 participants* 
Age, years 64.8 (9.7)
Women, n (%) 5342 (56.7)
Smoking, n (%)
 current 2001 (21.2) 
 former 4481 (47.6)
 never 2938 (31.2)
TSH, mIU/L 1.9 (1.2-2.8)
FT4, ng/dL 1.2 (0.2)
TPOAb positive, n (%) 1251 (13.3)
Use of thyroid medication, n (%) 303 (3.2)
Thyroid surgery, n (%) 170 (1.8)
History of thyroid disease, n (%) 765 (8.1)
Body mass index, kg/m2 27.2 (4.2)
Total cholesterol, mmol/l 5.7 (1.0)
Triglycerides, mmol/l 1.5 (0.8)
Use of lipid-lowering medications, n (%) 1518 (16.1)
Systolic blood pressure, mm Hg 139.4 (21.0)
Use of antihypertensive medications, n (%) 2176 (23.1)
History of diabetes mellitus, n (%) 1077 (11.4)
History of atherosclerotic cardiovascular disease, n (%) 922 (9.8)
Follow-up time for atherosclerotic events, years 7.1 (4.3-11.6)
Follow-up time for atherosclerotic mortality, years 8.8 (4.5-11.8)
Abbreviations: TSH, thyroid-stimulating hormone; FT4, free thyroxine; TPOAb, thyroid peroxidase antibodies (cutoff 35 
kU/ml). *Data are presented as mean (standard deviation) or median (25th-75th percentiles), unless otherwise specified.
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Thyroid function and incident aScv events
There was a positive association of FT4 levels with the risk of incident ASCV events 
(HR, 1.87; 95% CI, 1.34 to 2.59 per 1 ng/dL), which remained statistically significant 
after controlling for the false discovery rate (false discovery rate-corrected P value, 
0.0006; Table 3). There was no association of TSH levels (HR, 0.96; 95% CI, 0.89 to 
1.03 per 1 logTSH) with the risk of incident ASCV events (Table 3). No evidence of 
nonlinearity was observed (P for nonlinearity for FT4 and TSH, 0.6 and 0.8, respec-
tively; Supplemental Figure 2). Restricting the analyses to participants with thyroid 
function within the reference ranges resulted in similar or increased point estimates, 
with wider 95% CIs (HR, 2.50; 95% CI, 1.58 to 3.94 per 1 ng/dL; HR, 0.96; 95% CI, 0.82 
to 1.11 per 1 logTSH; Table 3). This corresponds to a 2.70–times higher risk of incident 
ASCV events, for a participant with an FT4 in the higher limit of the reference range 
(1.94 ng/dL), compared with a participant with an FT4 in the lower limit of the refer-
ence range (0.86 ng/dL). The associations became slightly stronger after excluding 
participants using thyroid function-altering medications; and slightly attenuated 
after censoring the analyses at the time of incident AF (Supplemental Table 2). The 
associations remained similar after censoring the analyses at the time of incident HF; 
or after additionally adjusting for physical activity or estimated glomerular filtration 
rate. Results did not change substantially after excluding events that occurred dur-
ing the first 2 years of follow-up (Supplemental Table 3). Furthermore, we found no 
Table 2. Cross-sectional association of thyroid function with high CAC score*
high cac score /Tn, %
or (95% ci)
model 1 P value
or (95% ci)
model 2 P value
All participants
TSH 817/1763 (46.3%) 0.98 (0.88; 1.10) 0.79 0.94 (0.84; 1.05) 0.29‡
FT4 817/1763 (46.3%) 2.15 (1.22; 3.77) 0.008 2.28 (1.30; 4.02) 0.004§
Thyroid function within the reference ranges†
TSH 626/1336 (46.8%) 1.00 (0.78; 1.27) 0.98 0.91 (0.72; 1.16) 0.48
FT4 626/1336 (46.8%) 2.50 (1.18; 5.29) 0.01 2.43 (1.14; 5.16) 0.02
Model 1: age, sex, and cohort. Model 2: Model 1, smoking, alcohol intake, body mass index, total cholesterol, triglyc-
erides, systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medications, and use of lipid-low-
ering medications. *CAC ≥100 AU was defined as high CAC score. All included participants were free of atherosclerotic 
cardiovascular disease. †Normal reference ranges of thyroid function were defined as serum TSH levels of 0.4 to 4.0 
mIU/L and serum FT4 levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with history 
of thyroid disease. ‡False discovery rate-corrected P value, 0.34. §False discovery rate-corrected P value, 0.008. ORs of 
TSH are denoted per 1 unit increase of natural log transformed TSH (mIU/L). ORs of FT4 are denoted per 1 unit increase 
in FT4 (ng/dL). Abbreviations: CAC, coronary artery calcification; TN, total number; OR, odds ratio; CI, confidence inter-
val; TSH, thyroid-stimulating hormone; FT4, free thyroxine.
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association of TPOAb with the risk of incident ASCV events (HR, 0.95; 95% CI, 0.78 to 
1.16; Supplemental Table 1). In the analyses of incident ASCV events, the interaction 
terms between the exposure (TSH or FT4) and each covariate in the most adjusted 
model were not statistically significant. In particular, there were no significant sex or 
age differences (P for interaction of TSH and FT4 with sex [men versus women], 0.92 
and 0.62, respectively; P for interaction of TSH and FT4 with age [<65 and ≥65 years], 
0.30 and 0.34, respectively; Supplemental Table 4).
Thyroid function and aScv mortality
Higher FT4 levels were associated with a higher risk of ASCV mortality (HR, 2.41; 95% 
CI, 1.68 to 3.47 per 1 ng/dL; Table 4). The association remained statistically significant 
after controlling for the false discovery rate (false discovery rate-corrected P value, 
<0.0001; Table 4). In line, higher TSH levels were associated with a lower risk of 
ASCV mortality (HR, 0.92; 95% CI, 0.84 to 1.00 per 1 logTSH), although the associa-
tion was borderline significant (Table 4). No evidence of nonlinearity was observed 
(P for nonlinearity for FT4 and TSH, 0.8 and 0.8, respectively; Supplemental Figure 2).
In the analysis of ASCV mortality, we found statistically significant differences 
by prevalent ASCV disease at baseline and by sex (P for interaction of FT4 with 
prevalent ASCV disease [present versus absent], 0.002; P for interaction of TSH and 
FT4 with sex [men versus women], 0.03 and 0.002, respectively), but no statistically 
Table 3. Association of thyroid function with incident atherosclerotic cardiovascular events*
events/Tn, %
hr (95% ci)
model 1 P value
hr (95% ci)
model 2 P value
All participants
TSH 934/8498 (11.0%) 0.96 (0.89; 1.03) 0.34 0.96 (0.89; 1.03) 0.35‡
FT4 934/8498 (11.0%) 1.89 (1.37; 2.61) <0.0001 1.87 (1.34; 2.59) 0.0002§
Thyroid function within the reference ranges†
TSH 736/6826 (10.8%) 0.95 (0.81; 1.10) 0.50 0.96 (0.82; 1.11) 0.59
FT4 736/6826 (10.8%) 2.67 (1.69; 4.20) <0.0001 2.50 (1.58; 3.94) <0.0001
Model 1: age, sex, and cohort. Model 2: Model 1, smoking, alcohol intake, body mass index, total cholesterol, triglyc-
erides, systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medications, and use of lipid-low-
ering medications. *All included participants were free of atherosclerotic cardiovascular disease at baseline. †Normal 
reference ranges of thyroid function were defined as serum TSH levels of 0.4 to 4.0 mIU/L and serum FT4 levels of 0.85 
to 1.95 ng/dL, after excluding thyroid medication users and participants with history of thyroid disease. ‡False discov-
ery rate-corrected P value, 0.35. §False discovery rate-corrected P value, 0.0006. HRs of TSH are denoted per 1 unit in-
crease of natural log transformed TSH (mIU/L). HRs of FT4 are denoted per 1 unit increase in FT4 (ng/dL). Abbreviations: 
TN, total number; HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; FT4, free thyroxine.
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significant age differences (P for interaction of TSH and FT4 with age [<65 versus ≥65 
years], 0.35 and 0.78, respectively; Figure 1, Supplemental Table 4). The association 
of FT4 with atherosclerotic mortality was more pronounced among participants with 
ASCV disease (HR, 5.59; 95% CI, 2.90 to 10.80 per 1 ng/dL) and among men (HR, 
4.63; 95% CI, 2.70 to 7.94 per 1 ng/dL) (Figure 1, Supplemental Table 4). Within the 
strata of prevalent ASCV disease (absent versus present), none of the interaction 
terms of TSH or FT4 concentrations with sex or age were statistically significant (P 
for interaction, >0.05; Figure 1). Within the strata of sex (men versus women), none 
of the interaction terms of TSH or FT4 concentrations with prevalent ASCV disease 
or age were statistically significant (P for interaction, >0.05). Among euthyroid 
participants, none of the interaction terms between the exposure (TSH or FT4) and 
prevalent ASCV disease (absent versus present), sex (men versus women) or age (<65 
versus ≥65 years) were statistically significant (P for interaction, >0.05).
The association of thyroid function with ASCV mortality became slightly stronger 
after restricting the analyses to participants with thyroid function within the reference 
ranges (HR, 3.84; 95% CI, 2.23 to 6.60 per 1 ng/dL FT4; HR, 0.80; 95% CI, 0.67 to 0.96 
per 1 logTSH; Table 4, Figure 1). This corresponds to a 4.15–times higher risk of ASCV 
mortality, for a participant with an FT4 in the higher limit of the reference range (1.94 
ng/dL), compared with a participant with an FT4 in the lower limit of the reference 
range (0.86 ng/dL). The associations remained similar after excluding participants us-
Table 4. Association of thyroid function with atherosclerotic cardiovascular mortality
events/Tn, %
hr (95% ci)  
model 1 P value
hr (95% ci)  
model 2 P value
All participants
TSH 612/9420 (6.5%) 0.93 (0.86; 1.01) 0.12 0.92 (0.84; 1.00) 0.06†
FT4 612/9420 (6.5%) 2.23 (1.58; 3.14) <0.0001 2.41 (1.68; 3.47) <0.0001‡
Thyroid function within the reference ranges*
TSH 483/7575 (6.4%) 0.82 (0.68; 0.98) 0.02 0.80 (0.67; 0.96) 0.01
FT4 483/7575 (6.4%) 3.92 (2.29; 6.71) <0.0001 3.84 (2.23; 6.60) <0.0001
Model 1: age, sex, and cohort. Model 2: Model 1, smoking, alcohol intake, body mass index, total cholesterol, tri-
glycerides, systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medications, and use of lipid-
lowering medications. Both models are adjusted for presence of prevalent atherosclerotic cardiovascular disease at 
baseline. *Normal reference ranges of thyroid function were defined as serum TSH levels of 0.4 to 4.0 mIU/L and 
serum FT4 levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with history of thyroid 
disease. †False discovery rate-corrected P value, 0.09. ‡False discovery rate-corrected P value, <0.0001. HRs of TSH are 
denoted per 1 unit increase of natural log transformed TSH (mIU/L). HRs of FT4 are denoted per 1 unit increase in FT4 
(ng/dL). Abbreviations: TN, total number; HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; 
FT4, free thyroxine.
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ing thyroid function-altering medications, after censoring the analyses at the time of 
incident HF or after additionally adjusting for physical activity or estimated glomerular 
filtration rate. The associations slightly attenuated after censoring the analyses at the 
time of incident AF (Supplemental Table 2). Results did not change substantially after 
excluding events that occurred during the first 2 years of follow-up (Supplemental 
Table 3). The magnitude of association for ASCV mortality was larger than for non-
ASCV mortality (Table 5). Furthermore, we found no association of TPOAb with the 
risk of ASCV mortality (HR, 0.99; 95% CI, 0.77 to 1.27; Supplemental Table 1).
Figure 1. Association of thyroid function with atherosclerotic cardiovascular mortality, strati-
fied by presence of atherosclerotic cardiovascular disease at baseline.
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Analyses are adjusted for age, sex, cohort, smoking, alcohol intake, body mass index, total cholesterol, triglycerides, 
systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medications, and use of lipid-lowering 
medications. The P for interactions of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) with prevalent ath-
erosclerotic cardiovascular (ASCV) disease (absent vs present) were 0.09 and 0.002, respectively. Among participants 
without ASCV disease, the P for interactions of TSH and FT4 with sex (men vs women) were 0.18 and 0.07, respectively; 
the P for interactions of TSH and FT4 with age (<65 vs ≥65 years) were 0.38 and 0.29, respectively. Among participants 
with ASCV disease, the P for interactions of TSH and FT4 with sex (men vs women) were 0.34 and 0.44, respectively; the 
P for interactions of TSH and FT4 with age (<65 vs ≥65 years) were 0.61 and 0.13, respectively. Normal thyroid function 
was defined as serum TSH levels of 0.4 to 4.0 mIU/L and FT4 levels of 0.85 to 1.95 ng/dL, after excluding thyroid medica-
tion users and participants with history of thyroid disease. Error bars represent the 95% confidence interval (CI) of HRs 
(black dots). Within brackets: Number of ASCV deaths / Total number (TN).
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diScuSSion
In this large population-based cohort study, higher FT4 levels were associated with 
an increased risk of atherosclerosis, independent of cardiovascular risk factors. The 
association was consistent throughout the spectrum of atherosclerosis, from sub-
clinical atherosclerosis to overt atherosclerosis to atherosclerotic mortality.
Various cardiovascular risk factors have been implicated in the pathways linking 
thyroid function to atherosclerosis. Low thyroid function has been associated with 
unfavorable levels of blood lipids and BMI,6 whereas high thyroid function has been 
associated with an increased prevalence of AF.16 Our study suggests that the associa-
tion of thyroid function with atherosclerosis is independent of these cardiovascular 
risk factors because our results remained statistically significant after accounting 
for serum lipid levels, BMI, and AF. Thyroid autoimmunity has been suggested as 
another potential contributor to atherogenesis. Thus far, it has been speculated 
that thyroid autoantibodies may target the arterial wall and ultimately enhance 
the development of atherosclerotic plaque.27,28 However, we found no association 
between TPOAb positivity and atherosclerotic outcomes. Taken together, these data 
suggest that the link between thyroid function and atherosclerosis could be ex-
plained by yet unexplored cardiovascular risk factors, alternative markers of thyroid 
autoimmunity (eg, TSH receptor antibodies) or other pathways.
Plausible mechanisms that can link high thyroid function to atherosclerosis 
include endothelial damage, hemostasis, thrombosis and hemodynamic changes. 
First, excess concentrations of thyroid hormones can increase the production of 
reactive oxygen species that further induce the expression of adhesion molecules on 
endothelial cells.29 Hence, hyperthyroidism has been commonly associated with early 
atherosclerosis and markers of endothelial dysfunction such as E-selectin, intracel-
Table 5. Comparison on the association of thyroid function with the risk of ASCV mortality and 
non-ASCV mortality
aScv  
deaths/Tn (%)
aScv mortality
hr (95% ci) P value
non-aScv  
deaths/Tn (%)
non-aScv mortality
hr (95% ci) P value
TSH 612/9420 (6.5%) 0.92 (0.84; 1.00) 0.06 1476/9420 (15.7%) 0.94 (0.89; 0.99) 0.03
FT4 612/9420 (6.5%) 2.41 (1.68; 3.47) <0.0001 1476/9420 (15.7%) 1.65 (1.29; 2.10) <0.0001
Adjusted for age, sex, cohort, prevalent atherosclerotic cardiovascular disease, smoking, alcohol intake, body mass in-
dex, total cholesterol, triglycerides, systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medi-
cations, and use of lipid-lowering medications. HRs of TSH are denoted per 1 unit increase of natural log transformed 
TSH (mIU/L). HRs of FT4 are denoted per 1 unit increase in FT4 (ng/dL). Abbreviations: ASCV, atherosclerotic cardiovascu-
lar; TN, total number; HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; FT4, free thyroxine.
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lular adhesion molecule-1, and vascular cell-adhesion molecule.30 Second, thyroid 
hormones regulate the synthesis of procoagulant proteins.31 Excess FT4 levels have 
been linked with increased concentrations of various procoagulant proteins, namely 
von Willebrand factor, fibrinogen, and factors VIII and IX, that can accelerate plaque 
vulnerability and rupture.5 Third, high levels of thyroid hormones can generate in-
creased cardiac contractility and workload, augmenting myocardial oxygen demand 
that could eventually precipitate ischemic events and death.3 These deleterious 
effects of high thyroid function may also be extended to the high-normal range of 
thyroid function.11 Future research should pinpoint the exact mechanisms underly-
ing the association of thyroid function with atherogenesis.
Our large cohort study sought to disentangle the association of thyroid function 
with atherosclerotic and non-atherosclerotic mortality. The effect of thyroid func-
tion on atherosclerotic mortality was greater compared with non-atherosclerotic 
mortality, indicating that atherosclerosis plays a major role in the pathways linking 
high thyroid function to increased mortality risk.
Previous cohort studies among middle-aged and elderly subjects have mainly 
reported an increased mortality risk with higher thyroid function.32-35 In an attempt 
to identify potential subgroups at risk, prior research has suggested that the effect 
of thyroid function on mortality might be age 32-35 or sex dependent.33,34 Generally, 
studies performed in older participants have reported an increased risk of mortal-
ity with higher FT4 levels,33,34 whereas studies including younger participants have 
failed to show an association.36,37 Additional studies have reported an association 
of thyroid function with mortality risk exclusively in men 38 or women.7 Our data 
on atherosclerotic mortality revealed stronger risk estimates among participants 
with preexisting atherosclerotic disease and among men. Prevalent atherosclerotic 
disease and sex might, therefore, be effect modifiers of the association between 
thyroid function and atherosclerotic mortality. However, these results should be 
interpreted with caution because the differences by atherosclerotic disease and 
sex were not statistically significant after restricting the analyses to the euthyroid 
participants.
Alternatively, one might argue that thyroid hormone is not a contributor but 
rather a marker of subclinical atherosclerosis or a marker of increased mortality in 
the setting of chronic atherosclerosis. In particular, it could be hypothesized that 
health problems underlying atherosclerotic disease can affect thyroid parameters. 
This condition, known as non-thyroidal illness, is typically characterized by normal 
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serum TSH levels combined with low serum triiodothyronine and FT4 levels.39 In 
contrast, we found an association of higher rather than lower FT4 levels with an 
increased risk of atherosclerotic manifestations. Additionally, non-thyroidal illness 
occurs mainly in critically ill patients, whereas our population consists of relatively 
healthy community-dwelling adults. Furthermore, our study showed that higher FT4 
levels among participants without preexisting atherosclerotic disease were associ-
ated with higher risk of atherosclerotic events and atherosclerotic mortality. We 
took reverse causation into account by excluding events that occurred during the 
first 2 years of follow-up; and results remained similar. Overall, these data suggest 
that it is more likely that thyroid function affects atherosclerotic manifestations 
than vice versa.
Variations of thyroid function within the reference range markedly affected the 
risk of atherosclerotic morbidity and mortality in our participants. In line with these 
results, a recent individual participant data analysis reported a positive association 
between thyroid function within the reference range and the risk of stroke.9 How-
ever, another analysis from the same collaboration failed to show an association 
between thyroid function within the reference range and the risk of CHD,8 although 
this could be because of the relatively low proportion of CHD deaths (3.3%). We 
observed larger risk estimates after restricting the analyses to participants with TSH 
and FT4 levels within the reference ranges, although one would expect a higher 
outcome risk within the full range of thyroid function. However, euthyroid par-
ticipants are known to have a small intra-individual variation of thyroid function.40 
In contrast, participants with thyroid dysfunction are prone to treatment during 
follow-up, which could eventually reduce their risk for atherosclerotic morbidity and 
mortality over time. This can explain the increased atherosclerotic risk after we ex-
cluded the users of thyroid function-altering medications from the analyses. Future 
interventional studies, however, can provide more insight into the impact of thyroid 
function-altering medications on the risk of atherosclerosis. Finally, our data pro-
vide supporting evidence for a reevaluation of TSH and FT4 reference ranges, which 
are currently based on arbitrary statistical approaches (2.5th and 97.5th percentiles) 
rather than on clinical outcomes. Previous prospective studies have also reported 
that variations in thyroid function within the reference range are associated with 
an increased risk of various adverse outcomes.9,11,16 Thus, the challenge for future 
research will be to integrate the associated risk of relevant adverse outcomes, in 
order to eventually define the clinically relevant normal range of thyroid function.
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In our study population, there was a positive association between FT4 levels and 
atherosclerotic outcomes. Although the association between TSH levels and ath-
erosclerotic outcomes was in the expected opposite direction of FT4, it sometimes 
did not reach statistical significance. Similar observations have been also reported 
by studies investigating the relationship of thyroid function with various clinical 
end points.9,33 Serum FT4 levels are tightly regulated by the hypothalamic-pituitary-
thyroid axis, with a different set point for each individual. This might explain why FT4 
levels are associated with various clinical end points, especially within the euthyroid 
range which is generally defined by TSH. Alternatively, these results may reflect a 
slight shift in the TSH-FT4 set point, which may be because of ageing.41
To our knowledge, this is the first population-based cohort study that inves-
tigates the relationship of thyroid function with atherosclerosis throughout its 
spectrum, from subclinical atherosclerosis to overt atherosclerosis to atherosclerotic 
mortality. Thyroid function measurements were performed before the occurrence 
of atherosclerotic events. Another major strength is the long-term follow-up (maxi-
mum follow-up time was almost 15 years). Moreover, we included a large number 
of participants with extensive data on covariates and outcomes. Our large numbers 
further allowed us to perform multiple sensitivity analyses which provided consis-
tent findings. Also, we were able to account for the main determinants of thyroid 
function in the Rotterdam Study population.
Several limitations should also be considered. Thyroid function was measured 
only at baseline and we had no information on its fluctuations over time. Never-
theless, because of the intra-individual variability of TSH and FT4 levels, the lack 
of repeated measurements would tend to underestimate the association between 
thyroid function and atherosclerotic outcomes rather than generate spurious find-
ings.42 In addition, our results were consistent within the normal range of thyroid 
function, which is considered to be stable with small intra-individual variability.40 
We lacked information on serum triiodothyronine levels. However, TSH and FT4 
represent the most relevant measurements of thyroid function in clinical practice. 
Given that our study comprised mainly white middle-aged and older adults, the 
generalizability of our findings to nonwhite and younger populations remains to 
be investigated. Lastly, the possibility of residual confounding in an observational 
study design cannot be entirely ruled out.
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conclusions
Higher FT4 levels in middle-aged and elderly subjects were associated with an 
increased risk of atherosclerotic morbidity and mortality, independent of cardio-
vascular risk factors. These findings suggest that FT4 measurement can be a predic-
tive marker of atherosclerotic mortality. Furthermore, our findings underscore the 
importance of identifying the modifiable mediators of the association between thy-
roid function and atherogenesis. Preventive strategies targeting thyroid function or 
certain mediators could further lead to a reduction in atherosclerotic events. Lastly, 
our findings provide supporting evidence for a reevaluation of the current refer-
ence ranges of TSH and FT4 tests, which are based on arbitrary statistical approaches 
rather than on clinical outcomes such as atherosclerotic morbidity and mortality.
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Supplemental Figure 1. Flow chart for the selection of study participants.
11740 in cohorts RS I.3, II.1, III.1* 
10050 had blood measurements
9683 had complete thyroid function 
measurements (TSH, FT4   and TPOAb) 
367 without complete thyroid 
function measurements  
263 without complete information 
on atherosclerotic disease 
308 without informed consent  
1382 without blood measurements 
9420 included participants 
*A total of 11740 participants were enrolled during the third visit of the first cohort (n = 4797) and the first visit of the 
second (n = 3011) and third (n = 3932) cohorts of the Rotterdam Study.
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Supplemental Figure 2. Association of thyroid function with atherosclerotic risk.
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Continuous CAC score, log relative hazard of incident ASCV events and ASCV mortality are plotted against TSH and 
FT4 concentrations, by using restricted cubic splines with 3 knots. Adjusted for age, sex, and cohort. Analyses of ASCV 
mortality are additionally adjusted for prevalent ASCV disease at baseline. Abbreviations, TSH, thyroid-stimulating 
hormone; FT4, free thyroxine; CAC, coronary artery calcification; ASCV, atherosclerotic cardiovascular.
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STrobe Statement. Checklist of items that should be included in reports of observational 
studies
item no recommendation Paragraph
Title and 
abstract
1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract
Title
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found
Abstract
Introduction
Background/
rationale
2 Explain the scientific background and rationale for the investigation being 
reported
1
Objectives 3 State specific objectives, including any prespecified hypotheses 1
Methods
Study design 4 Present key elements of study design early in the paper 2
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection
2
Participants 6 (a) Cohort study: Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up
Case-control study: Give the eligibility criteria, and the sources and methods 
of case ascertainment and control selection. Give the rationale for the choice 
of cases and controls
Cross-sectional study: Give the eligibility criteria, and the sources and methods 
of selection of participants
4
(b) Cohort study: For matched studies, give matching criteria and number of 
exposed and unexposed
Case-control study: For matched studies, give matching criteria and the 
number of controls per case
NA
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable
3-5
Data sources/ 
measurement
8* For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group
3-5
Bias 9 Describe any efforts to address potential sources of bias 7
Study size 10 Explain how the study size was arrived at 2
Quantitative 
variables
11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why
6
Statistical 
methods
12 (a) Describe all statistical methods, including those used to control for 
confounding
6
(b) Describe any methods used to examine subgroups and interactions 6
(c) Explain how missing data were addressed 6
(d) Cohort study: If applicable, explain how loss to follow-up was addressed
Case-control study: If applicable, explain how matching of cases and controls 
was addressed
Cross-sectional study: If applicable, describe analytical methods taking account 
of sampling strategy
7
(e) Describe any sensitivity analyses 7
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STrobe Statement. Checklist of items that should be included in reports of observational 
studies (continued)
item no recommendation Paragraph
Results
Participants 13* (a) Report numbers of individuals at each stage of study: (eg, numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analyzed)
2, Suppl
(b) Give reasons for non-participation at each stage 2, Suppl
(c) Consider use of a flow diagram Suppl
Descriptive data 14* (a) Give characteristics of study participants (eg, demographic, clinical, social) 
and information on exposures and potential confounders
2
(b) Indicate number of participants with missing data for each variable of 
interest
Suppl
(c) Cohort study: Summarize follow-up time (eg, average and total amount) 8
Outcome data 15* Cohort study: Report numbers of outcome events or summary measures over 
time
8
Case-control study: Report numbers in each exposure category, or summary 
measures of exposure
NA
Cross-sectional study: Report numbers of outcome events or summary 
measures
NA
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear which 
confounders were adjusted for and why they were included
9-11
(b) Report category boundaries when continuous variables were categorized 6
(c) If relevant, consider translating estimates of relative risk into absolute risk 
for a meaningful time period
NA
Other analyses 17 Report other analyses done: eg, analyses of subgroups and interactions, and 
sensitivity analyses
6,7
Discussion
Key results 18 Summarize key results with reference to study objectives 12
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias 
or imprecision. Discuss both direction and magnitude of any potential bias
12
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence
12
Generalizability 21 Discuss the generalizability (external validity) of the study results 12
Other information
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based
†
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and un-
exposed groups in cohort and cross-sectional studies. note: An Explanation and Elaboration article discusses each 
checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.
plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.
com/). Information on the STROBE Initiative is available at www.strobe-statement.org. †The Rotterdam Study is sup-
ported by the Erasmus Medical Center and Erasmus University of Rotterdam; the Netherlands Organization for Scien-
tific Research; the Netherlands Organization for Health Research and Development; the Research Institute for Diseases 
in the Elderly; the Netherlands Genomics Initiative; the Ministry of Education, Culture and Science; the Ministry of 
Health Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam.
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Supplemental Table 1. Association of TPOAb positivity with atherosclerotic outcomes
events/Tn, %
hr (95% ci)
model 1 P value
hr (95% ci)
model 2 P value
TPOAb positivity and high CAC score*†
All 817/1763 (46.3%) 1.01 (0.75; 1.37) 0.93 0.85 (0.63; 1.15) 0.28
Euthyroid participantsǂ 626/1336 (46.9%) 1.06 (0.69; 1.62) 0.80 0.93 (0.61; 1.41) 0.71
TPOAb positivity and incident atherosclerotic cardiovascular events†
All 934/8498 (11.0%) 0.98 (0.80; 1.20) 0.87 0.95 (0.78; 1.16) 0.63
Euthyroid participants‡ 736/6826 (10.8%) 1.18 (0.91; 1.52) 0.21 1.16 (0.90; 1.50) 0.25
TPOAb positivity and atherosclerotic cardiovascular mortality§
All 612/9420 (6.5%) 1.03 (0.80; 1.32) 0.82 0.99 (0.77; 1.27) 0.94
Euthyroid participantsǂ 483/7575 (6.4%) 1.07 (0.77; 1.49) 0.67 1.09 (0.78; 1.51) 0.62
Model 1: age, sex, cohort, and lnTSH. Model 2: Model 1, smoking, alcohol intake, body mass index, total cholesterol, 
triglycerides, systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medications, and use of 
lipid-lowering medications. *CAC ≥100 AU was defined as high CAC score. †All included participants were free of ath-
erosclerotic cardiovascular disease at baseline. ‡Normal reference ranges of thyroid function were defined as serum 
TSH levels of 0.4 to 4.0 mIU/L and serum FT4 levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and 
participants with personal history of thyroid disease. §Additionally adjusted for prevalent atherosclerotic cardiovascu-
lar disease. Abbreviations: TPOAb, thyroid peroxidase antibodies (cutoff 35 kU/ml); TN, total number; HR, hazard ratio; 
CI, confidence interval; TSH, thyroid-stimulating hormone.
Supplemental Table 2. Sensitivity analyses for the association between thyroid function within 
the reference ranges* and atherosclerotic outcomes
events/Tn, %
hr (95% ci) 
model 1 P value
hr (95% ci) 
model 2 P value
Incident atherosclerotic cardiovascular events†
Thyroid function within the reference ranges*
TSH 736/6826 (10.8%) 0.95 (0.81; 1.10) 0.50 0.96 (0.82; 1.11) 0.59
FT4 736/6826 (10.8%) 2.67 (1.69; 4.20) <0.0001 2.50 (1.58; 3.94) <0.0001
Excluding users of thyroid function-altering medications‡
TSH 638/5964 (10.7%) 0.92 (0.78; 1.09) 0.34 0.93 (0.79; 1.10) 0.41
FT4 638/5964 (10.7%) 3.05 (1.86; 4.98) <0.0001 2.70 (1.64; 4.42) <0.0001
Additionally adjusted for physical activity
TSH 736/6826 (10.8%) 0.95 (0.82; 1.11) 0.56 0.96 (0.83; 1.12) 0.67
FT4 736/6826 (10.8%) 2.62 (1.67; 4.12) <0.0001 2.47 (1.57; 3.90) <0.0001
Additionally adjusted for eGFR
TSH 736/6826 (10.8%) 0.93 (0.80; 1.08) 0.35 0.94 (0.81; 1.10) 0.48
FT4 736/6826 (10.8%) 2.56 (1.62; 4.03) <0.0001 2.39 (1.51; 3.78) <0.0001
Excluding subjects with prevalent AF and censoring at the time of incident AF
TSH 574/6270 (9.2%) 0.94 (0.79;1.12) 0.50 0.96 (0.80; 1.14) 0.63
FT4 574/6270 (9.2%) 2.25 (1.33; 3.82) <0.003 2.05 (1.20; 3.48) 0.008
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Supplemental Table 2. Sensitivity analyses for the association between thyroid function within 
the reference ranges* and atherosclerotic outcomes (continued)
events/Tn, %
hr (95% ci) 
model 1 P value
hr (95% ci) 
model 2 P value
Excluding subjects with prevalent HF and censoring at the time of incident HF
TSH 693/6640 (10.4%) 0.89 (0.77; 1.04) 0.17 0.91 (0.78; 1.06) 0.24
FT4 693/6640 (10.4%) 2.70 (1.68; 4.33) <0.0001 2.35 (1.46; 3.78) 0.0004
Atherosclerotic cardiovascular mortality§
Thyroid function within the reference ranges*
TSH 483/7575 (6.4%) 0.82 (0.68; 0.98) 0.02 0.80 (0.67; 0.96) 0.01
FT4 483/7575 (6.4%) 3.92 (2.29; 6.71) <0.0001 3.84 (2.23; 6.60) <0.0001
Excluding users of thyroid function-altering medications‡
TSH 389/6476 (6.0%) 0.74 (0.61; 0.90) 0.003 0.72 (0.58; 0.88) 0.001
FT4 389/6476 (6.0%) 3.82 (2.05; 7.14) <0.0001 3.47 (1.84; 6.51) <0.0001
Additionally adjusted for physical activity
TSH 483/7575 (6.4%) 0.82 (0.69; 0.99) 0.04 0.81 (0.67; 0.97) 0.02
FT4 483/7575 (6.4%) 3.79 (2.22; 6.46) <0.0001 3.74 (2.18; 6.43) <0.0001
Additionally adjusted for eGFR
TSH 483/7575 (6.4%) 0.79 (0.66; 0.95) 0.01 0.79 (0.65; 0.94) 0.01
FT4 483/7575 (6.4%) 3.65 (2.13; 6.26) <0.0001 3.60 (2.09; 6.20) <0.0001
Excluding subjects with prevalent AF and censoring at the time of incident AF
TSH 357/6906 (5.2%) 0.81 (0.66; 0.99) 0.04 0.80 (0.65; 0.99) 0.04
FT4 357/6906 (5.2%) 2.90 (1.52; 5.56) 0.001 3.15 (1.64; 6.05) 0.001
Excluding subjects with prevalent HF and censoring at the time of incident HF
TSH 356/7307 (4.9%) 0.75 (0.61; 0.92) 0.007 0.73 (0.59; 0.90) 0.004
FT4 356/7307 (4.9%) 4.94 (2.61; 9.34) <0.0001 4.23 (2.22; 8.09) <0.0001
Model 1: age, sex, and cohort. Model 2: Model 1, smoking, alcohol intake, body mass index, total cholesterol, tri-
glycerides, systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medications, and use of lipid-
lowering medications. *Normal reference ranges of thyroid function were defined as serum TSH levels of 0.4 to 4.0 
mIU/L and serum FT4 levels of 0.85 to 1.95 ng/dL, after excluding thyroid medication users and participants with 
personal history of thyroid disease.†All included participants were free of atherosclerotic cardiovascular disease at 
baseline.‡Thyroid function-altering medications included thyroid medications, analgesics, corticosteroids and amioda-
rone. §Additionally adjusted for prevalent atherosclerotic cardiovascular disease. HRs of TSH are denoted per 1 unit in-
crease of natural log transformed TSH (mIU/L). HRs of FT4 are denoted per 1 unit increase in FT4 (ng/dL). Abbreviations: 
TN, total number; HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; FT4, free thyroxine; 
eGFR, estimated glomerular filtration rate; AF, atrial fibrillation; HF, heart failure.
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Supplemental Table 3. Association of thyroid function with atherosclerotic events, after ex-
cluding events that occurred during first 2 years of follow-up
events/Tn, %
hr (95% ci)  
model 1 P value
hr (95% ci)  
model 2 P value
Incident atherosclerotic cardiovascular events*
All participants
TSH 775/8339 (9.3%) 0.93 (0.86; 1.01) 0.10 0.93 (0.86; 1.01) 0.09
FT4 775/8339 (9.3%) 1.91 (1.34; 2.72) 0.0003 1.87 (1.30; 2.69) 0.001
Thyroid function within the reference ranges†
TSH 611/6701 (9.1%) 0.95 (0.80; 1.12) 0.57 0.96 (0.81; 1.14) 0.66
FT4 611/6701 (9.1%) 2.51 (1.52; 4.15) 0.0003 2.30 (1.39; 3.81) <0.0001
Atherosclerotic cardiovascular mortality‡
All participants
TSH 535/9343 (5.7%) 0.94 (0.86; 1.03) 0.23 0.93 (0.84; 1.02) 0.12
FT4 535/9343 (5.7%) 1.95 (1.34; 2.84) 0.0004 2.12 (1.42; 3.16) 0.0002
Thyroid function within the reference ranges†
TSH 419/7511 (5.5%) 0.80 (0.66; 0.97) 0.02 0.78 (0.64; 0.95) 0.01
FT4 419/7511 (5.5%) 3.57 (1.99; 6.39) <0.0001 3.49 (1.93; 6.29) <0.0001
Model 1: age, sex, and cohort. Model 2: Model 1, smoking, alcohol intake, body mass index, total cholesterol, triglyc-
erides, systolic blood pressure, prevalent diabetes mellitus, use of antihypertensive medications, and use of lipid-low-
ering medications. *All included participants were free of atherosclerotic cardiovascular disease at baseline. †Normal 
reference ranges of thyroid function were defined as serum TSH levels of 0.4 to 4.0 mIU/L and serum FT4 levels of 0.85 
to 1.95 ng/dL, after excluding thyroid medication users and participants with history of thyroid disease. ‡Additionally 
adjusted for prevalent atherosclerotic cardiovascular disease. HRs of TSH are denoted per 1 unit increase of natural log 
transformed TSH (mIU/L). HRs of FT4 are denoted per 1 unit increase in FT4 (ng/dL). Abbreviations: TN, total number; 
HR, hazard ratio; CI, confidence interval; TSH, thyroid-stimulating hormone; FT4, free thyroxine.
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abSTracT
background The underlying mechanism of the association between thyroid function 
and atrial fibrillation (AF) is poorly understood, but epicardial adipose tissue (EAT) 
could be a promising mediator.
methods In 1995 participants (mean age, 64.5 years) from the population-based 
Rotterdam Study, we measured thyroid function (thyroid-stimulating hormone 
[TSH], free thyroxine [FT4]), and performed computed tomography to quantify EAT 
volumes. All participants were followed for the occurrence of AF. We assessed as-
sociations of TSH and FT4 with EAT and AF, and performed causal mediation analysis 
to decompose the overall effect of thyroid function on AF with EAT as mediator.
results Higher FT4 levels were associated with larger EAT volumes in persons with 
large waist circumferences, defined by sex-specific cutoffs (0.08 mL more EAT per 1 
standard deviation increase in FT4; 95% confidence interval [95% CI], 0.02 to 0.14), 
but not in persons with a normal waist circumference. In persons with a large waist 
circumference, higher FT4 levels were associated with a higher AF risk (hazard ratio, 
1.50; 95% CI, 1.22 to 1.83). We found no evidence of a mediating role of epicardial 
adipose tissue in the association of thyroid function with AF (mediated interaction, 
1.6%; pure indirect effect, 3.2%). The estimate of reference interaction of EAT with 
thyroid function on AF risk was more substantial (10.8%), but statistically nonsig-
nificant.
conclusions Higher FT4 levels are associated with larger EAT volumes in persons with 
abdominal obesity. We report no mediating role of EAT in the association of thyroid 
function with AF, but found evidence for a suggested interaction of FT4 with EAT 
volumes on AF risk.
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inTroducTion
The association of high and high-normal thyroid function with atrial fibrillation 
(AF) has been established in several large studies and meta-analyses.1-3 Possible 
pathophysiological mechanisms include direct effects of thyroid hormone on the 
sympathetic nervous system and indirect effects through accumulation of cardiovas-
cular risk factors. However, the link between thyroid function and AF seems largely 
independent of traditional cardiovascular risk factors such as blood pressure, diabe-
tes and cholesterol.1,2 This suggests that yet unexplored cardiovascular risk factors or 
alternative pathways could mediate the association of thyroid dysfunction with AF. 
Further elucidation of these mediators is not only important for pathophysiologi-
cal understanding but, possibly, also for future treatment decisions (ie, treatment 
targeted at thyroid dysfunction, modifiable mediators or both).
Against this background, epicardial adipose tissue (EAT) might be of great inter-
est. EAT is a rapidly emerging risk factor for cardiovascular disease, and particularly 
for AF.4,5 Thyroid hormones may be linked to EAT through several mechanisms. For 
example, thyroid hormones act on pathways leading to atherogenesis, including 
endothelial damage and increased procoagulation factors,6 which are in turn 
closely related to EAT increase. Thyroid hormones may also exert direct effects on 
EAT by activating adipose tissue, mainly brown adipose tissue. Thyroid hormones 
are important for energy regulation and thermogenesis. Thyroid hormone excess 
leads to an increase in basal metabolic rate and thermogenesis, and patients with 
hyperthyroidism often present with weight loss. However, thyroid hormones have 
also shown to play a role in brown adipose tissue activity and white adipose tissue 
browning.7 In mice, lack of thyroid hormone reduces activity of brown adipose tis-
sue, while hyperthyroidism shows an increase in brown adipose tissue mass.8 EAT 
is generally perceived as solely consisting of white adipose tissue.4 This concept is 
under debate since brown adipose tissue-specific genes, UCP1 gene in particular, 
have been identified in human EAT, suggesting that EAT additionally possesses 
brown adipose tissue-like characteristics.4
Hence, EAT may represent a potential explanation for the association of high 
thyroid function with AF. In the past years, several small studies (n<100 participants) 
have indicated a possible role of hypothyroidism or hyperthyroidism on EAT forma-
tion and progression.9-13 This association has neither been explored in larger studies, 
nor has it been investigated in the full range of thyroid function in the general 
population. Hence, we aimed to assess the association of thyroid function with EAT 
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measured by computed tomography and to investigate whether EAT is a mediator 
of the association of thyroid function with AF in a large population-based cohort 
study.
meThodS
Study Population
The study was performed in the context of the Rotterdam Study (RS), a prospective 
population-based cohort study that investigates determinants and occurrence of 
cardiovascular, neurological, ophthalmologic, psychiatric, and endocrine diseases in 
the middle-aged and elderly population. The aims and design of the Rotterdam 
Study have been described in detail elsewhere.14 We included participants from two 
independent cohorts within the Rotterdam Study. The first cohort (RS I) includes 
participants aged 55 years and older and baseline data were collected from 1990 to 
1993. The second cohort (RS II) includes participants aged ≥55 years, and baseline 
data were collected from 2000 to 2001. Between 2003 and 2006, all participants 
who visited the research center were invited to undergo a multidetector computed 
tomography (MDCT) examination on which the amount of epicardial fat was as-
sessed. This was part of a larger project on the assessment of vascular calcification. 
In total, 2524 participants were scanned.
For the current study, we included all participants from the Rotterdam Study, 
cohort I wave 3 and cohort II wave 1, with available thyroid function measurements, 
CT EAT measurements (assessed after laboratory measurement in all participants) 
and data on AF incidence. We excluded participants using thyroid function altering 
medication (levothyroxine, anti-thyroid drugs, amiodarone or corticosteroids) and 
with prevalent AF at baseline. Eligible participants were followed-up for incident AF 
events from CT EAT measurement onward. Detailed information on the selection of 
study participants is provided in Figure 1.
The study protocol was approved by the Medical Ethics Committee of the Eras-
mus University and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rot-
terdam Study)”. All included participants provided a written informed consent in 
accordance with the Declaration of Helsinki to participate in the study and to obtain 
information from their family physicians.
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assessment of thyroid function
Thyroid function was measured through thyroid-stimulating hormone (TSH) and 
free thyroxine (FT4) using the same methods and assay for all cohorts (The elec-
trochemiluminescence immunoassay for thyroxine and thyrotropine, ECLIA, Roche) 
in serum samples stored at -80°C. We determined the reference values for normal 
range TSH as 0.4 to 4.0 mIU/L and FT4 as 11 to 25 pmol/L (alternatively, 0.85 to 1.95 
ng/dL) according to national guidelines as well as our previous studies.1,15
assessment of epicardial fat volume
Non-contrast MDCT images were acquired using 16-slice (n=593) or 64-slice (n=1402) 
MDCT scanners (Somatom Sensation 16 or 64, Siemens, Forchheim, Germany). De-
tailed information on the imaging parameters are described elsewhere.16 We used 
an ECG-gated cardiac scan to visualize the epicardium, and applied a previously de-
scribed, fully automatic tool to quantify the amount of epicardial fat in milliliters.17
assessment of atrial fibrillation
For the assessment of AF during follow-up, three methods are used in the Rot-
terdam Study and have been described in detail previously.18,19 First, electrocar-
Figure 1. Flow chart for the selection of study participants.
2265 with CT scan 
2126 had valid CT scan 
2036 had thyroid function 
measurements and 
no medications 
1995 included participants 
139 had invalid CT scan 
(eg, artefacts) 
7 had no thyroid 
function measurements 
83 had thyroid function 
altering medications 
41 no information on 
incident or prevalent AF 
Baseline measurements for the present study were performed during the cohort I wave 3 and cohort II wave 1 of 
the Rotterdam Study. Thyroid function was assessed at baseline. Epicardial adipose tissue volumes were measured by 
CT scans, which were performed in cohort I wave 4 and cohort II wave 2 of the Rotterdam Study. The median time 
between CT scans and laboratory measurements was 4.6 years. Eligible participants were followed-up for incident AF 
events from CT assessment onward. Abbreviations: CT, computed tomography; AF, atrial fibrillation.
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diograms (ECGs) were recorded at study entry and at each follow-up examination 
and analyzed with the Modular ECG Analysis System (MEANS).20,21 All ECGs with a 
diagnosis of AF, atrial flutter, or any other rhythm disorder were reviewed by two 
independent research physicians who were blinded to the MEANS diagnosis. In case 
of disagreement, a senior specialist was consulted and the final decision was made. 
Second, information on AF was obtained through general practitioners’ records, 
which includes their own results as well as hospitals discharge letters and outpatient 
clinic reports. Third, the national medical registry of all hospital discharge diagnoses 
was linked to the Rotterdam Study database. Any cases detected through linkage 
were verified by review of the medical records. Participants who developed AF as a 
consequence of severe systemic illness (eg, septic shock), resulting in death shortly 
after the detection of AF, were not considered to have AF. Furthermore, partici-
pants with transitory AF during myocardial infarction or after thoracic surgery were 
not considered as AF cases. All potential new diagnoses of AF were adjudicated 
by two independent research physicians, and in case of disagreement, consensus 
was sought. In case of persistent disagreement, a senior specialist made the final 
decision. Given that AF and atrial flutter are similar with respect to risk factors and 
consequences, these conditions were combined into a single composite outcome.22 
Follow-up for AF was complete until 1 January, 2014.
additional measurements
We collected detailed information on cardiovascular risk factors and medica-
tion use in a standardized fashion by interview, physical examination, and blood 
sampling. Waist circumference was measured and expressed in centimeters. Waist 
circumference was stratified according to sex-specific clinical cutoffs. For women, 
normal waist circumference was defined as ≤88 cm, while large waist circumference 
was defined as >88 cm. For men, normal waist circumference was defined as ≤102 
cm, while large waist circumference was defined as >102 cm. Systolic and diastolic 
blood pressure were measured twice at the right brachial artery using random-
zero sphygmomanometer, and the mean of the two measurements was used for 
analyses. Fasting blood samples were obtained, and serum total cholesterol and 
high-density lipoprotein cholesterol were measured using an automatic enzymatic 
procedure (Hitachi analyzer, Roche Diagnostics). Information on lipid-lowering and 
antihypertensive medication use was derived from questionnaires and pharmacy 
information. Smoking information was derived from baseline questionnaires and 
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categorized into never, previous, and current smokers. Alcohol use information was 
derived from questionnaires and recorded as grams per day. History of diabetes 
mellitus was defined by a repeated (two measurements within one year) impaired 
fasting glucose ≥7 mmol/L or a non-fasting glucose of ≥7 mmol/L (when fasting 
samples were absent) or use of anti-glycemic medication at baseline. Prevalent 
coronary heart disease was ascertained as previously described and consisted of a 
prior myocardial infarction or revascularization.19
Statistical analysis
We analyzed the association of thyroid function (ie, FT4 or TSH) with EAT with or-
dinary least-squared regression models. The association of thyroid function or EAT 
with AF was investigated by Cox-proportional hazards regression models. We used 
restricted cubic splines at three knots for all covariates in our analyses to assess and 
account for possible nonlinearity of the associations, but no evidence of nonlinear-
ity was observed.
All primary analyses were performed for three models. Potential confounders 
were selected based on biological plausibility and previous literature (Supplemental 
Figures 1-4). The first model adjusted for age, sex, cohort, smoking, alcohol intake 
and time between laboratory measurement and CT scan. In the second model, we 
additionally adjusted for cardiovascular risk factors, including total cholesterol, high-
density lipoprotein cholesterol, lipid-lowering medications, systolic blood pressure, 
diastolic blood pressure, antihypertensive medications, prevalent diabetes mellitus, 
and prevalent coronary heart disease. The third model additionally adjusted for 
waist circumference (within the waist circumference categories). Of note, the first 
model was regarded as the primary model for the analyses where thyroid function 
is the exposure, because all included covariates in the other models are more likely 
to be possible mediators rather than confounders. For the analyses where EAT is 
the exposure and AF is the outcome, we additionally adjusted for TSH and FT4 and 
considered Model 2 as the primary model (Supplemental Material).
Due to the possible differential effect of thyroid function on adiposity in general, 
in contrast to EAT specifically, we tested interaction of TSH and FT4 with waist cir-
cumference on the association with EAT and AF. There was a statistically significant 
interaction between FT4 and waist circumference on EAT and on the risk of AF, and 
we therefore stratified the analyses according to sex-specific clinical cutoffs of waist 
circumference. We considered waist circumference rather than BMI as a marker of 
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obesity, because: (1) waist circumference is perceived as a better marker of visceral 
adiposity as compared to BMI and (2) waist circumference showed better statisti-
cal properties as compared to BMI (eg, statistical significance for the interaction 
terms while avoiding multicollinearity that occurred when introducing both waist 
circumference and BMI to the model). The association of thyroid function with 
waist circumference in our study is provided in Supplemental Table 1. There was no 
interaction of thyroid function with sex or age on any of the outcomes.
Given a possible synergic effect of thyroid function and EAT volumes on AF risk, 
our mediation analysis was based on the approach of a four-way decomposition, 
which combines methods assessing mediation and interaction. In the four-way 
decomposition approach, the overall effect of thyroid function on AF with EAT as 
mediator (with which the thyroid function may interact) is decomposed into 4 com-
ponents: (1) the direct effect of thyroid function (ie, TSH or FT4) on AF in the absence 
of EAT, (2) the interactive effect when the EAT is at the value it would be in the 
absence of the thyroid function, (3) a mediated interaction (due to mediation and 
interaction by EAT), and (4) a pure mediated effect.23 These concepts will be referred 
to as controlled direct effect, reference interaction, mediated interaction, and pure 
indirect effect, respectively. The method assumes baseline covariates control for 
exposure-outcome, mediator-outcome, and exposure-mediator confounding and 
that there is no mediator-outcome relationship affected by exposure. In order not 
to violate the final condition, we used the predicted value of these factors on EAT: 
total cholesterol, high-density lipoprotein cholesterol, lipid-lowering medications, 
diastolic blood pressure, systolic blood pressure, use of antihypertensive medica-
tions, prevalent CHD, and prevalent diabetes mellitus as covariates. We performed 
a sensitivity analysis including these variables separately in the mediation analysis 
(Supplemental Table 2), but no meaningful differences were detected.
We used Z scores of FT4, TSH and EAT for all analyses, after log-transformation, 
when appropriate. Statistical analyses were conducted using R statistical software 
(rms, Himsc, visreg packages, R-project, Institute for Statistics and Mathematics, R 
Core Team (2013), Vienna, Austria, version 3.0.2).
reSulTS
We included 1995 participants with valid CT-scans, thyroid function measurements, 
and information on AF follow-up that did not use thyroid-function altering medica-
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tion (Figure 1). Baseline characteristics of study participants, total and stratified by 
waist circumference, are shown in Table 1. During an overall median follow-up of 
12.9 (interquartile range, 12.07 to 13.70) years, 109 of 1189 participants with a nor-
mal waist circumference and 87 of 806 participants with a large waist circumference 
developed AF.
Table 1. Baseline characteristics of study participants*
Total sample
Small waist 
circumference
large waist 
circumference
Number 1995 1189 806
Age, years 64.5 (6.4) 64.4 (6.3) 64.7 (6.5)
Age, range 55-94 55-90 55-94
Women, n (%) 1018 (51.0) 516 (43.4) 502 (62.3)
TSH, mIU/L, median (IQR) 1.84 (1.27 – 2.72) 1.78 (1.22 – 2.61) 1.92 (1.33 – 2.90)
FT4, pmol/L 15.6 (2.1) 15.8 (2.1) 15.4 (2.2)
Waist circumference, cm 93.4 (11.0) 87.7 (8.4) 101.7 (8.8)
Body mass index, kg/m2 27.0 (3.8) 25.0 (2.5) 29.9 (3.5)
Diabetes mellitus, n (%) 194 (9.7) 64 (5.4) 130 (16.1)
Total cholesterol, mmol/L 5.82 (0.96) 5.79 (0.94) 5.86 (0.98)
Use of lipid-lowering medications 256 (12.8) 120 (10.1) 136 (16.9)
High-density lipoprotein cholesterol, 
mmol/L
1.39 (0.37) 1.44 (0.39) 1.31 (0.34)
Systolic BP, mmHg 141.5 (20.6) 139.5 (20.7) 144.5 (20.2)
Diastolic BP, mmHg 78.4 (10.8) 77.6 (10.8) 79.6 (10.8)
Use of antihypertensive medications, n 
(%)
511 (25.6) 229 (19.3) 282 (35.0)
Smoking, n (%)
 Current 348 (17.3) 217 (18.3) 131 (16.3)
 Past 1039 (52.1) 605 (50.9) 434 (53.8)
 Never 608 (30.6) 366 (30.8) 240 (29.9)
Alcohol intake, median, IQR 10.0 (1.4 – 20.0) 10.0 (1.9 – 20.0) 9.7 (1.0 – 20.0)
Prevalent coronary heart disease, n (%) 104 (5.2) 61 (5.1) 43 (5.3)
Epicardial fat volume, median, IQR 101.4 (80.0 – 130.4) 92.9 (72.9 – 118.4) 115.4 (93.7 – 148.2)
Time between laboratory measurement 
and scan (years) median, IQR
4.6 (4.4 – 4.8) 4.6 (4.4 – 4.8) 4.6 (4.3 – 4.6)
*Values are means (standard deviation), unless otherwise specified. Abbreviations: BP, blood pressure; TSH, thyroid-
stimulating hormone; FT4, free thyroxine; IQR, interquartile range.
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Thyroid function and eaT
There was no association of TSH or FT4 with EAT in participants with a normal waist 
circumference (Table 2). In participants with a large waist circumference, higher 
values of FT4, but not TSH, were associated with a larger volume of EAT (β, 0.08 per 
standardized FT4; 95% confidence interval [95% CI], 0.02 to 0.14; Table 2). This is in 
contrast to the association of FT4 with waist circumference, where higher FT4 levels 
were associated with a lower risk of having a large waist circumference (odds ratio, 
0.84; 95% CI, 0.74 to 0.94 per one Z score increase of FT4, Supplemental Table 1).
Thyroid function, eaT, and aF
In participants with a normal waist circumference, TSH and FT4 were not associated 
with incident AF while larger volumes of EAT were associated with an increased risk 
of AF with a hazard ratio (HR) of 1.53 per standardized EAT (95% CI, 1.19 to 1.97) 
(Table 3). In participants with large waist circumference, TSH was not associated 
with AF risk. However, FT4 and EAT were both associated with AF risk with HRs of 
1.45 (95% CI, 1.20 to 1.76) and 1.38 (95% CI, 1.00 to 1.89), respectively (Table 3).
None of the estimated excess risks of the 4 components was statistically sig-
nificant (Table 4). The largest proportion attributable to the effect of FT4 on AF 
in participants with a large waist circumference was the controlled direct effect 
(84.4%; excess risk, 0.424; 95% CI, -0.065 to 0.711; Table 4). The remainder of the 
Table 2. Association of TSH or FT4 with EAT stratified for waist circumference*
β (95% ci )
model 1
β (95% ci )
model 2
β (95% ci )
model 3
Small waist circumference (TN, 1189)
TSH 0.03 (-0.01; 0.07) 0.01 (-0.03; 0.06) 0.03 (-0.01; 0.07)
FT4 0.02 (-0.04; 0.08) 0.03 (-0.02; 0.09) 0.03 (-0.01; 0.03)
Large waist circumference (TN, 806)
TSH 0.01 (-0.05; 0.06) -0.00 (-0.05; 0.05) -0.00 (-0.05; 0.05)
FT4 0.08 (0.02; 0.14) 0.09 ( 0.02; 0.15) 0.10 ( 0.04; 0.16)
Model 1: age, sex, cohort, alcohol intake, smoking, and time between laboratory measurement and scan. Model 
2: Model 1, total cholesterol, high-density lipoprotein cholesterol, use of lipid-lowering medications, systolic blood 
pressure, diastolic blood pressure, use of antihypertensive medications, prevalent diabetes mellitus, and prevalent 
coronary heart disease. Model 3: Model 2, and WC at baseline. *For both thyroid function parameters and epicar-
dial adipose tissue, Z scores were used in the analysis. WC was stratified according to sex-specific clinical cutoffs. For 
women, small WC was defined as ≤88 cm, while large WC was defined as >88 cm. For men, small WC was defined as ≤ 
102 cm, while large WC was defined as >102 cm. Abbreviations: TSH, thyroid-stimulating hormone; FT4, free thyroxine; 
EAT, epicardial fat tissue; CI, confidence interval; WC, waist circumference; TN, total number.
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Table 3. Association of TSH, FT4 and EAT with atrial fibrillation, stratified by waist circumference
hr (95% ci )
model 1
hr (95% ci )
model 2
hr (95% ci )
model 3
Small waist circumference (Events/TN, 109/1189)
TSH 1.10 (0.89; 1.35) 1.10 (0.90; 1.35) 1.12 (0.91; 1.38)
FT4 1.09 (0.90; 1.33) 1.09 (0.90; 1.33) 1.10 (0.90; 1.34)
EAT 1.50 (1.18; 1.91) 1.53 (1.19; 1.97) 1.48 (1.12; 1.96)
Large waist circumference (Events/TN, 87/806)
TSH 0.90 (0.74; 1.09) 0.90 (0.74; 1.10) 0.88 (0.72; 1.07)
FT4 1.45 (1.20; 1.76) 1.46 (1.19; 1.78) 1.50 (1.22; 1.83)
EAT 1.37 (1.01; 1.86) 1.38 (1.00; 1.89) 1.22 (0.87; 1.70)
Model 1: age, sex, cohort, alcohol intake, smoking, and time between laboratory measurement and scan. Model 2: 
Model 1, total cholesterol, high-density lipoprotein cholesterol, use of lipid-lowering medications, systolic blood pres-
sure, diastolic blood pressure, use of antihypertensive medications, prevalent diabetes mellitus, and prevalent coro-
nary heart disease. Model 3: Model 2, and WC at baseline. For all EAT analyses, the models are additionally adjusted 
for TSH and FT4. WC was stratified according to sex-specific clinical cutoffs. For women, small WC was defined as ≤88 
cm, while large WC was defined as >88 cm. For men, small WC was defined as ≤102 cm, while large WC was defined 
as >102 cm. Abbreviations: TSH, thyroid-stimulating hormone; FT4, free thyroxine; EAT, epicardial fat tissue; TN, total 
number; CI, confidence interval; WC, waist circumference.
Table 4. Proportions of the effect of FT4 on AF due to mediation and/or interaction with EAT
excess risk (95% ci) Proportion attributable
Small WC
CDE 0.077 (-0.150; 0.285) 89.7%
INTref -0.001 (-0.062; 0.018) -1.0%
INTmed 0.002 (-0.009; 0.009) 2.5%
PIE 0.008 (-0.016; 0.025) 8.8%
Total 0.085 (-0.151; 0.276) 100%
Large WC
CDE 0.424 (-0.065; 0.711) 84.4%
INTref 0.054 (-0.138; 0.242) 10.8%
INTmed 0.008 (-0.030; 0.038) 1.6%
PIE 0.016 (-0.024; 0.036) 3.2%
Total 0.502 (0.085; 0.733) 100%
WC was stratified according to sex-specific clinical cutoffs. For women, small WC was defined as ≤88 cm, while large 
WC was defined as >88 cm. For men, small WC was defined as ≤102 cm, while large WC was defined as >102 cm. 
Analyses for the association of FT4 with EAT and AF were adjusted for age, sex, cohort, alcohol intake, and smoking. 
Analyses for the association of EAT with AF were additionally adjusted for total cholesterol, high-density lipopro-
tein cholesterol, lipid-lowering medications, systolic blood pressure, diastolic blood pressure, use of antihypertensive 
medications, prevalent diabetes mellitus, prevalent coronary heart disease, TSH and FT4 levels. Abbreviations: FT4 free 
thyroxine; AF, atrial fibrillation; EAT, epicardial fat tissue; CI, confidence interval; CDE, Controlled direct effect; INTref, 
reference interaction; INTmed, mediated interaction; PIE, pure indirect effect; TSH, thyroid stimulating hormone; WC, 
waist circumference.
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overall effect was due to reference interaction (ie, the interactive effect between 
FT4 and EAT when the EAT is at the value it would be in the absence of the thyroid 
function) with a proportion attributable of 10.8% (excess risk, 0.054, 95% CI, -0.138 
to 0.242). The natural indirect effect (ie, sum of pure indirect effect and mediated 
interaction) was 0.024 (95% CI, -0.043 to 0.063; Table 4).
diScuSSion
In this large sample of community-dwelling middle-aged and elderly subjects, higher 
FT4 levels among participants with a large waist circumference were associated with 
larger EAT volumes. Among participants with a normal waist circumference, we 
observed no association between thyroid function and EAT volumes. The known 
relation between higher thyroid function and AF was not mediated by EAT.
Similar to previous studies, we found high and high-normal thyroid hormone 
levels to be associated with an increased risk of AF.1,24 Prior prospective research 
has also reported a positive association of EAT volumes with AF risk.25 Interestingly, 
a thyroid hormone-dependent gene, namely uncoupling protein-1 (UCP1) gene, is 
highly expressed in EAT,26,27 thus suggesting a potential direct effect of thyroid hor-
mones on mitochondrial uncoupling and in turn on EAT activation. In our study, we 
indeed describe an association of higher FT4 levels with larger EAT volumes, mainly 
among participants with a large waist circumference. Therefore, we can speculate 
that higher FT4 levels among participants with abdominal obesity may additionally 
increase the likelihood of having larger EAT volumes and the risk of developing AF. 
Due to the negative feedback mechanism of hypothalamic-pituitary-thyroid axis, 
one would expect TSH levels to be inversely associated with EAT. However, TSH levels 
were not associated with EAT volumes in our study. We hypothesize that this may 
reflect a dysregulation of the hypothalamic-pituitary-thyroid axis by overproduction 
of leptin in the setting of abdominal obesity.28,29
The relation of thyroid function with obesity is complex.30 As described in previ-
ous literature and confirmed in our study, FT4 levels are known to be negatively 
associated with abdominal obesity, which is in turn linked to increased EAT vol-
umes.30 However, in our study, there was a positive association of FT4 levels with 
EAT volumes, which remained consistent after additionally adjusting for waist 
circumference. These results indicate that waist circumference does not explain the 
link between thyroid hormone and EAT. The opposing association of FT4 levels with 
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EAT volumes as compared to FT4 levels with waist circumference could suggest that 
the role of thyroid hormones on body fat distribution depends on the location and 
composition of visceral adipose tissue (eg, presence of brown adipose tissue-like 
characteristics or lack thereof). Along with other stimuli, increased thyroid hormones 
can enhance the transdifferentiation of white adipocytes to brown adipocytes in 
the EAT of obese patients. However, further research is needed to elucidate the 
exact mechanisms underlying the association of thyroid function with abdominal 
obesity and EAT.
Our study suggests that abdominal obesity may potentiate the effect of FT4 
on the development of AF. Among our participants with abdominal obesity, we 
found no evidence that the association between FT4 and AF was mediated by EAT. 
Alternative mechanisms other than EAT could, therefore, explain the link between 
thyroid function and AF. For example, thyroid hormones may contribute to the ini-
tiation and maintenance of AF via the activation of automatic foci in the pulmonary 
veins,31,32 the stimulation of sympathetic nervous system,33,34 the elevation of left 
atrial pressure secondary to ventricular hypertrophy, and atrial ischemia second-
ary to an increased heart rate,35 among others. On the other hand, we observed a 
notable proportion of reference interaction (10.8%), which indicates that the occur-
rence of AF can be partly explained by synergistic effects between thyroid hormones 
and EAT, though the 95% CI was quite wide. The results of our mediation analyses, 
however, should be interpreted with caution, as we may have lacked a sufficient 
sample size to detect statistically significant findings.
To our knowledge, this is the largest population-based cohort study investigat-
ing the relation of thyroid function with EAT volumes. Moreover, this is the first 
study that explores the potential mediating role of EAT in the association between 
thyroid function and AF. The mediation analysis was based on the approach of a 
four-way decomposition, which unifies within a single framework the methods 
assessing mediation and interaction.23 The detailed information on potential con-
founders allowed us to perform multivariate-adjusted analyses. Another strength 
of our study is the comprehensive adjudication of end points. AF cases were ex-
tensively evaluated at baseline and during follow-up. EAT was assessed by using a 
standardized computed tomography-based procedure. Though most previous stud-
ies have utilized ultrasound measurements to evaluate EAT, computed tomography 
is considered superior to the ultrasound in the detection and, particularly, in the 
quantification of EAT.13,36
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Several limitations of our study should also be considered. Thyroid function and 
EAT volumes were assessed only once and we had no information regarding their 
changes over time. However, due to the intra-individual variability of TSH and FT4 
levels, the lack of repeated measurements would tend to underestimate rather than 
overestimate the association of thyroid function with EAT and AF.37 EAT volumes 
were assessed after the thyroid function measurements (median time between CT 
scans and laboratory measurements was 4.6 years). However, we adjusted all analyses 
for the time interval between the measurements. Another limitation is the lack of 
information on serum triiodothyronine levels. However, TSH and FT4 represent the 
most relevant measurements of thyroid function in clinical practice. The majority of 
our participants were white middle-aged and older adults, limiting the generaliz-
ability of our findings to other populations. Lastly, given the observational study 
design, we cannot rule out the possibility of residual or unmeasured confounding.
conclusions
Our findings suggest that in subjects with abdominal obesity, FT4 measurement can 
help identify those with larger EAT volumes and higher risk of AF. Our results do not 
suggest EAT as a mediating factor between thyroid function and AF. However, the 
occurrence of AF may be influenced by potential synergic effects between thyroid 
hormones and EAT. Future research is warranted to replicate our results and provide 
further insight into the relation between thyroid function and AF.
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SuPPlemenTal maTerial
Supplemental Figure 1. Directed acyclic graph for the association of free thyroxine (FT4) with 
epicardial adipose tissue.
M
C L 
A
Corresponds to Table 2, Model 1. A, FT4; M, epicardial adipose tissue; C, age, sex, cohort, smoking, alcohol intake, and 
time between measurements; L, waist circumference. Effect modification of FT4 by waist circumference (interaction 
FT4*waist circumference, P value <0.05) on M, not included in the primary model.
Supplemental Figure 2. Directed acyclic graph for the association of FT4 with atrial fibrillation.
Y
C 
A
Corresponds to Table 3, Model 1. A, FT4; Y, atrial fibrillation; C, age, sex, cohort, smoking, alcohol intake, and (large) 
waist circumference. Effect modification of FT4 by waist circumference (interaction FT4 * waist circumference, P value 
<0.05) on Y.
Supplemental Figure 3. Directed acyclic graph for the association of epicardial adipose tissue 
with atrial fibrillation.
Y
C L 
M
Corresponds to Table 3, Model 2. M, epicardial adipose tissue; Y, atrial fibrillation; C, (1) age, sex, cohort, smoking, 
alcohol intake, free thyroxine, thyroid-stimulating hormone, and time between measurements, (2) total cholesterol, 
high-density lipoprotein cholesterol, use of lipid-lowering medications, diastolic blood pressure, systolic blood pres-
sure, use of antihypertensive medications, prevalent coronary heart disease, and prevalent diabetes mellitus; L, waist 
circumference (omitted in this model due to collinearity with M). No interactions observed.
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Supplemental Figure 4. Final directed acyclic graph, stratified by waist circumference dichoto-
mized according to sex-specific clinical cutoffs.
M Y
C1 C2 
C3 
A
A, FT4; M, epicardial adipose tissue; Y, atrial fibrillation; C1, age, sex, cohort, smoking, alcohol intake, and time between 
measurements; C2, age, sex, cohort, smoking, alcohol intake, and predicted values using the following variables: total 
cholesterol, high-density lipoprotein cholesterol, use of lipid-lowering medications, diastolic blood pressure, systolic 
blood pressure, use of antihypertensive medications, prevalent coronary heart disease and prevalent diabetes mellitus 
(sensitivity analysis with original covariates); C3, age, sex, cohort, smoking, and alcohol intake. 
Building final directed acyclic graph for mediation analysis 
Conditions:
(1) The effect the exposure A has on the outcome Y is unconfounded conditional on C;
(2) The effect the mediator M has on the outcome Y is unconfounded conditional on (C, A);
(3) The effect the exposure A has on the mediator M is unconfounded conditional on C;
(4) None of the mediator-outcome confounders are themselves affected by the exposure.
Condition 4 is violated due to the relationship of A with several individual variables C; however, A is not associated 
with the composite of these variables. Due to the interaction of free thyroxine with waist circumference, all analyses 
are stratified by large and small waist circumference (sex-specific clinical cutoffs).
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Supplemental Table 1. Association of Z scores of TSH or FT4 with waist circumference*
or (95% ci )
model 1
or (95% ci )
model 2
TSH 1.17 (1.06; 1.28) 1.13 (1.02; 1.25)
FT4 0.82 (0.73; 0.92) 0.84 (0.74; 0.94)
Model 1: age, sex, cohort, alcohol intake, smoking, and time between laboratory measurement and scan. Model 
2: Model 1, total cholesterol, high-density lipoprotein cholesterol, use of lipid-lowering medications, systolic blood 
pressure, diastolic blood pressure, use of antihypertensive medications, prevalent diabetes mellitus, and prevalent 
coronary heart disease. *WC was stratified according to sex-specific clinical cutoffs. For women, small WC was defined 
as ≤88 cm, while large WC was defined as >88 cm. For men, small WC was defined as ≤102 cm, while large WC was de-
fined as >102 cm. Abbreviations: TSH, thyroid-stimulating hormone; FT4, free thyroxine; OR, odds ratio; CI, confidence 
interval; WC, waist circumference.
Supplemental Table 2. Proportions of the effect of Z scores FT4 on AF due to mediation and/or 
interaction with EAT, using all confounders of M→Y relation separately
excess risk (95% ci) Proportion attributable
Small waist circumference
CDE 0.076 (-0.154; 0.305) 84.3%
INTref -0.001 (-0.061; 0.024) -1.2%
INTmed 0.004 (-0.011; 0.014) 4.0%
PIE 0.012 (-0.014; 0.031) 12.9%
Total 0.090 (-0.140; 0.306) 100%
Large waist circumference
CDE 0.394 (-0.043; 0.675) 77.6%
INTref 0.080 (-0.149; 0.282) 15.6%
INTmed 0.013 (-0.038; 0.045) 2.5%
PIE 0.022 (-0.019; 0.046) 4.3%
Total 0.508 (0.063; 0.765) 100%
WC was stratified according to sex-specific clinical cutoffs. For women, small WC was defined as ≤88 cm, while large 
WC was defined as >88 cm. For men, small WC was defined as ≤102 cm, while large WC was defined as >102 cm. Ab-
breviations: CDE, controlled direct effect; CI, confidence interval; EAT, epicardial fat tissue; FT4, free thyroxine; INTref, 
reference interaction; INTmed, mediated interaction; PIE, pure indirect effect; TSH, thyroid-stimulating hormone; WC, 
waist circumference.
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abSTracT
background Thyroid hormones affect metabolism in various tissues, organs and 
systems. However, the overall impact of thyroid function on an individual’s vulner-
ability to adverse outcomes remains unclear. We therefore aimed to investigate the 
cross-sectional and prospective association of thyroid function with frailty index, 
a well-established measure of overall health, in a population-based, prospective 
cohort study.
methods Participants of the Rotterdam Study with baseline measurements of thyroid 
function and frailty index were eligible. The frailty index was measured at baseline 
and after a median follow-up time of 10.1 (interquartile range, 5.7 to 10.8) years. 
A higher frailty index indicated a worse health state. We assessed the association 
of thyroid function with frailty at baseline, frailty at follow-up, and frailty changes 
over time, adjusting for age, sex, cohort, smoking, alcohol intake, and education.
results We included 9640 participants (mean age, 64.9 years). There was a U-shaped 
association of TSH (P value, 0.0003) and FT4 (P value, <0.0001) with frailty at base-
line. There was no association of TSH, but a positive association of FT4 with frailty 
at follow-up and frailty changes over time (β, 1.22; 95% confidence interval, 0.73 to 
1.72 per 1 unit FT4).
conclusions In this population-based study, participants with low and high thyroid 
function were more likely to be frail than participants with normal thyroid function. 
However, only those with higher FT4 levels had an increased risk of becoming more 
frail over time. The identification of FT4 as a potential marker of health deterioration 
could have future implications regarding the prediction and prevention of frailty.
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inTroducTion
Frailty is a condition of reduced physiological reserves, decreased resistance to 
stressors and enhanced vulnerability to poor health outcomes, such as diseases, dis-
ability, falls, institutionalization and death.1 With the aging of the population, the 
prevalence of frailty is expected to rise.2 Therefore, various tools are being utilized 
to evaluate and identify vulnerable subjects.3 One of the most common measure-
ments is the frailty index, which has been validated as a robust predictor of adverse 
outcomes in many patient and community settings.3-6 The frailty index, also known 
as the “multidomain phenotype”, was developed to reflect the multidimensional 
and dynamic nature of frailty. It is composed of >30 items covering a broad range 
of health domains, and it is considered a useful tool to quantify overall health and 
its changes over time.7,8
Thyroid hormones, which are key regulators of metabolism, are likely to be im-
plicated in the development of frailty.9 So far, variations in thyroid hormone levels 
have been linked to alterations in cardiometabolic, cognitive and musculoskeletal 
functioning, which in turn contribute to a reduction in physiological capacity and 
resistance to stressors.9 Most previous research, however, has focused on the system-
specific effects of thyroid function, suggesting that lower thyroid hormone levels 
are associated with a higher risk of metabolic outcomes (ie, diabetes, dyslipidemia, 
and nonalcoholic fatty liver disease),10-12 whereas higher thyroid hormone levels 
are associated with a higher risk of cognitive decline, atrial fibrillation, and osteo-
porosis.13-17 Meanwhile, the overall impact of thyroid function on general health 
remains to be clarified. This could be important to further improve the prediction 
and prevention of health deterioration over time.
To date, only very few studies have investigated the association of thyroid func-
tion with frailty assessed either by the “physical phenotype” 18 or the Frail scale,19 
with inconsistent results. In a cross-sectional study assessing frailty by the Frail scale, 
higher free thyroxine (FT4) levels were associated with an increased frailty risk, but 
there was no association for thyroid-stimulating hormone (TSH).19 Another study 
assessing frailty by the “physical phenotype” showed that men with a low thyroid 
function (ie, highest TSH quintile) and women with a high thyroid function (ie, low-
est TSH quintile) had an increased frailty risk.18 Notably, both the Frail scale and 
the physical phenotype are derived from only 5 items mainly reflecting the physical 
aspect of frailty.20,21 What previous research is lacking, however, is the utilization 
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of a multidimensional tool that would be able to capture the pleiotropic effects of 
thyroid hormones on general health.
Therefore, in a large population-based prospective study of middle-aged and 
elderly subjects, we aimed to investigate the cross-sectional and prospective associa-
tion of thyroid function with the frailty index, a well-established measure of overall 
health.
meThodS
Study population
The Rotterdam Study is a prospective population-based cohort study that aims to 
investigate the determinants, occurrence, and progression of chronic diseases in 
the middle-aged and elderly. The objectives and study design have been described 
in detail previously.22 The Rotterdam Study was initiated in 1989, including 7983 
participants ≥55 years of age (RS I) residing in Ommoord district of Rotterdam, the 
Netherlands. In 2000, the study was extended with a second cohort of 3011 subjects 
(RS II). In 2006, a third cohort of 3932 subjects ≥45 years of age was added (RS III). 
Study participants undergo extensive follow-up medical examinations every 3 to 5 
years.
For the current study, baseline measurements were performed during the third 
visit of the first cohort (n=4797) and the first visits of the second (n=3011) and third 
(n=3932) cohorts of the Rotterdam Study (Supplemental Figure 1). A total of 9640 
participants with data available on thyroid function and frailty index at baseline 
were considered eligible. Of these, 6416 participants had repeated measurements 
on frailty index (Table 1).
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus University and by the Ministry of Health, Welfare and Sport of the Nether-
lands, implementing the Population Study Act Rotterdam Study. In accordance with 
the Declaration of Helsinki, all participants provided written informed consent.
assessment of thyroid function
Thyroid function was assessed at baseline in three study cohorts using the same 
method and assay. Concentrations of TSH, FT4, and thyroid peroxidase antibodies 
(TPOAbs) were measured on baseline serum samples stored at -80°C using the elec-
trochemiluminescence immunoassay ECLIA Roche. The reference ranges of serum 
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TSH (0.40 to 4.0 mIU/L) and serum FT4 (11 to 25 pmol/L; alternatively, 0.86 to 1.94 ng/
dL) were determined based on national guidelines and our previous studies.10,11,23 
The time of blood sampling was recorded. 99% of the blood samplings were per-
formed between 8.00 AM and 11.00 AM.
assessment of frailty index
Frailty was assessed by the frailty index, which is defined as the accumulation of 
health deficits including symptoms, signs, diseases and functional impairments.7 A 
45-item frailty index has been recently validated in the Rotterdam Study and has 
been described extensively elsewhere.5 In short, health deficits were selected using 
a stepwise procedure, on the basis of the following predefined criteria: (1) the defi-
cit is associated with health; (2) the prevalence or severity of the deficit generally 
increases with age; (3) the deficit is not too exceptional (ie, prevalence <5 %) or too 
Table 1. Baseline characteristics of 9640 participants* 
Total
Follow-up 
available
died before 
follow-up
no follow-up 
available
Number 9640 6416 2364 860
Age, years 64.9 (9.7) 61.8 (7.8) 74.6 (8.4) 62.2 (8.6)
Women, n (%) 5467 (56.7) 3709 (57.8) 1233 (52.2) 525 (61)
Smoking, n (%)
 current 2042 (21.2) 1321 (20.6) 506 (21.4) 215 (25.0)
 former 4549 (47.2) 3059 (47.7) 1124 (47.5) 366 (42.6)
 never 3010 (31.2) 2018 (31.5) 714 (30.2) 278 (32.3)
Education, n (%)
 Elementary 1189 (12.3) 595 (9.3) 469 (19.8) 125 (14.5)
 Lower secondary 3874 (40.2) 2555 (39.8) 957 (40.5) 362 (42.1)
 Higher secondary 2787 (28.9) 1897 (29.6) 670 (28.3) 220 (25.6)
 Tertiary 1720 (17.8) 1331 (20.7) 244 (10.8) 145 (16.9)
TSH, mIU/L, median (IQR) 1.9 (1.2-2.8) 1.9 (1.3-2.8) 1.8 (1.1-2.6) 1.9 (1.2-2.8)
FT4, ng/dL 1.2 (0.1) 1.2 (0.1) 1.2 (0.2) 1.2 (0.1)
TPOAb positive, n (%) 1272 (13.2) 870 (13.6) 282 (11.9) 120 (14.0)
TPOAb, kU/ml, median (IQR) 7.6 (5.0-13.6) 7.7 (5.0-13.8) 6.5 (5.0-12.6) 8.7 (5.2-14.7)
Use of thyroid medication, n (%) 308 (3.2) 210 (3.3) 71 (3.0) 27 (3.1)
Thyroid surgery, n (%) 167 (1.7) 100 (1.6) 49 (2.1) 18 (2.1)
Frailty index† 17.1 (8.7) 15.0 (7.1) 22.7 (10.4) 16.7 (8.0)
*Data are mean (standard deviation), unless otherwise specified. †To increase the interpretability of the risk estimates, 
the frailty index score was multiplied by 100. Abbreviations: TSH, thyroid-stimulating hormone; IQR, interquartile 
range; FT4, free thyroxine; TPOAb, thyroid peroxidase antibodies (cutoff 35 kU/ml).
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common (ie, prevalence >80%).4,5 In case of a high correlation between variables 
of the same domain (r >0.7), only the one with the highest correlation with age 
was eventually included in the score.4,5 To be able to evaluate changes of frailty 
over time, we used a slightly adapted version of the Rotterdam Study frailty index 
score that consisted of 38 health-related variables covering various health domains, 
including functional status (n=13), health conditions (n=6), diseases (n=6), cognition 
(n=6), mood (n=4), and nutritional status (n=3).24 The remaining 7 items (namely 
vitamin D, sex hormone binding globulin, mobility, uric acid, pro-B-type natriuretic 
peptide, C-reactive protein, and homocysteine) were not assessed at follow-up and 
were therefore removed from the original Rotterdam Study frailty index score.24 To 
obtain a stable frailty index score, it is recommended to have data available on at 
least 20 items.4 Therefore, participants of the Rotterdam Study with <20 observed 
items were excluded. For individuals with data available on ≥20 items, missing values 
were imputed using multiple imputation.5 Deficits were dichotomized or catego-
rized into a score ranging from 0 (deficit absent) to 1 (deficit present) (Supplemental 
Table 1). Per person, the frailty index score was calculated as the sum of present 
deficits divided by the total number of potential deficits. For instance, if 10 out of 38 
deficits were present, the frailty index would be 10/38. A higher score of the frailty 
index indicated a worse health state. In order to increase the interpretability of our 
risk estimates, frailty index score was multiplied by 100.
additional measurements
The baseline home interview provided extensive information on medical history, 
tobacco smoking, alcohol consumption, education level, and medication. Smoking 
habits were categorized as current, past, and never smoking. Education level was 
classified as low, intermediate, and high.
Statistical analysis
We performed ordinary least-squares linear regression, using restricted cubic splines 
with three knots to allow for potential nonlinearity. First, we cross-sectionally inves-
tigated the association of thyroid function (ie, TSH and FT4 levels) with the frailty 
index at baseline. Second, we investigated the association of thyroid function with 
the frailty index at follow-up. Third, we prospectively investigated the association 
of thyroid function with changes in the frailty index over time (calculated by sub-
tracting the frailty index at baseline from the frailty index at follow-up). Potential 
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confounders were selected on the basis of biological confounding plausibility. The 
first analysis was adjusted for age, sex, cohort, smoking status, alcohol intake, 
and education level. The second and third analyses were additionally adjusted for 
the frailty index at baseline and time interval between the measurements of the 
frailty index. To assess the potential role of thyroid autoimmunity on frailty, we 
also investigated the cross-sectional and prospective association of TPOAb with the 
frailty index, additionally adjusting for TSH or FT4 levels. TSH and TPOAb values 
were logarithmically transformed, because of their skewed distribution. All models 
were tested for effect modification by separately adding product interaction terms 
of TSH, FT4 or TPOAbs with each covariate of the multivariable model, but none of 
the interaction terms were significant.
Multiple imputations were performed for covariates with missing data (<5% for 
all covariates). Statistical analyses were performed using R statistical software (rms 
package, R project, Institute for Statistics and Mathematics, R Core Team, version 
3.2.2) and SPSS version 21 (IBM SPSS).
Sensitivity analyses
We performed several analyses to test the robustness of our findings. (1) We reran 
the cross-sectional analysis using the original 45-item frailty index instead of the 
adapted frailty index. (2) We restricted the cross-sectional analysis to participants 
with both baseline and prospective data on the frailty index. (3) We restricted the 
cross-sectional and prospective analyses to: (i) participants without past thyroid 
surgery and not using thyroid medications; (ii) participants with thyroid function 
within the reference range, without past thyroid surgery and not using thyroid 
medications. (4) To address the issue of attrition, we used the inverse probability 
weighting method. We fitted two logistic regression models predicting the pos-
sibility of having follow-up data. The first model used as covariates the baseline 
frailty index, age, sex, cohort, smoking status, alcohol intake, education level, and 
TSH. The second model used as covariate only TSH. The stabilized weights for each 
participant were calculated as the predicted probability of the second model di-
vided by that of the first model. Subsequently, we used the stabilized weights to 
examine the association of TSH with frailty changes over time. The analyses were 
also repeated for FT4. (5) In our prospective analysis, we added product interac-
tion terms of thyroid parameters with the frailty index at baseline to test for effect 
modification by the baseline health status of participants. (6) To explore a potential 
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influence of the time of blood sampling or thyroid autoimmunity on our results, our 
cross-sectional and prospective analyses were additionally adjusted for the time of 
blood withdrawal (recorded in hours and minutes) or TPOAb levels.
reSulTS
Baseline characteristics of 9640 eligible participants are shown in Table 1. The mean 
age was 64.9 years and 56.7% were women. The median TSH was 1.9 mIU/L, with an 
interquartile range of 1.2 to 2.8 mIU/L. Of participants, 3.0% had TSH below, 86.8% 
within, and 10.2% above the reference range. The mean (standard deviation) FT4 
was 1.2 (0.1) ng/dL. Of participants, 1.2% had FT4 below, 98.4% within, and 0.4% 
above the reference range. The mean (standard deviation) frailty index was 17.1 
(8.7), with a range of 0 to 66.4 (Table 1). After a median follow-up time of 10.1 
(interquartile range, 5.7 to 10.8) years, the frailty index was remeasured in 6416 par-
ticipants. Of participants, 2364 died before having a follow-up frailty measurement. 
The remaining 860 participants did not have complete follow-up data available on 
frailty (Table 1). The median TSH and mean FT4 concentrations at baseline were 
very similar among participants who died, those with repeated measurements of 
frailty, and those without follow-up data available on frailty (Table 1). Participants 
with prospective data had a lower frailty index than those without prospective data 
(Table 1).
cross-sectional analysis: thyroid function and frailty index at baseline
There was a U-shaped association of both TSH (P value, 0.0003) and FT4 levels (P 
value, <0.0001) with the baseline frailty index (Figure 1a). Results remained similar 
after using the original 45-item frailty index (Supplemental Figure 2a), after ex-
cluding participants without prospective data on frailty (Supplemental Figure 2b), 
after excluding participants with known thyroid disease (Supplemental Figure 2c), 
and after additionally adjusting for the time of blood withdrawal or TPOAb levels. 
Among euthyroid participants, there was a U-shaped association of FT4 with frailty 
index (P value, <0.0001), but no association of TSH with frailty index (P value, 0.3) 
(Supplemental Figure 3a).
Thyroid function and frailty 161
3
Thyroid function and frailty index at follow-up
TSH was not associated with frailty index at follow-up (β, 0.05; 95% confidence 
interval [95% CI], -0.11 to 0.21 per 1 unit logTSH) (Figure 1b). Increasing FT4 levels 
were associated with a higher frailty index at follow-up (β, 1.22; 95% CI, 0.73 to 1.72 
per 1 unit FT4) (Figure 1b).
Prospective analysis: thyroid function and changes in frailty index
There was no association of TSH (β, 0.05; 95% CI, -0.11 to 0.21 per 1 unit logTSH) and 
a positive association of FT4 with frailty changes over time (β, 1.22; 95% CI, 0.73 to 
1.72 per 1 unit FT4; Figure 2). Results remained similar after excluding participants 
with known thyroid disease (Supplemental Figure 2d), after additionally adjusting 
Figure 1. Association of thyroid function with the frailty index.
lnTSH
(mIU/l)
B
as
el
in
e 
 F
I
FT4
(ng/dl)
Fo
llo
w
-u
p
 F
I
Fo
llo
w
-u
p
 F
I
a
B
as
el
in
e 
FI
b
P value 0.0003
TSH
(mIU/l)
0.02 0.1 7.3 34.5
P value < 0.0001
-4 -2 0 2 4
18
20
22
24
26
0.5 1 1.5 2 2.5
-4 -2 0 2 4
0.02 0.1 1 7.3 34.5
1
18
0.5 1 1.5 2 2.5
20
22
24
26
18
20
22
24
26
18
20
22
24
26
lnTSH
(mIU/l)
FT4
(ng/dl)
TSH
(mIU/l)
P value 0.5
β, 0.05 (-0.11; 0.21)
P value 0.01
β, 1.22 (0.73; 1.72)
a. Cross-sectional association of thyroid function with frailty index at baseline (TN, 9640); b. Association of thyroid 
function with the frailty index at the end of the follow-up (TN, 6416). We used linear regression models with restricted 
cubic splines. Predicted means of frailty index (black lines) with 95% confidence intervals (gray areas) are plotted 
against TSH and FT4 concentrations. Dashed lines indicate the limits of TSH or FT4 reference ranges. A higher value 
of frailty index represents a worse health state. P values are for the plotted association. Abbreviations: TSH, thyroid-
stimulating hormone; FT4, free thyroxine; FI, frailty index, TN, total number.
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for the time of blood withdrawal or TPOAb levels. The association became stronger 
after the inverse probability weighting (β, 0.19; 95% CI, -0.03 to 0.42 per 1 unit 
logTSH; β, 1.99; 95% CI, 0.97 to 3.0 per 1 unit FT4). Among euthyroid participants, 
the association was not statistically significant (β, 0.18; 95% CI, -0.11 to 0.48 per 1 
unit logTSH; β, 1.0; 95% CI, -0.17 to 2.18 per 1 unit FT4) (Supplemental Figure 3b). 
Also, the interaction terms of TSH and FT4 with the frailty index at baseline were not 
statistically significant.
TPoab and frailty index
In the cross-sectional analysis, TPOAb were not associated with frailty index (β, -0.01; 
95% CI,-0.15 to 0.13 per 1 unit logTPOAb; Supplemental Figure 4). In the prospective 
analysis, there was an inverse U-shaped association of TPOAb with frailty changes 
over time (P value, 0.0002; Supplemental Figure 4). Results remained similar after 
additionally adjusting for TSH or FT4.
diScuSSion
In this large population-based cohort study, participants with low and high thyroid 
function were more likely to be frail than participants with normal thyroid function. 
Figure 2. Prospective association of thyroid function with changes in the frailty index.
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However, only those with higher FT4 levels had an increased risk of becoming more 
frail over time.
Thyroid hormones exert pleiotropic effects on nearly all organs and sys-
tems,9,10,12-14 the resultant of which can be reflected in overall health. However, 
whereas most previous research has focused on the system-specific effects of thyroid 
function,13,14,16,17,23,25-27 our study provides novel insights into the impact of thyroid 
function on general health. Most importantly, our findings suggest that high cir-
culating FT4 levels can contribute to health deterioration over time. This can be 
attributed to the combination of many deleterious system-specific effects of excess 
thyroid hormones, as arrhythmias, hemodynamic changes, hypercoagulability, neu-
rodegeneration, and reduction in bone mineral density. In line, large prospective 
population-based studies have reported that subjects with high FT4 levels have an 
increased risk of developing a broad range of adverse outcomes, including atrial 
fibrillation, chronic kidney disease, age-related macular degeneration, dementia, 
osteoporosis, and fractures.13,14,16,17,25,26 A more general pathway linking high thyroid 
function to frailty could be related to the perturbation of the prooxidant-antioxi-
dant balance.28,29 Excess circulating thyroid hormones stimulate the production of 
reactive oxygen species via accelerating basal metabolism and increasing oxygen 
consumption.30 In turn, reactive oxygen species predispose to altered gene expres-
sion, mitochondrial dysfunction, and cumulative cellular damage,31 which increase 
the susceptibility to physical, cognitive, and functional decline. Conversely, low 
thyroid function can reduce the frailty risk via decreasing basal metabolic rate and 
promoting energy conservation.32 As shown in experimental research, age-related 
chronic disorders occur less often in the mutant hypothyroid dwarf mice than in the 
wild-type mice.33
Thyroid autoimmunity could additionally be involved in the development of 
frailty. To date, the association of thyroid autoimmunity with frailty risk has been 
investigated in only one population-based study, reporting a low frailty risk in 
TPOAb-positive women.34 However, this study was cross-sectional, assessed frailty by 
the physical phenotype and included only women aged ≥65 years of age (n=641). 
We addressed some limitations of this study, by exploring the prospective associa-
tion of TPOAb levels with the risk of frailty assessed by the multidomain phenotype, 
in a much larger population of >6000 middle-aged and elderly men and women 
(n=6416). Our results point toward the possibility of protective autoimmunity 35 and 
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confirm that the association of TPOAbs with frailty risk is independent of thyroid 
function.
During follow-up, the frailty risk increased with higher FT4 levels. Based on the 
negative feedback mechanism of the hypothalamus-pituitary-thyroid axis, one 
would expect an increased frailty risk with lower TSH levels. However, TSH was not 
associated with frailty risk in our study. Similarly, many other population-based 
cohort studies have suggested that in middle-aged and elderly subjects, FT4 rather 
than TSH levels can predict various adverse outcomes, including atrial fibrillation, 
dementia and mortality.15,27,36 These observations may reflect an alteration in the 
TSH-FT4 set point of the negative feedback mechanism, due to the ageing process.37 
After restricting the study population to euthyroid participants, the association of 
thyroid function with frailty risk attenuated and/or lost statistical significance. This 
suggests that elevated levels of FT4 have a larger effect on frailty risk over time as 
compared to FT4 levels within the reference range.
Our cross-sectional and prospective analyses examined the relationship of thyroid 
function with the likelihood of being frail and the risk of becoming more frail over 
time, respectively. Cross-sectional designs, however, do not provide evidence on the 
temporal relationship between the exposure and outcome. Therefore, the results of 
our cross-sectional analysis may be partly influenced by reverse causation. In other 
words, health-related problems underlying a high frailty index can potentially alter 
thyroid function parameters. Notably, our participants with low thyroid function 
had an increased likelihood of being frail, but did not have an increased risk of 
becoming more frail over time. This can be explained by the condition of non-
thyroidal illness syndrome, which is typically characterized by low thyroid hormones 
and normal TSH levels, secondary to a poor health status.38
Alternatively, the discrepancy between our cross-sectional and prospective find-
ings could have been explained by the selective dropout of participants with low 
thyroid function. This is unlikely, given that the median TSH levels and the mean 
FT4 levels among participants with prospective data were similar to those without 
prospective data. Another important issue is whether the participants of our pro-
spective analysis were representative of the baseline sample population. Indeed, 
participants with prospective data had a lower baseline frailty index than did those 
without prospective data, which indicates that the more frail participants at base-
line may have died during follow-up. However, we do not expect our conclusions 
to be compromised by the selective dropout of frail participants for several reasons. 
Thyroid function and frailty 165
3
First, we obtained consistent results after restricting our cross-sectional analyses to 
participants with complete follow-up data on the frailty index. Second, the prod-
uct interaction term of thyroid function with the frailty index at baseline was not 
statistically significant, suggesting that our prospective findings were independent 
of the baseline health status of participants. Third, we addressed the issue of at-
trition by using the inverse probability weighting method. Originally, the effect of 
FT4 on frailty seemed to wane over time, as it was smaller in the prospective than 
in the cross-sectional analysis. However, the effect of FT4 on frailty became stronger 
after the inverse probability weighting, indicating that the selective dropout of 
participants may have led to an underestimation rather than an overestimation of 
our prospective results.
To the best of our knowledge, this is the first population-based cohort study 
that explores the relationship of thyroid function with the frailty index. The latter 
represents a well-validated frailty measure that is considered useful to evaluate 
overall health and trajectories of health over time.3 Our frailty index data were 
available at two time points with a long follow-up time interval, allowing us to 
explore the relation between thyroid function variations and health changes over 
time. The frailty index characteristics of our population were similar to most other 
populations of similar age.4,6,39 Moreover, our study is the largest investigation on 
thyroid function and frailty. The large sample size enabled us to perform multiple 
sensitivity analyses. Additionally, to our knowledge, our study is the first to examine 
the prospective association of TPOAb levels with frailty risk. Other strengths include 
the well-characterized population-based study sample, the laboratory assessment of 
thyroid parameters and the available data on potential confounding factors.
Several limitations should also be mentioned. Considering the observational 
character of our study, one can argue that reverse causation may have affected 
even our prospective findings. This is very unlikely, given that non-thyroidal illness 
syndrome is typically characterized by low thyroid hormones;38 whereas we found 
an increased frailty risk among participants with high rather than low FT4 levels. 
Moreover, we did not have repeated measurements of thyroid function. This, how-
ever, would tend to underestimate the association between thyroid function and 
frailty risk, based on the low intra-individual variability of TSH and FT4 levels.40 Also, 
we did not measure serum triiodothyronine levels. Nevertheless, TSH and FT4 are 
considered the most relevant measurements of thyroid function in clinical practice. 
In certain circumstances (eg, pregnancy or critical illnesses), substances interfering 
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with the FT4 immunoassay can alter the affinity of thyroid hormones to plasma 
proteins. In our study, there were no data available on thyroid hormone-binding 
proteins. However, the concentrations of these proteins were most likely unaltered, 
given that our population consists of community-dwelling middle-aged and elderly 
individuals. Moreover, the possibility of residual confounding cannot be ruled out, 
even though we adjusted for various potential confounders. Lastly, our findings 
require confirmation in other ethnicities, given that the Rotterdam Study includes 
predominantly white participants.
conclusions
In this large population-based cohort study, participants with low and high thyroid 
function are more likely to be frail than are participants with normal thyroid func-
tion. However, only those with higher FT4 levels have an increased risk of becoming 
more frail over time. Our study provides novel insights into the possible impact of 
thyroid function on overall health, suggesting that elevated circulating FT4 levels 
can constitute a useful marker of health deterioration. Therefore, our findings may 
have future implications regarding the prediction and prevention of frailty. Further 
studies are warranted to replicate our results in other population settings.
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Supplemental Figure 1. Measurements of thyroid function and frailty index.
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(baseline) 
Frailty index  
(end of follow-up)
Median follow-up time 10.14 y 
Thyroid function and frailty index were measured at baseline, during the first visit of the third cohort (RS I.3), the first 
visits of the second and third cohorts (RS II.1, RS III.1). Frailty index was remeasured at the end of the follow-up, during 
the fifth visit of the first cohort (RS I.5), the third visit of the second cohort (RS II.3) and the  second visit of the third 
cohort  (RS III.2). Abbreviation: RS, Rotterdam Study.
Supplemental Figure 2. Sensitivity analyses.
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a. Cross-sectional association of thyroid function with original frailty index score (TN, 9640); b. Cross-sectional associa-
tion of thyroid function with frailty index, restricted to participants with follow-up data on frailty index (TN, 6416); 
c. Cross-sectional association of thyroid function with frailty index at baseline, after excluding participants with past 
thyroid surgery and users of thyroid medication (TN, 9199); d. Prospective association of thyroid function with changes 
in frailty index, after excluding participants with past thyroid surgery and users of thyroid medication (TN, 6126). The 
changes in frailty index were calculated by subtracting the frailty index at baseline from frailty index at follow-up. 
We used linear regression models with restricted cubic splines. Predicted means of frailty index (black lines) with 95% 
confidence intervals (gray areas) are plotted against TSH and FT4 concentrations. Dashed lines indicate the limits of 
TSH or FT4 reference ranges. A higher value of frailty index represents a worse health state. P values are for the plotted 
association. Abbreviations: TSH, thyroid-stimulating hormone; FT4, free thyroxine; FI, frailty index; TN, total number.
172 Chapter 3.1
Supplemental Figure 3. Association of thyroid function with frailty index among euthyroid 
participants.
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the frailty index at baseline from frailty index at follow-up. We used linear regression models with restricted cubic 
splines. Predicted means of frailty index (black lines) with 95% confidence intervals (gray areas) are plotted against 
TSH and FT4 concentrations. A higher value of frailty index represents a worse health state. P values are for the plotted 
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Supplemental Figure 4. Association of TPOAb with frailty index.
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a. Cross-sectional association of TPOAb with frailty index at baseline (TN, 9640); b. Prospective association of TPOAb 
with changes in frailty index (TN, 6416). The changes in frailty index were calculated by subtracting the frailty index 
at baseline from frailty index at follow-up. We used linear regression models with restricted cubic splines. Predicted 
means of frailty index (black lines) with 95% confidence intervals (gray areas) are plotted against TPOAb concentra-
tions. A higher value of frailty index represents a worse health state. Dashed lines indicate the cutoff of TPOAb positiv-
ity (35 kU/ml). P values are for the plotted association. Abbreviations: TPOAb, thyroid peroxidase antibodies; FI, frailty 
index; TN, total number.
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Supplemental Table 1. Items of the frailty index score
items additional information on the items cutoff values
1 Dressing and 
grooming a
Able to get the clothes from closets 
or drawers; able to dress; able to 
shampoo the hair; able to comb the 
hair or do the make up
without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
2 Arising a Able to stand up from a straight chair 
without using the arms for support; 
able to get in and out of bed
without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
3 Eating a Able to cut meat; able to lift a full cup 
or glass to the mouth; able to open a 
new carton of milk
without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
4 Walking a Able to walk outdoors on flat ground; 
able to climb up five steps
without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
5 Hygiene a Able to wash and dry the entire body; 
able to take a shower or bath
without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
6 Reach a Able to reach and get down a 1 kg 
object from just above the head; able 
to bend down to pick up clothing from 
the floor
without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
7 Grip a Able to open a car door; able to 
open jars which have been previously 
opened
without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
8 Riding a bike b Able to ride a bike without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
9 Telephone b Able to use the telephone without any difficulty = 0; with some 
difficulty or using a customized phone = 
0.33; with much difficulty = 0.66; unable 
to do = 1
10 Meal b Able to prepare meals without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
11 Gardening b Able to maintain a garden without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
12 Landry b Able to do the laundry without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
13 Financial b Able to do finances without any difficulty = 0; with some 
difficulty = 0.33; with much difficulty = 
0.66; unable to do = 1
14 Depressed affect c I felt that I could not shake off the 
blues even with help from family or 
friends; I felt depressed; I thought my 
life had been a failure; I felt lonely; I 
had crying spells; I felt sad
rarely or none of the time = 0; some or a 
little of the time = 0.33; occasionally or a 
moderate amount of time = 0.66; most or 
all of the time = 1
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Supplemental Table 1. Items of the frailty index score (continued)
items additional information on the items cutoff values
15 Positive affect c I felt that I was just as good as other 
people; I felt hopeful about the future; 
I was happy; I enjoyed life
rarely or none of the time = 1; some or a 
little of the time = 0.66; occasionally or a 
moderate amount of time = 0.33; most or 
all of the time = 0
16 Somatic and 
retarded activity c
I did not feel like eating; my appetite 
was poor; I had trouble keeping my 
mind on what I was doing; I felt that 
everything I did was an effort; I felt 
fearful; my sleep was restless; I talked 
less than usual; I could not get going
rarely or none of the time = 0; some or a 
little of the time = 0.33; occasionally or a 
moderate amount of time = 0.66; most or 
all of the time = 1
17 Interpersonal c I was bothered by things that usually 
don’t bother me; people were 
unfriendly; I felt that people dislike me
rarely or none of the time = 0; some or a 
little of the time = 0.33; occasionally or a 
moderate amount of time = 0.66; most or 
all of the time = 1
18 Falling How often did you fall over the past 12 
months?
no falling = 0; less than once a month = 
0.5; more than once a month = 1
19 Joint complains Did you have joint pain or other 
complaints from the knees, hips, back 
or hands?
no = 0; yes = 1
20 Forgetfulness Do you sometimes forget what you 
were about to do?
no = 0; yes = 1
21 Aphasia Do you have difficulties finding the 
right words?
no = 0; yes = 1
22 Liver enzymes d Aspartate aminotransferase, alanine 
aminotransferase, gamma-glutamyl 
transferase
all values within the range = 0; abnormal 
values = 1
23 Creatinine d Males: 65-115 µmol/L = 0; other values = 1
Females: 55-90 µmol/L = 0; other values = 1
24 Hyperlipidemia d statin use and/or cholesterol levels >6.5 
mmol/L; no statin use and cholesterol 
levels 2.9-6.5 mmol/L
25 High density 
lipoprotein d
values ≥1.55 = 0; values <1.55 = 1
26 Systolic blood 
pressure d
Measured three times, average was 
taken
values 90-140 = 0; values 140-160 = 0.5; 
values <90 = 0.5; values >160 = 1
27 Mini Mental State 
Examination
unimpaired >25 = 0; impaired ≤25 =1
28 Letter-Digit 
Substitution Test
The number of correct digits above the mean or less than 1 sd below 
the mean = 0; 1 sd below the mean = 0.5; 
2 sd below the mean = 1
29 Stroop test above the mean or less than 1 sd above 
the mean = 0; 1 sd above the mean = 0.5; 
2 sd above the mean = 1
30 Word Fluency test above the mean or less than 1 sd below 
the mean = 0; 1 sd below the mean = 0.5; 
2 sd below the mean = 1
31 Cancer no = 0; yes = 1
32 Lung condition 
(COPD/Asthma)
no = 0; yes = 1
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Supplemental Table 1. Items of the frailty index score (continued)
items additional information on the items cutoff values
33 Coronary heart 
disease
Prevalent coronary heart disease no = 0; yes = 1
34 Stroke Prevalent stroke no = 0; yes = 1
35 Diabetes mellitus no = 0; high glucose levels= 0.5; yes = 1
36 BMI BMI < 18.5 = underweight
BMI ≤25 and ≥18.5 = normal weight
BMI <25 and ≤30 = overweight
BMI <30 = obese
normal weight = 0; overweight = 0.5; 
obese or underweight = 1
37 Hospital 
admission
Last 12 months no = 0; yes = 1
38 Age-related 
macular 
degeneration
Fundus photography after 
pharmacologic mydriasis. The eyes 
of each participant were graded and 
classified separately. The eye with the 
more severe grade was used to classify 
the person.
0 = 5-year risk of developing advanced 
age-related macular degeneration in at 
least one eye is 0.5%; 0.25 = 5-year risk 
is 3%; 0.50 = 5-year risk is 12% ; 0.75 = 
5-year risk is 25%; 1= 5-year risk is 50%
The original frailty index score, which was designed and validated among 11539 participants of the RS, consisted of 45 
variables. However, 7 items from the original RS frailty index (namely vitamin D, sex hormone binding globulin, mobil-
ity, uric acid, proBNP, C-reactive protein and homocysteine) were not assessed at follow-up. In order to assess frailty 
changes over time, these items were removed, resulting in an adapted RS frailty index that consisted of the remaining 
38 health-related variables. Sources: a Stanford Health Assessment Questionnaire; b Lawton Instrumental Activities of 
Daily Living scale; c The CESD scale: a self-report depression scale; d Serum blood measurement; cutoff values derived 
from the Laboratory guide Erasmus Medical Center Rotterdam. Abbreviations: sd, standard deviation; RS, Rotterdam 
Study; BMI, body mass index.
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abSTracT
background Gait is an important health indicator and poor gait is strongly associ-
ated with disability and risk of falls. Thyroid dysfunction is suggested as a potential 
determinant of gait deterioration, but this has not been explored in a population-
based study.
methods We therefore investigated the association of thyroid function with gait 
patterns in 2645 participants from the Rotterdam Study with data available on 
TSH (thyroid-stimulating hormone), FT4 (free thyroxine), and gait, without known 
thyroid disease or dementia. The primary outcome was global gait (standardized Z 
score), while secondary outcomes included gait domains (rhythm, variability, phases, 
pace, base of support, tandem, turning), and velocity. Gait was assessed by electronic 
walkway.
results Multivariable regression models revealed an inverted U-shaped association 
of TSH (P value, <0.001), but no association of FT4 concentrations with global gait (P 
value, 0.2). TSH levels were positively associated with base of support (P value, 0.01) 
and followed an inverted U-shaped curve with tandem (P value, 0.002) and velocity 
(P value, 0.02). Clinical and subclinical hypothyroidism were associated with worse 
global gait than euthyroidism (β, -0.61; 95% confidence interval, -1.03 to -0.18; and 
β, -0.13; 95% confidence interval, -0.26 to -0.00; respectively). In euthyroid partici-
pants, higher thyroid function was associated with worse gait patterns.
conclusions Both low and high thyroid function are associated with alterations in 
global gait, tandem, base of support, and velocity.
Thyroid function and gait patterns 181
3
inTroducTion
Gait is an important marker of general health. Disturbances in gait gradually increase 
with advancing age and affect approximately one third of community-dwelling 
individuals older than 60 years.1 Gait impairment has a substantial impact on quality 
of life and is strongly associated with increased risk of falls, which can in turn cause 
soft-tissue injuries, fractures, and death.2,3 Quantitative gait assessment comprises 
many parameters that can be summarized into seven independent domains, namely 
rhythm, variability, phases, pace, base of support, tandem, and turning (Figure 1).4,5 
These gait domains reflect distinct functional abilities and their investigation is 
crucial to identify novel modifiable contributors to gait deterioration.5
Thyroid hormones regulate metabolism in most tissues, including neurological 
and musculoskeletal systems, whose integrated functioning is reflected in gait.6-8 
As gait disturbances, thyroid dysfunction increases in prevalence with advancing 
age. However, the clinical symptoms of thyroid dysfunction become less pronounced 
among older adults9 and this may result in a diagnostic delay and increased risk of 
systemic complications. Research to date has suggested a possible role of thyroid 
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Figure 1. Walking conditions.
The three walking conditions, including five gait domains for normal walk (rhythm, variability, phases, pace, base of 
support), one for turn (turning) and one for tandem walk (tandem).
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dysfunction in gait impairment. Adult mice lacking the thyroid-hormone activat-
ing enzyme type 2 deiodinase have shown progressive gait impairment in the late 
stages of life.10 In humans, several case series11,12 and case reports13-15 have shown a 
restoration of gait disturbances after treatment of thyroid disease.
Thyroid function in the general population has been linked to gait velocity, which 
constitutes only one of the parameters in the pace domain.16,17 However, the link 
of thyroid function with gait and its spatiotemporal aspects remains unexplored. 
Therefore, we aimed to investigate the association of thyroid function with global 
gait and its separate domains, in a large population-based cohort of middle-aged 
and elderly subjects.
meThodS
Study population
The Rotterdam Study is an ongoing prospective population-based cohort study that 
investigates chronic diseases in the middle-aged and elderly. The objectives and 
study design of the Rotterdam Study have been described in detail elsewhere.18 
Rotterdam Study was initiated in 1990, including 7983 participants aged 55 years or 
older (RS I). In 2000, the cohort was expanded with 3011 participants aged 55 or older 
(RS II). In 2006, a third cohort of 3932 participants aged 45 years and over was added 
(RS III). As of now, the Rotterdam Study comprises a total of 14926 participants, who 
undergo extensive follow-up medical examinations every 3 to 5 years. From 2009 
onwards, quantitative gait assessment was included in the study protocol. Between 
March 2009 and March 2012, 3651 participants of the Rotterdam Study were invited 
for gait assessment. An overview on the selection of study participants can be found 
in the flowchart (Supplemental Figure 1).
A total of 2857 subjects had complete information on thyroid function and gait. 
Of these, we excluded 212 subjects with at least one out of several conditions: (1) 
dementia diagnosis (n=14); (2) thyroid medication use (n=79); (3) history of thyroid 
disease (n=192) and (4) previous thyroid surgery (n=33) (Supplemental Figure 1). The 
remaining 2645 eligible participants were enrolled in the study.
The Medical Ethics Committee of the Erasmus University and the Ministry of 
Health, Welfare and Sport of the Netherlands have approved the study protocols, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rot-
terdam Study)”. The methods were performed in accordance with the approved 
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guidelines. All included participants provided written informed consent in accor-
dance with the Declaration of Helsinki.
assessment of thyroid function
Thyroid function tests were performed during the third visit of the first cohort (RS 
I.3), the first visit of the second cohort (RS II.1) and the first visit of the third cohort 
(RS III.1) using the same method and assay. Concentrations of thyroid-stimulating 
hormone (TSH), free thyroxine (FT4) and thyroid peroxidase antibodies (TPOAb) 
were measured on baseline serum samples stored at -80°C using the electrochemi-
luminescence immunoassay, ECLIA, Roche. We determined the reference range of 
serum TSH as 0.40–4.0 mIU/L and serum FT4 as 11–25 pmol/L (alternatively 0.86–1.94 
ng/dL), according to national guidelines and our previous studies.19,20 Euthyroidism 
was defined as serum TSH within the reference range. Subclinical hypothyroidism 
was defined as serum TSH >4.0 mIU/L and FT4 levels within the reference range. 
Overt hypothyroidism was defined as serum TSH >4.0 mIU/L and FT4 levels <11 
pmol/L. Subclinical hyperthyroidism was defined as serum TSH <0.40 mIU/L and FT4 
levels within the reference range. Overt hyperthyroidism was defined as serum TSH 
<0.40 mIU/L and FT4 levels >25 pmol/L. TPOAb positivity was defined as TPOAb levels 
above the cutoff of 35 kU/ml, in accordance with the recommendations of the assay 
manufacturer.19,20
assessment of gait
Quantitative gait assessment was performed during the fifth visit of the first cohort 
(RS I.5), the third visit of the second cohort (RS II.3) and the first visit of the third co-
hort (RS III.1). Gait was evaluated using a 5.79 m long walkway (GAITRite Platinum; 
CIR systems, Sparta, NJ: 4.88-m active area; 120 Hz sampling rate). The reliability 
and validity of this device have been previously established.4,21-23 The standardized 
gait protocol comprises three walking conditions: normal walk, turning, and tan-
dem walk (Figure 1). In the normal walk, participants walked at their usual pace 
across the walkway. This walk was repeated eight times, of which the first recording 
was considered a practice walk and excluded from the analyses. In turning, par-
ticipants walked at their usual pace, turned halfway, and returned to the starting 
position. In the tandem walk, participants walked heel-to-toe on a line across the 
walkway. Based on the recorded footfalls, the walkway software calculated thirty 
gait parameters, including twenty five from the normal walk, two from turning, 
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and three from the tandem walk. Subsequently, principal component analysis (PCA) 
was performed to avoid multiple testing and collinearity across the variables. While 
capturing the largest amount of variance, PCA summarizes gait parameters into 
seven independent gait domains: rhythm, variability, phases, pace, base of support, 
tandem, and turning.5 Rhythm reflects cadence and stride time; variability reflects 
variations in length and time among strides; phases reflects double support time 
and double support as a percentage of the gait cycle; pace reflects stride length 
and gait velocity; base of support reflects stride width and stride width variability; 
tandem reflects errors in tandem walking; turning reflects turning time and the 
number of turn steps.5 When necessary, gait domains were inverted so that lower 
values represent “worse” gait. Global gait was calculated by averaging gait domains 
into a standardized Z score.5 Gait velocity was additionally included in our analysis 
in order to compare our findings with previous studies investigating the association 
between thyroid function and gait velocity.16,17
additional measurements
The baseline home interview provided information on medical history, tobacco 
smoking, alcohol consumption, education level, medication, knee and hip pain or 
stiffness. Participants were categorized based on their smoking status (current, past 
and never smokers) and education level (low, intermediate and high). Height and 
weight were measured during the examinations at the research center. Stroke cases 
were reviewed and verified by an experienced vascular neurologist using hospital 
letters, information from practitioners and nursing home physicians. Depressive dis-
orders were evaluated based on the Centre for Epidemiological Studies Depression 
Scale (CESD) questionnaire. A score above 16 was considered indicative of a depres-
sive disorder.24 Cerebellar cortical volume and intracranial volume were examined 
by standardized magnetic resonance imaging (MRI) scanning of the brain.18
Statistical analysis
We investigated the association of thyroid parameters (TSH, FT4, and TPOAb positiv-
ity) with global gait and spatiotemporal gait components, by performing ordinary 
least-squares linear regression. The primary outcome was global gait, while second-
ary outcomes included gait domains (ie, rhythm, variability, phases, pace, base of 
support, tandem, and turning), and gait velocity. We fitted restricted cubic splines 
to allow for potential nonlinearity. Moreover, we evaluated global gait and gait ve-
Thyroid function and gait patterns 185
3
locity throughout thyroid function categories, with euthyroid subjects as reference 
group. Next, we examined the association of thyroid function with gait in euthyroid 
participants. In addition, we performed a sensitivity analysis excluding participants 
with prevalent stroke (n=66) and Parkinson’s disease (n=3).
All analyses were adjusted for potential confounding by age, sex, cohort, smok-
ing status, alcohol intake (Model 1). As thyroid function measurement preceded the 
gait assessment, we also adjusted for the time interval between measurements. In 
Model 2, we additionally adjusted for covariates that could be either confounders 
or mediators, including education level, height, weight, knee pain or stiffness, hip 
pain or stiffness, prevalent stroke, CESD depression score, cerebellar cortical volume, 
intracranial volume, TPOAb concentrations. Step count and mean step size can af-
fect the score of tandem walk. Therefore, all models including tandem walk were 
further adjusted for step count and mean step size.
TSH values were logarithmically transformed, because of its skewed distribution. 
The assumption of normally distributed residuals was checked and met. All models 
were tested for effect modification by separately adding product interaction terms 
of the exposure (TSH or FT4 or TPOAb) with covariates of the multivariable model, 
but none of the interaction terms were significant. Multiple imputations were per-
formed for covariates with missing data (less than 4.6% for all covariates). A P value 
(two-tailed) <0.05 was considered statistically significant. Statistical analyses were 
conducted using R statistical software (rms package, R project, Institute for Statistics 
and Mathematics, R Core Team, version 3.2.2) and IBM SPSS version 21 (IBM Corp).
reSulTS
We included a total of 2645 eligible participants with data available on thyroid func-
tion and gait, without known thyroid disease or dementia (Supplemental Figure 1). 
The baseline characteristics of the study population are shown in Table 1. The mean 
age was 59.6 years and 52.6% were females (Table 1).
Thyroid function and global gait
Our results did not change after primary and additional adjustments for potential 
confounders; therefore, we further report only the most adjusted model (Model 
2). TSH concentrations within the full range followed an inverted U-shaped curve 
with global gait (P value, <0.001; Figure 2a). However, there was no association of 
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FT4 concentrations with global gait (P value, 0.2; Figure 2b). When we restricted the 
analysis to euthyroid participants, higher TSH concentrations were associated with 
a better global gait (β, 0.08; 95% confidence interval [95% CI], 0.02 to 0.13 per 1 
unit logTSH). Moreover, there was a borderline statistically significant association 
between FT4 levels within the normal range and global gait (β, -0.05; 95% CI, -0.10 
to 0.00 per 1 pmol/L FT4; Figure 2 and Supplemental Table 1). Clinical and subclini-
cal hypothyroidism were associated with a worse global gait than euthyroidism (β, 
-0.61; 95% CI, -1.03 to -0.18 and β, -0.13; CI, -0.26 to -0.00, respectively; Figure 3a). 
No association was observed between TPOAb and global gait in the main analysis or 
after restricting to euthyroid participants (Supplemental Table 2). Results remained 
similar after excluding participants with prevalent stroke and Parkinson’s disease 
(Supplemental Figure 2).
Table 1. Baseline characteristics of 2645 participants*
Age, years 59.6 (6.6)
Women, n (%) 1392 (52.6)
Smoking, n (%)
 current 561 (21.2)
 past 1242 (47.0)
 never 842 (31.8)
Alcohol intake >14 drinks/week, n (%) 565 (21.4)
Education level, n (%)
 low 195 (7.4)
 intermediate 1821 (68.8)
 high 629 (23.7)
Height, cm 170.0 (9.2)
Weight, kg 78.4 (14.1)
Knee pain or stiffness, n (%) 693 (26.2)
Hip pain or stiffness, n (%) 401 (15.2)
Past stroke, n (%) 66 (2.5)
CESD depressive symptoms, n (%) 298 (11.3)
Cerebellar cortical volume, ml 99.3 (10.6)
Intracranial volume, ml 1479.6 (159.6)
TSH, mIU/L, median (IQR) 1.9 (1.3-2.8)
FT4, pmol/L 15.5 (2.1)
TPOAb positive, n (%) 312 (11.8)
*Data are presented as mean (standard deviation), unless otherwise specified. Abbreviations: CESD, Centre for Epide-
miological Studies Depression Scale; TSH, thyroid-stimulating hormone; IQR, interquartile range; FT4, free thyroxine; 
TPOAb, thyroid peroxidase antibodies (cutoff 35 kU/ml).
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Thyroid function, gait domains and gait velocity
TSH levels were positively linearly associated with base of support (P value, 0.01; 
Figure 4e) and followed an inverted U-shaped curve with respect to tandem (P value, 
0.002; Figure 4f) and gait velocity (P value, 0.02; Figure 2c). In euthyroid participants, 
higher TSH levels were associated with higher base of support (β, 0.07; 95% CI, 0.01 
to 0.14) and tandem (β, 0.06; 95% CI, 0.01 to 0.12), whereas higher FT4 levels were as-
sociated with lower gait velocity (β, -0.96; 95% CI, -1.85 to -0.07; Supplemental Table 
1). Clinical and subclinical hypothyroidism were associated with lower gait velocity 
than euthyroidism, with borderline statistical significance (β, -7.11; 95% CI, -14.69 to 
0.49 and β, -2.22; 95% CI,- 4.50 to 0.05, respectively). Gait velocity decreased gradu-
ally from euthyroidism to clinical hypothyroidism (P for trend, 0.01) (Figure 3b).
Figure 2. Association of thyroid function with global gait and velocity.
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Adjusted for age, sex, cohort, smoking, alcohol intake, education level, height, weight, time interval between thyroid 
function measurement and gait assessment, knee pain or stiffness, hip pain or stiffness, prevalent stroke, CESD de-
pression score, cerebellar cortical volume, intracranial volume, and thyroid peroxidase antibodies. We utilized linear 
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95% CI (gray areas) are plotted against TSH/FT4 concentrations. Dashed lines indicate the limits of TSH or FT4 reference 
ranges. A higher value of global gait represents better gait.
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diScuSSion
In a large cohort of middle-aged and elderly subjects, we reported an inverted 
U-shaped association between TSH concentrations and global gait, indicating that 
both low and high thyroid function are associated with worse gait. TSH levels were 
positively associated with base of support and followed an inverted U-shaped curve 
with tandem and gait velocity. In euthyroid subjects, higher thyroid function was 
associated with worse gait patterns.
The association between thyroid function and gait could be explained by differ-
ent pathophysiological mechanisms, particularly involving the neurological and mus-
culoskeletal systems. Low and high thyroid function may increase the risk of stroke 
via unfavorable cardiovascular risk profile and atrial fibrillation, respectively.25,26 
Low thyroid function can additionally induce immune-mediated cerebellar degen-
eration.14 Furthermore, low and high thyroid function can lead to a dysregulation 
of the neurotransmission systems and subsequent depressive symptoms.27 Low and 
high thyroid function may also contribute to myopathy and fractures, by affecting 
muscle mass and bone mineral density.28,29 In turn, stroke, cerebellar degeneration, 
Figure 3. Association of thyroid status categories with global gait and velocity.
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depression, myopathy and fractures are all implicated in gait deterioration.14,25-29 In 
our study, adjustments for stroke, cerebellar cortical volume, TPOAb, CESD depres-
sion score, hip and knee pain or stiffness (proxy for musculoskeletal dysfunction) did 
not change the results, suggesting that the association between thyroid function 
and gait patterns is independent of these factors. Alternative underlying pathways 
can explain the association. The most plausible may be peripheral neuropathy, given 
that thyroid dysfunction has been commonly associated with axonal degeneration 
and nerve conduction abnormalities.28,30,31 Both hypothyroid and hyperthyroid 
patients usually experience symmetric distal sensory disturbances that can resolve 
after treatment of thyroid dysfunction.28,32 Also, genetic disorders affecting thyroid 
hormone transport and metabolism may play a role in gait impairment.33 However, 
the exact mechanisms through which thyroid function could affect the gait patterns 
Figure 4. Association of TSH with the seven gait domains.
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remain unexplored and further studies should be directed towards unravelling the 
underlying pathophysiology.
Although gait is a multidimensional concept, gait assessment in prior compa-
rable studies has been limited to the measurement of gait velocity.16,17 A relatively 
small study (n=602) reported an association of high-normal FT4 levels with slower 
walk.17 A second study reported a faster walk in individuals with mildly elevated 
TSH levels (4.5-7.0 mIU/L) compared with euthyroid individuals.16 Our conclusions 
are in line with the results of the first study, but do not support those of the second 
study. Most likely, the discrepancy between our results and those of the second 
study may be attributable to differences in TSH reference ranges and thyroid status 
definitions. In the second study, participants with TSH levels between 4.5 and 7.0 
mIU/L were considered to have mild subclinical hypothyroidism, though they lacked 
FT4 measurements. Instead, we used both TSH and FT4 measurements to define the 
thyroid status of our participants. Therefore, our conclusions may add valuable 
information to the ongoing debate on the effects of untreated or undetected 
subclinical hypothyroidism. Most importantly, our large population-based cohort 
study extends the previous literature by addressing for the first time the associa-
tion of thyroid function with global gait and gait domains. Our results indicate the 
importance of comprehensive gait evaluation, as we observe a stronger association 
of thyroid status with global gait than with gait velocity.
We were able to identify tandem, base of support and gait velocity as spatio-
temporal gait aspects related to thyroid function. Likewise, past case reports have 
described hypothyroid patients with a “wide-based gait” and tandem walking 
errors on neurological examination.12-15 In addition, adult mice lacking type 2 deio-
dinase walked slower and with wider base of support than the wild-type mice.10 Our 
results confirm these findings in the setting of a general population cohort study. 
Of note, the identification of thyroid-related gait domains may provide valuable 
hints on the pathways linking thyroid function to gait. Tandem, base of support, 
and gait velocity have been associated with distinct brain structures (ie, prefrontal 
regions, parietal cortex, pallidum, putamen, and cerebellum), executive functioning 
and balance, that might be specific targets of thyroid hormone action.4,15,34-38
A limitation of our study is its cross-sectional design, which does not enable us to 
draw conclusions on causality. Though it is more likely that thyroid function affects 
gait than vice-versa, one could also hypothesize that health problems underlying 
gait abnormalities may alter thyroid parameters in the setting of non-thyroidal 
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illness syndrome (NTIS). This condition is characterized by low thyroid hormones 
and normal TSH levels.39 Instead, we reported a nonlinear association between TSH 
levels and global gait. Also, NTIS is typical in critically ill patients, whereas the Rot-
terdam Study consists of community-dwelling adults.39 Therefore, NTIS is unlikely to 
be the explanation of our findings. Furthermore, turning and tandem walk lacked 
repeated measurements, which would have reduced the intra-individual variability. 
However, we did perform up to eight consecutive recordings of the normal walk, 
and used a well validated instrument for an objective gait evaluation in three walk-
ing conditions. Also, the Rotterdam Study does not have data available on serum 
triiodothyronine levels, which is a limitation for most population-based studies. 
However, TSH and FT4 concentrations are considered as the most relevant measure-
ments of thyroid function in clinical practice. Moreover, Rotterdam Study includes 
predominantly Caucasians over 45 years old, which limits the generalizability of our 
findings to other populations. Lastly, the possibility of residual confounding cannot 
be excluded, even though we controlled for multiple potential confounders.
conclusions
Both low and high thyroid function are associated with worse gait patterns. There 
is an inverted U-shaped association of TSH levels with global gait, tandem, and gait 
velocity, as well as a positive association of TSH levels with base of support. Subjects 
with clinical and subclinical hypothyroidism have worse gait patterns than euthy-
roid individuals. These conclusions might have future implications regarding the 
prevention and treatment of thyroid and gait disorders. Further studies are needed 
to confirm our findings, determine the underlying mechanisms linking thyroid func-
tion to gait patterns and subsequently investigate the possible motor benefits of 
thyroid treatment.
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SuPPlemenTal maTerial
Supplemental Figure 1. Flow chart for the selection of study participants.
2645 without known thyroid disease or 
dementia 
Excluded (n=212) if at least one of the following:
Dementia (n=14)
Thyroid medication (n=79)   
Past thyroid disease (n= 192)   
Previous thyroid surgery (n=33) 
2857 had data available on thyroid function
3066 had data available on gait patterns
3369 accepted the invitation
3651 invited for gait assessment
Excluded (n=282)
Perceived physical inability (n=204)  
Technical (n=57) 
Refusal (n=19) 
Other (n=2)
Excluded (n=303)
Technical, eg, errors in parameter calculation (n=239)   
Performed <16 steps in the normal walk (n=34)
Did not follow the instructions correctly (n=27) 
User of walking aids (n=3) 
Excluded (n=209)
Missing data on thyroid function (n=202)   
No informed consent (n=7)
Supplemental Figure 2. Association of thyroid function with global gait, after excluding par-
ticipants with prevalent stroke and Parkinson’s disease.
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Supplemental Table 1. Association of thyroid function with global gait, gait domains and gait 
velocity in euthyroid participants*
TSh
β (95% ci) 
FT4
β (95% ci)
Global gait 0.08 ( 0.02; 0.13) -0.05 (-0.10; 0.00)
 Rhythm 0.00 (-0.06; 0.06) -0.02 (-0.07; 0.03)
 Variability 0.02 (-0.04; 0.08) -0.01 (-0.06; 0.04)
 Phases 0.02 (-0.03; 0.08) -0.05 (-0.10; 0.00)
 Pace 0.05 ( 0.00; 0.10) -0.02 (-0.07; 0.02)
 Base of support 0.07 ( 0.01; 0.14) 0.01 (-0.04; 0.06)
 Tandem† 0.06 ( 0.01; 0.12) -0.03 (-0.08; 0.02)
 Turning -0.02 (-0.08; 0.04) -0.01 (-0.06; 0.05)
 Velocity 0.87 (-0.12; 1.87) -0.96 (-1.85;-0.07)
A higher value of gait represents better gait. Analyses are adjusted for age, sex, cohort, smoking, alcohol intake, edu-
cation level, height, weight, time interval between thyroid function measurement and gait assessment, knee pain or 
stiffness, hip pain or stiffness, prevalent stroke, CESD depression score, cerebellar cortical volume, intracranial volume, 
and thyroid peroxidase antibodies. *Euthyroidism was defined as TSH within the reference range (0.4 to 4.0 mIU/L).
†Additionally adjusted for step count and step size within tandem walk. Abbreviations: TSH, thyroid-stimulating hor-
mone, is per one unit increase of log transformed TSH (mIU/L); FT4, free thyroxine, is per one unit increase of FT4 
(pmol/L); β, regression coefficient; CI, confidence interval.
Supplemental Table 2. Association of TPOAb positivity* with global gait
β (95% ci)
All participants -0.05 (-0.16; 0.06)
Euthyroid participants† -0.06 (-0.19; 0.06)
A higher value of global gait represents better gait. Analyses are adjusted for age, sex, cohort, smoking, alcohol 
intake, education level, height, weight, time interval between thyroid function measurement and gait assessment, 
knee pain or stiffness, hip pain or stiffness, prevalent stroke, CESD depression score, cerebellar cortical volume, intra-
cranial volume, and lnTSH. *TPOAb >35 kU/ml were regarded as positive. †Euthyroidism was defined as TSH within 
the reference range (0.4 to 4.0 mIU/L). Abbreviations: TPOAb, thyroid peroxidase antibodies; TSH, thyroid-stimulating 
hormone.
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abSTracT
background Variations in thyroid function within reference ranges are associated 
with an increased risk of cardiovascular disease (CVD) and mortality. However, the 
impact of thyroid function on life expectancy and the number of years lived with 
and without CVD remains unknown. In a large population-based prospective cohort 
study, we therefore aimed to investigate the association of thyroid function with 
total life expectancy and life expectancy with and without CVD among euthyroid 
individuals.
methods We included participants of the Rotterdam Study without known thyroid 
disease and with thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels 
within the reference ranges. Multistate life tables were used to calculate total life 
expectancy and life expectancy with and without CVD among TSH and FT4 tertiles. 
Life expectancy estimates in men and women aged 50 years and older were ob-
tained using prevalence, incidence rates and hazard ratios for 3 transitions (healthy 
to CVD, healthy to death, and CVD to death), adjusting for sociodemographic and 
cardiovascular risk factors.
results The mean (standard deviation) age of 7785 participants was 64.7 (9.8) years 
and 52.5% were women. Over a median follow-up of 8.1 (interquartile range 2.7 to 
9.9) years, we observed 789 incident CVD events and 1357 deaths. Compared with 
those in the lowest tertile, men and women in the highest TSH tertile lived 2.0 (95% 
confidence interval [95% CI], 1.0 to 2.8) and 1.4 (95% CI, 0.2 to 2.4) years longer, 
respectively; of which 1.5 (95% CI, 0.2 to 2.6) and 0.9 (95% CI, -0.2 to 2.0) years 
longer without CVD. Compared with those in the lowest tertile, the difference in 
life expectancy for men and women in the highest FT4 tertile was -3.2 (95% CI,-5.0 
to -1.4) and -3.5 (95% CI, -5.6; -1.5), respectively; of which -3.1 (95% CI, -4.9 to -1.4) 
and -2.5 (95% CI, -4.4 to -0.7) years without CVD.
conclusions At the age of 50 years, participants with low-normal thyroid function 
live up to 3.5 years longer overall and up to 3.1 years longer without CVD than 
participants with high-normal thyroid function. These findings provide supporting 
evidence for a reevaluation of the current reference ranges of thyroid function and 
can help inform preventive and clinical care.
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inTroducTion
Thyroid dysfunction is one of the most common endocrine disorders.1 Clinical thy-
roid dysfunction is characterized by thyroid-stimulating hormone (TSH) and free 
thyroxine (FT4) levels outside the reference ranges, whereas subclinical thyroid dys-
function is characterized by TSH levels outside the reference range combined with 
FT4 levels within the reference range. At present, the reference ranges for TSH and 
FT4 levels are statistically determined on the basis of the 2.5th and 97.5th percentiles 
of an apparently healthy population. This arbitrary approach, however, has been re-
cently challenged by studies suggesting that the current reference ranges of thyroid 
function may need to be reevaluated by additionally taking into account the risk 
of clinical outcomes.2-5 In view of the ongoing debate on redefining the reference 
ranges of TSH and FT4 levels, there is a need for novel insights about the qualitative 
and quantitative impact of thyroid function on an individual’s life and health.
The cardiovascular system represents a major target of thyroid hormone action.6 
Both clinical and subclinical thyroid dysfunction have been associated with an in-
creased risk of coronary heart disease,7,8 heart failure9 and mortality.7,8,10,11 These 
deleterious effects of thyroid dysfunction might also be extended to the euthyroid 
range. Many studies conducted in middle-aged and elderly euthyroid individuals 
have reported an increased risk of cardiovascular disease (CVD) and mortality with 
lower TSH and/or higher FT4 levels.2-5,12-16 Other studies do not find an association,17-19 
probably due to the relatively small proportion of events,17,18 insufficient sample 
sizes19 or short term follow-up.17 However, it remains unclear whether there are 
meaningful differences in the remaining years of life lived with and without CVD 
within the reference range of thyroid function. Therefore, in a large population of 
euthyroid subjects, we aimed to investigate the association of thyroid function with 
total life expectancy (LE) and LE with and without CVD.
meThodS
Study population
This study was embedded within the Rotterdam Study, a large prospective popu-
lation-based cohort study. The objectives and design have been described in detail 
previously.20 The Rotterdam Study was initiated in 1989, including 7983 participants 
aged 55 years or older. In 2000, the study was extended with a second cohort of 3011 
subjects. In 2006, a third cohort of 3932 subjects aged 45 years or older was added. 
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Study participants undergo extensive follow-up medical examinations every 3 to 5 
years. Baseline measurements for our study were performed during the third visit 
of the first cohort (1997-1999, n=4797) and the first visit of the second (2000-2001, 
n=3011) and third (2006-2008, n=3932) cohorts of the Rotterdam Study. The original 
cohort during these three visits included a total of 11740 participants, of which 
10050 had available blood measurements. Thyroid function measurements were 
performed in a random sample of 9702 participants. Of these, we excluded 16 par-
ticipants without complete follow-up data, 1346 with TSH or FT4 outside the normal 
reference ranges and 555 with past thyroid disease or taking thyroid medications. 
The remaining 7785 participants were eligible for the analysis (Supplemental Figure 
1). Follow-up started at the date of thyroid function assessment.
The protocols of the Rotterdam Study have been approved by the Medical Ethics 
Committee of the Erasmus University and by the Ministry of Health, Welfare and 
Sport of the Netherlands, implementing the Population Study Act Rotterdam Study. 
In accordance with the Declaration of Helsinki, all included participants provided 
written informed consent to participate in the study and to obtain information 
from their treating physicians.
assessment of thyroid function
Thyroid function was assessed during the third visit of the first cohort (RS I.3) and 
the first visit of the second (RS II.1) and third (RS III.1) cohorts using the same method 
and assay. Measurements of TSH and FT4 were performed in baseline serum samples 
stored at -80°C using the electrochemiluminescence immunoassay ECLIA Roche. The 
reference ranges of TSH (0.40–4.0 mIU/L) and FT4 (0.86–1.94 ng/dL, alternatively 11–25 
pmol/L) were determined based on national guidelines and our previous studies.21,22
assessment of cvd and mortality
Outcome measures were incident nonfatal CVD, fatal CVD and overall mortality. 
CVD was defined as presence of coronary heart disease, stroke or heart failure. 
Coronary heart disease was defined as coronary revascularization (as a proxy for 
significant coronary artery disease), fatal or nonfatal myocardial infarction or fatal 
coronary heart disease.23 Based on the World Health Organization criteria, stroke 
was defined as a syndrome of rapidly developing symptoms, with an apparent 
vascular cause of focal or global cerebral dysfunction lasting 24 hours or longer or 
leading to death.20,24 Based on the European Society of Cardiology criteria, heart 
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failure was defined as the presence of typical symptoms and signs (ie, breathlessness 
at rest or during exertion, ankle edema, and pulmonary crepitations), confirmed 
by the objective evidence of cardiac dysfunction (ie, chest X-ray, echocardiography) 
or a positive response to the initiated treatment.25 Prevalent CVD was assessed at 
baseline through interview and medical records. After enrollment, participants were 
continuously monitored for incident CVD through linkage of the study database 
with files from general practitioners and hospital records.
Information on mortality was obtained from municipality records, general 
practitioners, and reports of medical specialists. The underlying cause of death was 
ascertained independently by 2 research physicians and subsequently validated by 
a medical specialist.23
additional measurements
The baseline home interview provided information on medical history, medication use, 
tobacco smoking, alcohol consumption, education level and marital status.20 Smoking 
habits were categorized as current, former and never smoking. Education level was di-
vided into four categories: elementary, lower secondary, higher secondary and tertiary 
education, in accordance with the standard international classification of education.26 
Marital status was categorized as single, married, widowed and divorced/separated. 
Serum glucose and lipid levels were measured by an automated enzymatic procedure 
(Mannheim System). Anthropometric measurements were performed in the research 
center by trained medical staff. Body mass index was calculated as weight in kilograms 
divided by height in meters squared. Blood pressure was measured in the sitting 
position on the right arm and calculated as the mean of two measurements using 
a random-zero sphygmomanometer. Diabetes mellitus was defined as fasting serum 
glucose level of 7 mmol/L or more, non-fasting plasma glucose level of 11.1 mmol/L 
or more (when fasting samples were absent) or the use of antidiabetic medications.20
Statistical analysis
Total LE and the number of years lived with and without CVD were calculated 
among tertiles of TSH and FT4, by using multistate lifetables. Differences in LE were 
evaluated using the lowest tertile as reference. Multistate life tables combined 
information from participants in 3 possible health states, namely “free of CVD”, 
“CVD”, and “death”. Possible transitions of participants were: (1) from free of CVD 
to CVD (incident CVD); (2) from free of CVD to death (mortality among those with-
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out CVD); (3) from CVD to death (mortality among those with CVD). Backflows were 
not allowed and only the first event into a state was considered.27 To calculate LE, 
we followed a similar approach to previous studies.28,29
Due to the known gender differences in LE, analyses were performed separately 
among men and women. We first calculated the prevalence of TSH tertiles among 
participants with and without CVD, categorized in 10-year age groups. In each tran-
sition, we calculated age-specific incidence rates. Next, we applied Poisson regres-
sion with Gompertz distribution to compute hazard ratios (HRs) of the association 
between TSH tertiles and incident CVD or mortality. The confidence intervals of LE 
estimates were calculated using Monte Carlo method with 10000 bootstrap simula-
tions.30 Moreover, we repeated the analyses for the FT4 tertiles.
Analyses were adjusted for potential confounders, which were selected on the 
basis of biological plausibility and previous literature. Model 1 was adjusted for age 
and cohort. Model 2 was adjusted for age, cohort, smoking, alcohol intake, educa-
tion level, marital status, diabetes mellitus, body mass index, systolic blood pres-
sure, total cholesterol, triglycerides, and use of antihypertensive and lipid-lowering 
medications.
Multiple imputations were performed in case of missing covariates (<5% for 
all covariates). Statistical analyses were conducted using IBM SPSS version 21 (IBM 
Corp), STATA version 13 for Windows (StataCorp, College Station, Texas) and @RISK 
software (Palisade).
Sensitivity analysis
Several sensitivity analyses were performed: (1) To account for potential reverse 
causation, we excluded CVD events (n=179) or deaths (n=293) that occurred during 
the first 2 years of follow-up; (2) We excluded participants using thyroid function-
altering medications (ie, amiodarone and corticosteroids) (n=137); (3) To exclude 
any potential bias caused by presence of cancer at baseline, we additionally adjusted 
our analyses for prevalent cancer at baseline; (4) To detect a potential influence of 
follow-up duration on our results, we performed the analyses restricting the length 
of follow-up to 8 years (median follow-up time).
To additionally explore the association between thyroid status categories (ie, 
hypothyroidism, euthyroidism, hyperthyroidism) and LE with and without CVD, we 
extended the study population, including participants of the Rotterdam Study with 
data available on thyroid function and CVD, without past thyroid disease and not 
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using thyroid function-altering medications (ie, thyroid medications, amiodarone or 
corticosteroids). Participants were categorized on the basis of their thyroid status. 
Euthyroidism was defined as serum TSH levels within the reference range. Hypothy-
roidism (clinical and subclinical combined) was defined as high TSH combined with 
low or normal FT4. Hyperthyroidism (clinical and subclinical combined) was defined 
as low TSH combined with high or normal FT4. Total LE and LE with and without 
CVD were calculated in men and women, among thyroid status categories, by using 
multistate lifetables. Differences in LE were evaluated using the euthyroid category 
as reference.
reSulTS
Baseline characteristics of 7785 eligible participants are presented in Table 1. The 
mean (standard deviation) age of participants was 64.7 (9.8) years and 52.5% were 
women. Over a median follow-up time of 8.1 (interquartile range, 2.7 to 9.9) years, 
789 incident CVD events and 1357 deaths occurred. Both models yielded similar esti-
mates, therefore we further report the results of the most adjusted model (Model 2).
association of thyroid function within the reference range with the risk of 
cvd and death
The association of TSH tertiles with the risk of incident CVD was not statistically 
significant (highest versus lowest TSH tertile: HR, 0.93; 95% CI, 0.79 to 1.11) (Table 
2). Compared with the lowest tertile, the highest TSH tertile was associated with a 
lower risk of mortality among participants without CVD (HR, 0.76; 95% CI, 0.64 to 
0.91) and with CVD (HR, 0.82; 95% CI, 0.67 to 1.01) (Table 2).
The highest FT4 tertile was associated with a 1.32 times higher risk of incident 
CVD than the lowest tertile (95% CI, 1.10 to 1.58) (Table 2). Compared with the low-
est tertile, the highest FT4 tertile was also associated with a 1.64 times higher risk of 
mortality among participants with CVD (95% CI, 1.32 to 2.02) and a 1.45 times higher 
risk of mortality among participants without CVD (95% CI, 1.21 to 1.73) (Table 2).
Results for TSH and FT4 analyses did not change substantially after the events 
that occurred during the first 2 years of follow-up were excluded (Supplemental 
Table 1). Also, results remained similar after excluding users of thyroid function-
altering medications and additionally adjusting for the presence of prevalent cancer 
at baseline (Supplemental Table 2).
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association of thyroid function within the reference range with total le 
and le with and without cvd
Total LE increased significantly from the lowest to the middle TSH tertile and did not 
change substantially from the middle to the highest TSH tertile (Figure 1). Compared 
with those in the lowest tertile, men in the highest TSH tertile lived 2.0 (95% CI, 1.0 
to 2.8) years longer overall, of which, 1.5 (95% CI, 0.2 to 2.6) years longer without 
CVD and 0.5 (95% CI, -0.5 to 1.4) years longer with CVD (Table 3). Compared with 
those in the lowest tertile, women in the highest TSH tertile lived 1.4 (95% CI, 0.2 to 
2.4) years longer overall, of which, 0.9 (95% CI, -0.2 to 2.0) years longer without CVD 
and 0.5 (95% CI, -0.5 to 1.2) years longer with CVD (Table 3).
Table 1. Baseline characteristics of 7785 participants* 
men Women
Number 3699 4086
Age, years 64.3 (9.3) 65.0 (10.2)
Smoking, n (%)
 current 906 (24.5) 828 (20.3) 
 former 2180 (58.9) 1553 (38.0)
 never 613 (16.6) 1705 (41.7)
Education, n (%)
 Elementary 342 (9.2) 605 (14.8)
 Lower secondary 1051 (28.4) 2060 (50.4)
 Higher secondary 1354 (36.6) 924 (22.6)
 Tertiary 952 (25.7) 497 (12.2)
Marital status, n (%)
 Single 115 (3.1) 252 (6.2)
 Married 3155 (85.3) 2515 (61.6)
 Widowed 227 (6.1) 897 (22.0)
 Divorced/Separated 202 (5.5) 422 (10.3)
Diabetes mellitus, n (%) 497 (13.4) 464 (8.9)
BMI, kg/m2 27.0 (3.5) 27.3 (4.6)
Systolic blood pressure, mm Hg 141.0 (20.2) 137.9 (21.5)
Use of antihypertensive medications, n (%) 816 (22.1) 942 (23.1)
Total cholesterol, mmol/l 5.4 (0.9) 5.9 (1.0)
Triglycerides, mmol/l 1.6 (0.9) 1.5 (0.7)
Use of lipid-lowering medications, n (%) 666 (18) 583 (14.3)
Prevalent cancer, n (%) 201 (5.4) 250 (6.1)
TSH, mIU/L, median (IQR) 1.8 (1.2-2.4) 1.9 (1.3-2.6)
FT4, pmol/L 15.9 (2.0) 15.6 (1.9)
*Data are presented as mean (standard deviation), unless otherwise specified. Abbreviations: BMI, body-mass index; 
TSH, thyroid-stimulating hormone; IQR, interquartile range; FT4, free thyroxine.
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Total LE decreased progressively with increasing FT4 tertiles (Figure 1). Compared 
with those in the lowest tertile, the differences in LE for men in the highest FT4 
tertile was -3.2 (95% CI, -5.0; -1.4) years overall; of which -3.1 (95% CI, -4.9 to -1.4) 
years without CVD and -0.1 (95% CI, -1.7 to 1.6) years with CVD (Table 3). Compared 
with those in the lowest tertile, the difference in LE for women in the highest FT4 
tertile was -3.5 (95% CI, -5.6 to -1.5) years fewer overall, of which -2.5 (95% CI, -4.4 to 
-0.7) years without CVD and -1.0 (95% CI, -2.4 to 0.4) years with CVD (Table 3). Results 
were consistent over the length of follow-up of 8 years (Supplemental Table 3).
association of thyroid status with total le and le with and without cvd
Compared with their euthyroid counterparts, hypothyroid men and women lived 
0.3 (95% CI, -1.7 to 1.9) and 1.1 (95% CI, -0.4 to 2.3) years longer, respectively 
(Supplemental Table 4). The difference in LE for hyperthyroid men was -1.4 (95% 
CI, -4.4 to 2.0) years compared with euthyroid men. However, these results were 
not statistically significant. The difference in LE for hyperthyroid women was 2.3 
(95% CI, 0.2 to 4.4) years without CVD and -1.9 (95% CI, -3.1 to -0.4) years with CVD, 
compared with euthyroid women (Supplemental Table 4).
Table 2. HRs for incident CVD and death among TSH and FT4 tertiles
Transition cases/Py
TSh/FT4 
tertiles
TSh FT4
hr (95% ci)
model 1
hr (95% ci)
model 2
hr (95% ci)
model 1
hr (95% ci)
model 2
Incident CVD 789/38417 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.85 (0.72; 1.01) 0.86 (0.72; 1.01) 1.16 (0.97; 1.38) 1.15 (0.97; 1.38)
Tertile 3 0.93 (0.79; 1.10) 0.93 (0.79; 1.11) 1.33 (1.11; 1.58) 1.32 (1.10; 1.58)
Mortality 
among those 
without CVD
801/41130 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.74 (0.62; 0.87) 0.75 (0.64; 0.89) 1.20 (1.00; 1.44) 1.19 (0.99; 1.42)
Tertile 3 0.72 (0.61; 0.86) 0.76 (0.64; 0.91) 1.50 (1.26; 1.79) 1.45 (1.21; 1.73)
Mortality 
among those 
with CVD
556/8718 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.95 (0.77; 1.15) 0.92 (0.75; 1.13) 1.24 (0.99; 1.55) 1.27 (1.01; 1.60)
Tertile 3 0.81 (0.62; 0.91) 0.82 (0.67; 1.01) 1.59 (1.29; 1.95) 1.64 (1.32; 2.02)
Model 1: age, sex, and cohort. Model 2: Model 1, smoking, alcohol intake, education level, marital status, diabetes 
mellitus, body mass index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, 
and use of lipid-lowering medications. Abbreviations: HR, hazard ratio; TSH, thyroid-stimulating hormone; FT4, free 
thyroxine; PY, person-years; CI, confidence interval; CVD, cardiovascular disease.
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diScuSSion
In a large prospective population-based cohort study among middle-aged and 
elderly participants, we investigated differences in LE with and without CVD within 
the reference range of thyroid function. Participants with low-normal thyroid func-
tion lived up to 3.5 years longer overall and up to 3.1 years longer without CVD than 
participants with high-normal thyroid function. Total LE in euthyroid participants 
increased from the lowest to the middle TSH tertile but did not change substantially 
from the middle to the highest TSH tertile. Total LE in euthyroid participants de-
creased progressively with increasing FT4 tertiles. Overall, there were no meaningful 
sex differences throughout TSH and FT4 tertiles.
LE without CVD is the resultant of 2 components: risk of incident CVD (transition 
1) and risk of mortality among participants without CVD (transition 2). Compared 
Figure 1. Life expectancy with and without CVD at age 50 years among TSH and FT4 tertiles, 
in men and women.
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with the lowest tertile, the highest FT4 tertile was associated with a higher risk of 
incident CVD, meaning an earlier clinical manifestation of CVD and fewer years 
lived without CVD. The highest FT4 tertile was also associated with an increased 
mortality risk among participants without CVD, resulting in a further decrease in 
total LE and LE without CVD. LE with CVD is the resultant of 2 components: risk of 
incident CVD (transition 1) and risk of mortality among subjects with CVD (transition 
3). Compared with the lowest tertile, the highest FT4 tertile was associated with a 
1.32 times higher risk of incident CVD, meaning an earlier clinical manifestation of 
CVD and more years lived with CVD. However, participants with CVD in the highest 
FT4 tertile had an even higher risk of mortality (ie, 1.64 times higher), which explains 
the decrease in the number of years lived with CVD.
Table 3. LE at age 50 years among TSH and FT4 tertiles, in men and women*
TSh/FT4
tertiles Total le
differences in 
total le† le free of cvd
differences 
in le free of 
cvd† le with cvd
differences in 
le with cvd†
TSH tertiles
Men
Tertile 1 29.8 (29.2; 30.2) Reference 24.1 (23.5; 24.6) Reference 5.7 (5.2; 6.2) Reference
Tertile 2 31.7 (30.9; 32.6) 1.9 (1.1; 3.1) 25.4 (24.5; 26.2) 1.3 (-0.0; 2.3) 6.3 (5.6; 7.0) 0.6 (-0.3; 1.4)
Tertile 3 31.8 (30.9; 32.5) 2.0 (1.0; 2.8) 25.6 (24.6; 26.5) 1.5 ( 0.2; 2.6) 6.2 (5.5; 7.2) 0.5 (-0.5; 1.4)
Women
Tertile 1 34.7 (34.2; 35.3) Reference 30.0 (29.5; 30.5) Reference 4.7 (4.2; 5.3) Reference
Tertile 2 36.1 (35.4; 36.9) 1.4 (0.5; 2.4) 32.4 (31.5; 33.2) 2.4 ( 1.4; 3.3) 3.7 (3.0; 4.3) -1.0 (-2.0; -0.1)
Tertile 3 36.1 (35.2; 36.8) 1.4 (0.2; 2.4) 30.9 (30.0; 32.0) 0.9 (-0.2; 2.0) 5.2 (4.4; 5.9) 0.5 (-0.5; 1.2)
FT4 tertiles
Men
Tertile 1 32.8 (31.8; 34.0) Reference 26.6 (25.6; 27.5) Reference 6.2 (5.3; 7.1) Reference
Tertile 2 31.2 (30.1; 32.6) -1.6 (-3.5; 0.2) 25.4 (23.9; 26.8) -1.2 (-3.2; 0.5) 5.8 (4.7; 7.0) -0.4 (-1.6; 1.0)
Tertile 3 29.6 (28.5; 30.8) -3.2 (-5.0; -1.4) 23.5 (22.3; 24.6) -3.1 (-4.9;-1.4) 6.1 (5.0; 7.3) -0.1 (-1.7; 1.6)
Women
Tertile 1 37.5 (36.5; 38.7) Reference 32.4 (31.5; 33.4) Reference 5.1 (4.3; 6.1) Reference
Tertile 2 35.9 (34.5; 37.6) -1.6 (-3.15; 0.0) 31.0 (29.7; 32.4) -1.4 (-3.0; 0.2) 4.9 (3.8; 6.2) -0.2 (-1.4; 1.1)
Tertile 3 34.0 (32.8; 35.4) -3.5 (-5.6; -1.5) 29.9 (28.7; 31.2) -2.5 (-4.4;-0.7) 4.1 (3.3; 5.1) -1.0 (-2.4; 0.4)
*Data are given as years (95% confidence intervals). All life expectancies have been calculated with hazard ratios 
adjusted for age, cohort, smoking, alcohol intake, education level, marital status, diabetes mellitus, body mass index, 
systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, and use of lipid-lowering 
medications. †Differences in LE are calculated using the first tertile as reference. Abbreviations: LE, life expectancy; 
TSH, thyroid-stimulating hormone; FT4, free thyroxine; CVD, cardiovascular disease.
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Our study confirms prior research, suggesting that high-normal thyroid function 
is associated with an increased risk of CVD and mortality, independent of traditional 
cardiovascular risk factors.2-5 Most importantly, it extends the previous literature 
by revealing considerable differences in LE within the reference range of thyroid 
function. These findings provide supporting evidence for a reevaluation of the cur-
rent reference ranges of TSH and FT4 measurements, implying the possibility of an 
upward shift of TSH and a downward shift of FT4 reference ranges in middle-aged 
and elderly people. Further investigations are needed to determine the clinically 
relevant normal range of thyroid function.
Overactivity of thyroid gland is known to have a negative effect on overall 
health. Higher thyroid hormone concentrations have been associated with an in-
creased heart rate (chronotropic effect), myocardial contractility (inotropic effect), 
and hypercoagulability, which may further predispose to CVD and mortality.6,31 
Moreover, elevated thyroid hormone levels can enhance oxygen consumption and 
production of reactive oxygen species, which may subsequently induce DNA damage 
and cell apoptosis.32,33 Also, elevated thyroid hormone levels can affect cognition, 
nerve conduction, and bone mineral density, thus contributing to an increased risk 
of dementia, polyneuropathy, osteoporosis, and death.34-36 However, the deleterious 
effects of high thyroid function could be also extended to the high-normal range of 
thyroid function.2,37 Therefore, the aforementioned mechanisms could be addition-
ally involved in the pathways linking high-normal thyroid function to a reduced life 
span.
Other mechanisms can explain the association of low-normal thyroid function 
with a prolonged life span. Low-normal thyroid function may promote energy 
conservation, which is necessary to adequately cope with acute and chronic stress-
ors.38 Low-normal thyroid function may also represent a heritable phenotype of 
exceptional longevity. In line with this hypothesis, Rozing et al39 observed lower 
circulating thyroid hormone levels in middle-aged offspring of nonagenarian sib-
lings compared with age-matched controls. In addition, decreased thyroid hormone 
levels in nonagenarian siblings have been associated with a prolonged life span in 
their parents.40
Based on the negative feedback mechanism of the hypothalamus-pituitary-
thyroid axis, each individual is expected to have a unique set point of thyroid 
function, with an inverse relation between TSH and FT4 concentrations. Our results 
were consistent with the feedback regulation because high-normal TSH levels and 
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low-normal FT4 levels were both associated with an increased LE. However, LE in our 
participants was more strongly associated with FT4 than with TSH levels. Likewise, 
previous cohort studies have reported a stronger association of adverse outcomes 
(including mortality) with FT4 than with TSH levels, particularly within the euthyroid 
range.2,4,13,14,22,35 Likely, genetic determinants and ageing can modify the TSH-FT4 set 
point of the feedback mechanism among euthyroid individuals.41,42 Various genetic 
polymorphisms that affect serum TSH but not FT4 levels have been identified.42
In addition, we investigated the differences in LE with and without CVD among 
thyroid status categories (ie, hypothyroidism, euthyroidism, hyperthyroidism). In line 
with the results of our main analysis, we found that hypothyroid participants lived 
longer than euthyroid subjects. Among hyperthyroid participants, we observed sex 
differences in the number of years lived with and without CVD. However, these 
results should be interpreted with caution, owing to the relatively small number of 
participants with thyroid dysfunction and their increased susceptibility to receiving 
treatment and changing health behaviors over time. Future studies can explore 
more extensively the effect of thyroid disease on LE with and without CVD.
To the best of our knowledge, this is the first population-based cohort study 
that investigates differences in LE with and without CVD within the reference 
range of thyroid function. Strengths include the prospective study design, the long 
follow-up period, and the large number of participants with extensive and detailed 
information on covariates and outcomes. The large sample size allowed us to con-
duct multiple sensitivity analyses, which provided consistent findings. Events were 
adjudicated using standardized criteria.
Several limitations should also be considered. The Rotterdam Study includes 
predominantly whites older than 45 years; therefore, our findings require confirma-
tion in other populations. Moreover, we lacked repeated measurements of thyroid 
function. Nevertheless, this is unlikely to have affected our results, given that the 
normal range of thyroid function is considered to be stable over time with a low 
intra-individual variability.43 Furthermore, we did not have data available on serum 
triiodothyronine levels. However, TSH and FT4 represent the most relevant measure-
ments of thyroid function in clinical practice. Due to the observational character of 
our study, the possibility of residual confounding cannot be entirely ruled out.
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conclusions
At the age of 50 years, participants with low-normal thyroid function lived up to 
3.5 years longer overall and up to 3.1 years longer without CVD than those with 
high-normal thyroid function. Our findings support a reevaluation of the current 
reference ranges of TSH and FT4 measurements, implying the possibility of an up-
ward shift of TSH and a downward shift of FT4 current limits in middle-aged and 
elderly people. Future research is needed to replicate our findings and elucidate 
the exact mechanisms underlying the LE differences within the reference range of 
thyroid function.
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SuPPlemenTal maTerial
Supplemental Figure 1. Flow chart for the selection of study participants.
11740 in cohorts RS I.3, II.1, III.1* 
10050 had blood measurements 
307 without thyroid function measurements 
16 without complete follow-up data  
 7785 included participants 
1346 with TSH/FT4 outside reference ranges 
555 with known thyroid disease 
9686 had complete information 
on thyroid function and CVD 
308 without informed consent   
1382 without blood measurements 
9702 had thyroid function    
measurements 
*A total of 11740 participants were enrolled during the third visit of the first cohort (n = 4797) and the first visit of 
the second (n = 3011) and third (n = 3932) cohorts of the Rotterdam Study. Abbreviations: RS, Rotterdam Study; CVD, 
cardiovascular disease; TSH, thyroid-stimulating hormone; FT4, free thyroxine.
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Supplemental Table 1. HRs of incident CVD and death among TSH and FT4 tertiles, excluding 
the first 2 years of follow-up for CVD and death
Transition cases/Py
TSh/FT4 
tertiles
TSh FT4
hr (95% ci)
model 1
hr (95% ci)
model 2
hr (95% ci)
model 1
hr (95% ci)
model 2
Incident CVD 610/38139 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.83 (0.69; 1.01) 0.84 (0.69; 1.02) 1.14 (0.94; 1.40) 1.14 (0.93; 1.40)
Tertile 3 0.95 (0.79; 1.16) 0.96 (0.79; 1.17) 1.25 (1.02; 1.53) 1.24 (1.02; 1.52)
Mortality 
among those 
without CVD
639/39950 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.78 (0.65; 0.94) 0.80 (0.67; 0.96) 1.21 (0.98; 1.47) 1.19 (0.97; 1.46)
Tertile 3 0.72 (0.60; 0.88) 0.77 (0.63; 0.94) 1.43 (1.18; 1.74) 1.35 (1.11; 1.65)
Mortality 
among those 
with CVD
425/7753 Tertile 1 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Tertile 2 0.98 (0.78; 1.23) 0.92 (0.73; 1.16) 1.29 (1.00; 1.67) 1.31 (1.01; 1.68)
Tertile 3 0.77 (0.61; 0.98) 0.76 (0.60; 0.97) 1.49 (1.17; 1.89) 1.49 (1.17; 1.90)
Model 1: age, sex, and cohort. Model 2: Model 1, smoking, alcohol intake, education level, marital status, diabetes 
mellitus, body mass index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, 
and use of lipid-lowering medications. Abbreviations: HR, hazard ratio; CVD, cardiovascular disease; TSH, thyroid-
stimulating hormone; FT4, free thyroxine; PY, person-years; CI, confidence interval.
Supplemental Table 2. HRs for incident CVD and death among TSH and FT4 tertiles, excluding 
users of thyroid function-altering medications and additionally adjusting for prevalent cancer
Transition cases/Py
TSh/FT4 
tertiles
TSh FT4
hr (95% ci) hr (95% ci)
Incident CVD 763/37814 Tertile 1 1 (Reference) 1 (Reference)
Tertile 2 0.87 (0.73; 1.03) 1.14 (0.95; 1.37)
Tertile 3 0.94 (0.78; 1.12) 1.32 (1.10; 1.57)
Mortality among those 
without CVD
771/40460 Tertile 1 1 (Reference) 1 (Reference)
Tertile 2 0.78 (0.65; 0.91) 1.16 (0.96; 1.39)
Tertile 3 0.76 (0.64; 0.91) 1.43 (1.20; 1.72)
Mortality among those 
with CVD
524/8445 Tertile 1 1 (Reference) 1 (Reference)
Tertile 2 0.93 (0.76; 1.15) 1.24 (0.98; 1.56)
Tertile 3 0.80 (0.65; 1.00) 1.57 (1.26; 1.94)
Hazard ratios are adjusted for age, sex, cohort, smoking, alcohol intake, education level, marital status, diabetes mel-
litus, body mass index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, use 
of lipid-lowering medications, and prevalent cancer. Abbreviations: HR, hazard ratio; CVD, cardiovascular disease; TSH, 
thyroid-stimulating hormone; FT4, free thyroxine; PY, person-years; CI, confidence interval.
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Supplemental Table 3. LE at age 50 years, among TSH and FT4 tertiles, in men and women over 
8 years of follow-up*
Total le
differences in 
total le
differences in le free 
of cvd
differences in le with 
cvd
TSH tertiles
Men
Tertile 1 29.6 Reference Reference Reference
Tertile 2 32.3 2.7 1.4 1.3
Tertile 3 31.5 2.0 1.3 0.6
Women
Tertile 1 34.6 Reference Reference Reference
Tertile 2 36.3 1.7 3.1 -1.3
Tertile 3 36.2 1.6 1.4 0.2
FT4 tertiles
Men
Tertile 1 31.8 Reference Reference Reference
Tertile 2 30.5 -1.2 -0.9 -0.3
Tertile 3 28.8 -3.0 -2.8 -0.2
Women
Tertile 1 37.9 Reference Reference Reference
Tertile 2 35.8 -2.1 -1.5 -0.6
Tertile 3 33.9 -4.0 -2.7 -1.3
*Data are given as years. Differences are calculated using the first tertile as reference. All LEs have been calculated 
with hazard ratios adjusted for age, cohort, smoking, alcohol intake, education level, marital status, diabetes mellitus, 
body mass index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, and use 
of lipid-lowering medications. Abbreviations: LE, life expectancy; TSH, thyroid-stimulating hormone; FT4, free thyrox-
ine; CVD, cardiovascular disease.
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Supplemental Table 4. LE at age 50 years, among thyroid status categories, in men and women*
Tn Total le
differences in 
total le
differences in le 
free of cvd
differences in le 
with cvd
Men
Euthyroidism 3667 31.0 (30.8; 31.3) Reference Reference Reference
Hypothyroidism† 245 31.3 (29.5; 32.9) 0.3 (-1.7; 1.9) 0.1 (-2.4; 2.5) 0.2 (-1.5; 2.1)
Hyperthyroidism† 80 29.6 (26.6; 32.9) -1.4 (-4.4; 2.0) -3.7 (-7.6; 0.1) 2.3 (-1.3; 6.4)
Women
Euthyroidism 4028 35.6 (35.3; 35.9) Reference Reference Reference
Hypothyroidism† 551 36.7 (35.5; 37.8) 1.1 (-0.4; 2.3) 0.8 (-0.7; 2.2) 0.3 (-0.8; 1.3)
Hyperthyrodism† 110 36.0 (33.7; 38.4) 0.4 (-2.1; 2.9) 2.3 (0.2; 4.4) -1.9 (-3.1;-0.4)
*For this analysis, we included participants without known thyroid disease and not using thyroid function-altering 
medications (ie, thyroid medications, amiodarone, corticosteroids). Differences are calculated using the euthyroid 
category as reference. Data are given as years (95% confidence intervals). All LEs have been calculated with hazard 
ratios adjusted for age, cohort, smoking, alcohol intake, education level, marital status, diabetes mellitus, body mass 
index, systolic blood pressure, total cholesterol, triglycerides, use of antihypertensive medications, and use of lipid-
lowering medications. †Includes subclinical and clinical range. Abbreviations: LE, life expectancy; TN, total number; 
CVD, cardiovascular disease.
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reFlecTion on The main FindinGS
Chapter 2 of this thesis investigated the association of thyroid function with specific 
aspects of cardiometabolic health, including fatty liver, fibrosis, atherosclerosis, co-
agulation and epicardial adipose tissue (EAT). Chapter 3 investigated the association 
of thyroid function with general health, using several multidimensional measures 
that can reflect the pleiotropic effects of thyroid hormones. The main findings of 
this thesis are summarized in Table 1.
Thyroid function and specific aspects of cardiometabolic health
Thyroid function and the risk of nonalcoholic fatty liver disease: Nonalcoholic fatty 
liver disease (NAFLD) comprises a broad spectrum, ranging from steatosis to nonalco-
holic steatohepatitis (NASH) with fibrosis.1 NAFLD is the most common chronic liver 
condition with a global prevalence of more than 25%.2,3 The prevalence of NAFLD 
is rapidly increasing, and NASH-related cirrhosis is becoming the leading cause of 
liver transplantation worldwide.4 Therefore, the identification of novel modifiable 
risk factors of NAFLD is of major importance. Thyroid hormones can influence the 
intrahepatic lipid metabolism and the development of hepatic steatosis.5 However, 
previous cross-sectional population-based studies investigating the association of 
thyroid function with hepatic steatosis have provided inconsistent results.6,7 The only 
prospective study to date was performed by Xu et al, who showed that subclinical 
hypothyroidism is associated with an increased risk of developing NAFLD.8 Still, the 
risk of NAFLD in the remaining categories of thyroid function, other than subclinical 
hypothyroidism, has not been prospectively explored. To address this gap, we inves-
tigated the association between the whole spectrum of thyroid function and the 
risk of NAFLD, in a large prospective population-based cohort study (Chapter 2.1).
Our results indicated that the association of thyroid function with NAFLD is not 
only limited to subclinical hypothyroidism, but is extended both within as well as 
outside the reference range of thyroid function. We found a negative linear associa-
tion between free thyroxine (FT4) levels and incident NAFLD, even among euthyroid 
subjects, as well as a positive linear association for thyroid-stimulating hormone 
(TSH) levels. The risk of NAFLD progressively decreased from a hypothyroid to a 
hyperthyroid state.
Aiming to provide some mechanistic insights, we further investigated whether 
and which cardiovascular risk factors could explain the association of thyroid func-
tion with NAFLD. Interestingly, our data indicated that circulating triglyceride levels 
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Table 1. Overview on the main findings of this thesis
TSh FT4
Thyroid function and specific aspects of cardiometabolic health
Nonalcoholic fatty liver disease (P) ↑/= ↓
Fibrotic diseases of the liver, lung and heart (C and P) ↑/= =
Atherosclerosis (P)
Coronary artery calcification = ↑
Incident atherosclerotic CV events = ↑
Atherosclerotic CV deaths ↓/= ↑
Coagulation factors (C)
Fibrinogen = ↑
VWF = ↑
ADAMTS13 = ↓
Epicardial adipose tissue (C) = ↑*
Potential mediating role (P)
Fibrinogen & CV outcomes = M
VWF & CV outcomes = M
ADAMTS13 & CV outcomes = =
Epicardial adipose tissue & AF = =
Thyroid function and general health
Frailty index changes (P) = ↑
Gait aspects related to thyroid function (C) Tandem, base of 
support, velocity
=
Life expectancy with and without NCD† (P) ↑ ↓
Life expectancy with and without CV disease† (P) ↑ ↓
Arrows represent the direction of the associations. Arrows pointing upwards represent positive associations, whereas 
arrows pointing downwards represent negative associations. Equal signs represent absence of statistically significant 
associations. *This finding applies only to subjects with large waist circumferences. †This study was performed among 
euthyroid participants. Abbreviations: TSH, thyroid-stimulating hormone (mIU/L); FT4, free thyroxine (ng/dL); CV, car-
diovascular; VWF, von Willebrand factor; ADAMTS13, a disintegrin and metalloprotease with thrombospondin motif 
repeats 13; AF, atrial fibrillation; M, mediator; NCD, non-communicable diseases; (P), prospective; (C), cross-sectional.
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and body mass index may play an important role in the pathways linking thyroid 
function to NAFLD (ie, excess risk mediated by triglycerides and BMI, up to 22.2%).
Another novel aspect of our study was the utilization of liver elastography, 
which allowed us to additionally explore the risk of developing NAFLD with fibrosis. 
We showed that the risk of developing NAFLD with fibrosis progressively decreases 
from a hypothyroid to a hyperthyroid state. In line, lower thyroid function was as-
sociated with a higher risk of having NAFLD with fibrosis. Based on these findings, 
we hypothesize that low thyroid function may either accelerate the progression of 
liver steatosis to fibrosis or may directly stimulate the development of liver fibrosis, 
independent of steatosis. Further research will need to pinpoint the exact underly-
ing mechanisms linking thyroid function to liver fibrosis. Moreover, future inter-
ventional studies in animals and humans are warranted to explore the potential 
beneficial effects of thyroid hormone supplementation on liver fibrosis.
Thyroid function and the risk of fibrosis: Current research is focused on the iden-
tification of novel determinants of fibrosis, which could be further translated into 
the development of effective antifibrotic drugs. Among other factors, low thyroid 
function has been implicated in the occurrence and progression of liver, pulmonary 
and myocardial fibrosis.9-11 However, evidence is fragmented and inconclusive. 
In Chapter 2.2, we aimed to summarize the current evidence regarding the link 
between thyroid function and the risk of developing fibrosis in the human liver, 
lung and heart. After screening 1764 titles and abstracts, we identified 10 studies 
meeting the inclusion criteria.6,12-20 Of the identified studies, 6 reported on liver 
fibrosis,6,12-16 2 on pulmonary fibrosis,17,18 and 2 on myocardial fibrosis.19,20 In the set-
ting of diverse study populations, low thyroid function was consistently associated 
with increased odds of liver fibrosis, pulmonary fibrosis, and myocardial fibrosis. 
However, most of the evidence on this topic was based on cross-sectional data. In 
the future, adequately powered studies are needed to prospectively investigate 
the long-term effects of thyroid hormones on the occurrence and progression of 
fibrosis. Furthermore, future interventional studies in humans are needed to ex-
plore whether thyroid hormones or thyroid hormone analogues can prevent the 
progression of fibrosis. These investigations could lead to new avenues regarding 
the development of new therapies against fibrotic diseases. Lastly, future research is 
needed to elucidate the exact underlying mechanisms linking low thyroid function 
to fibrosis.
250 Chapter 4
Thyroid function and the risk of atherosclerotic cardiovascular morbidity and 
mortality: Atherosclerosis is an accumulation of lipids and fibrous elements in the 
arterial walls, that can progress insidiously from an asymptomatic luminal narrow-
ing of the arteries known as subclinical atherosclerosis, to the clinical manifestation 
of serious cardiovascular events to death.21 Thyroid hormones have been linked to 
both proatherogenic22,23 and antiatherogenic processes.24 Epidemiological studies 
have so far investigated the association between specific ranges of thyroid function 
and distinct atherosclerosis events as coronary heart disease or stroke, with incon-
sistent results.25-28 However, the role of thyroid function on the different stages of 
atherosclerosis progression has been unclear. Therefore, Chapter 2.3 examined the 
association between the full range of thyroid function and atherosclerosis through-
out its spectrum, spanning from subclinical atherosclerosis (measured by coronary 
artery calcification) to clinical atherosclerotic cardiovascular (ASCV) events to ASCV 
mortality.
We found that FT4 levels were positively and linearly associated with subclinical 
and clinical atherosclerosis. Increasing circulating FT4 levels were associated with 
twice the odds of elevated coronary artery calcification scores, 87% greater risk of 
ASCV events, and double the risk of ASCV mortality. After restricting the analyses 
to euthyroid participants, these associations became even stronger. Specifically, the 
higher limit of the FT4 reference range was associated with a 2.70 and a 4.15 times 
higher risk of incident ASCV events and ASCV mortality, respectively, compared with 
the lower reference limit. Also, the magnitude of the association for ASCV mortality 
was greater compared with non-ASCV mortality, which indicates that atherosclerosis 
plays an important role in the pathways linking high thyroid function to increased 
mortality risk.
Interestingly, our findings were independent of traditional cardiovascular risk 
factors such as hypertension or dyslipidemia. This suggests that the link between 
thyroid hormones and atherosclerosis can be explained by mechanisms that go 
beyond traditional cardiovascular risk factors. Hemodynamic changes, endothelial 
damage and increased thrombogenesis might play a role.
Thyroid function and coagulation: Large meta-analyses and systematic reviews of 
clinical-based studies have shown an increased risk of bleeding in hypothyroidism 
and an increased risk of thrombosis in hyperthyroidism.23,29 Previous studies, how-
ever, did not investigate whether the anticoagulant effects of hypothyroidism and 
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the procoagulant effects of hyperthyroidism are extended even within the normal 
reference range of thyroid function. To address this, large studies in the general 
population are needed. Therefore, we performed a large population-based cohort 
study (Chapter 2.4), which investigated the association of thyroid function with sev-
eral coagulation factors, including fibrinogen, von Willebrand factor (VWF) antigen 
and ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motif 
repeats 13) activity.
We found that high and high-normal FT4 levels are associated with increased 
fibrinogen and VWF levels, which indicate a procoagulant state. In line with our 
results, a direct role of thyroid hormones on the transcription of fibrinogen and 
VWF genes has been suggested.30 Moreover, we found that high and high-normal 
FT4 levels are associated with a decreased activity of ADAMTS13. This suggests that 
thyroid hormones can attenuate the role of ADAMTS13 in cleaving the procoagu-
lant VWF multimers into less procoagulant forms. Future studies are warranted to 
explore the possibility of a direct effect of thyroid hormones on ADAMTS13.
Thyroid function and epicardial adipose tissue: The role of thyroid hormones on 
adiposity is complex and depends on the location and composition of adipose tis-
sue. EAT, which surrounds the myocardium, possesses both white and brown adi-
pose tissue properties.31 A thyroid-hormone dependent gene, namely uncoupling 
protein 1 gene is recently shown to be highly expressed in EAT, thus suggesting a 
potential direct effect of thyroid hormones on mitochondrial uncoupling and EAT 
activation.31 In line, several small studies (n<100) have suggested a potential role of 
thyroid dysfunction on EAT activation.32-36 However, the association of thyroid func-
tion with EAT has not been explored in larger studies, nor has it been investigated 
throughout the full range of thyroid function in the general population. To address 
this, we performed a large population-based cohort study (Chapter 2.5), in which 
we evaluated EAT volumes by using well-standardized CT scan measurements. We 
found that higher FT4 levels among participants with a large waist circumference 
are associated with larger EAT volumes. Hypothetically, increased thyroid hormone 
levels may contribute to the transdifferentiation of white adipocytes to brown 
adipocytes in the EAT of obese patients.
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Mediators linking thyroid function to cardiovascular disease: In Chapters 2.4 and 
2.5, we sought to provide mechanistic insights on the cardiovascular effects of thy-
roid hormones.
Previous evidence suggests that thyroid hormones regulate the synthesis of co-
agulation proteins, which in turn contribute to blood viscosity.30 In Chapter 2.4, we 
investigated the potential mediating role of coagulation factors in the association 
of thyroid function with cardiovascular disease and mortality. VWF and fibrinogen 
(but not ADAMTS13) were identified as partial mediators linking FT4 to cardio-
vascular events. The observed proportion of mediation was approximately 10%, 
which is quite considerable given the multiple mechanisms through which thyroid 
hormones affect cardiovascular health. Besides, it can be assumed that other coagu-
lation factors, such as factors VII, VIII, IX, X, XII, can play an additional mediating 
role.23,37,38 Unfortunately, data on these factors were not available in our study. If all 
the relevant coagulation factors could also be taken into account in our mediation 
analyses, the expected proportion of mediation related to coagulation may have 
been even higher than what we observed in our study.
Another explanation of the cardiovascular effects of thyroid hormones can be 
related to EAT. Thyroid hormones may affect the metabolism of EAT, which is a 
rapidly emerging risk factor for CVD, and particularly for atrial fibrillation (AF).31,39 
In Chapter 2.5, we investigated the potential mediating role of EAT in the associa-
tion of thyroid function with AF. No relevant mediating effect of EAT was found, 
but our study indicated that the combined effects of thyroid hormones and EAT may 
increase the risk of AF synergistically.
Thyroid function and general health
Thyroid function associated with frailty index, a measure of frailty and general 
health: In Chapter 3.1, we investigated the association of thyroid function with 
frailty index, a well-established measure of frailty and general health. Interestingly, 
higher FT4 levels were associated with increasing scores of frailty index, thus indicat-
ing an increased risk of health deterioration over time. These findings can reflect 
various deleterious effects of excess thyroid hormones, such as an increased risk of 
neurodegeneration, arrhythmias, hemodynamic changes, hypercoagulability, and 
reduction in bone mineral density.40-43
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Identification of gait aspects related to thyroid function: Thyroid function in the 
general population has been linked to gait velocity.44,45 However, it remains un-
known whether other gait aspects are related to thyroid function. In Chapter 3.2, 
we identified tandem and base of support as novel gait domains related to thyroid 
function. The identification of thyroid-related gait domains may provide valuable 
hints on  the pathways linking thyroid function to gait. Tandem, base of support 
and velocity have been so far associated with executive functioning, balance, and 
distinct brain structures (ie, prefrontal regions, parietal cortex, pallidum, putamen, 
and cerebellum) that may be targeted by thyroid hormones.46-51
Meaningful differences in life expectancy within the reference range of thyroid 
function: In view of the ongoing debate on redefining the reference ranges of 
TSH and FT4 levels, several population-based studies have shown that variations in 
thyroid function within the reference range are associated with an increased risk of 
chronic diseases and mortality.26,27,40,52-54 In Chapters 3.3 and 3.4, we extended the 
previous knowledge, by revealing meaningful differences in total life expectancy 
and life expectancy with and without diseases within the reference range of thyroid 
function. We found that subjects with low-normal thyroid function lived more 
years with and without non-communicable diseases than those with high-normal 
thyroid function. As a result, low-normal thyroid function was also associated with 
a prolonged life expectancy compared with high-normal thyroid function. These 
differences in life expectancy can reflect differences in the risk of adverse outcomes 
within the reference range of thyroid function. So far, low-normal TSH and high-
normal FT4 levels have been prospectively linked to an increased risk of AF, ASCV 
disease, heart failure, dementia and fractures, which are all associated with an 
increased risk of mortality.27,55,56
meThodoloGical conSideraTionS
Population-based cohort studies, strengths and pitfalls
Most studies included in this thesis were embedded within the framework of the 
Rotterdam Study, a prospective population-based cohort study in middle-aged and 
older adults.57 Major strengths of our studies are the well-characterized population-
based study sample, the large number of eligible participants, and the extensive 
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information on covariates including exposures, outcomes, potential confounders 
and mediators. Multiple sensitivity analyses provided consistent findings.
The following considerations should also be taken into account. Due to the 
observational character, population-based studies may be subject to bias including 
healthy volunteer bias or attrition bias. However, the possibility of these biases 
within the Rotterdam Study is minimized because of the random sampling of par-
ticipants from the general population, the high response rate of participants and 
the nearly complete follow-up. Another type of bias in observational studies is the 
information bias, which can be either differential or non-differential. However, the 
possibility of information bias in our studies is minimized because of the utilization 
of standardized procedures of data collection, blinding of both participants and 
investigators to thyroid function measurements, and the adjudication of events in 
accordance with the current guidelines. Another concern in observational studies is 
related to the possibility of confounding. To address confounding, we adjusted our 
analyses for potential confounders, that were selected based on biological plausibil-
ity and previous literature.58 However, the possibility of residual confounding can-
not be ruled out. Potential confounders as smoking status, alcohol consumption and 
diet were self-reported and therefore could have been affected by measurement 
errors. Furthermore, the Rotterdam Study includes predominantly white Northern 
Europeans older than 45 years.57 Therefore, we cannot ascertain the generalizability 
of our findings to other ethnicities or younger subjects.
The studies of this thesis are mostly characterized by a prospective design with 
a long term follow-up time. Prospective designs provide evidence for a temporal 
relation between the exposure and outcome, thus reducing the possibility of re-
verse causation.59 When applicable (eg, in Chapters 2.3, 3.3, 3.4), we additionally 
addressed reverse causation by excluding the events that occurred within the first 
two years of follow-up. However, some analyses in this thesis had a cross-sectional 
character, which does not provide evidence on the temporality of an association. 
This specifically applies to Chapter 3.2, in which we reported a nonlinear association 
of TSH levels with global gait. Similarly, the cross-sectional analysis in Chapter 3.1 
revealed a nonlinear association of TSH levels with frailty index. Taken together, the 
cross-sectional analyses in Chapters 3.1 and 3.2 indicated that subjects with low and 
high thyroid function are more likely to have a worse heath state than those with 
normal thyroid function. On the other hand, the prospective analysis in Chapter 3.1 
suggested that subjects with low thyroid function do not have an increased risk of 
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health deterioration over time. This discrepancy between the cross-sectional and 
prospective results can be attributed to the condition of “non-thyroidal illness”, 
which is typically characterized by low thyroid function secondary to a poor health 
status.60 The cross-sectional association between low thyroid function and poor 
health may reflect an alteration of thyroid parameters due to health-related issues 
rather than vice-versa. Therefore, the possibility of reverse causation due to the 
“non-thyroidal illness” needs to be taken into consideration when interpreting the 
results of cross-sectional studies on thyroid function.
mediation analyses
Mediation analyses are helpful tools to explore and identify the underlying mecha-
nisms of an association.61 Besides the potential direct effect of the exposure on the 
outcome, the model proposes that the exposure influences a mediator, which in 
turn influences the outcome (Figure 1). In this thesis, mediation analyses were used 
to explore some of the pathways through which thyroid hormones affect cardio-
vascular health. In Chapter 2.4, we investigated the potential mediating role of 
several coagulation factors, including fibrinogen, VWF, and ADAMTS13 activity. We 
found evidence of partial mediation, implying that the coagulation factors account 
for some, but not all, of the association between FT4 and cardiovascular events. In 
Chapter 2.5, we used the four-way decomposition approach, that unifies within a 
single framework the methods using mediation and interaction.62 Although we did 
not describe a mediating role of EAT, we found evidence for a suggested interaction 
of FT4 with EAT volumes on AF risk.
Figure 1. A statistical mediation model.
Exposure Outcome
Mediator
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multistate life tables
Multistate life tables is a demographic tool that is often used to estimate the total 
life expectancy and disease-specific life expectancies.63 This tool combines the in-
formation of individuals in three possible health states, namely “free of disease”, 
“disease” and “death”. Potential transitions of participants are: (1) from free of 
disease to disease, (2) from free of disease to death, (3) from disease to death (Fig-
ure 2). The age of each individual is measured at the study entry, when the event 
occurs and at the end of the follow-up.64 Age-specific rates of disease and mortality 
probabilities are used to calculate the total life expectancy and disease-specific life 
expectancies. A limitation of this approach is related to the arbitrary categorization 
of participants into health states, thus not accounting for the potential amelioration 
or aggravation of disease over time. Hence, the results derived from the multistate 
life table analysis are only an approximation of the real disease burden. In Chapters 
3.3 and 3.4, the multistate life table analysis was used to investigate the association 
of thyroid function with total life expectancy and disease-specific life expectancies 
among euthyroid subjects. We found considerable differences in life expectancy 
within the reference range of thyroid function. These findings provide supporting 
evidence for a reevaluation of the current reference ranges of thyroid function.
PoTenTial imPlicaTionS and FuTure direcTionS
causality
In this thesis, the biological plausibility of the research questions, the strength and 
consistency of the associations, the prospective designs of most studies and the 
various sensitivity analyses addressing reverse causation strongly suggest a causal 
Figure 2. Transitions in multistate life tables.
Free of disease Death
Disease
Transition 2
Tra
ns
itio
n  1
Transition 3
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relation between exposures and outcomes.65 Yet, the observational character of our 
studies does not allow us to establish causality.
In the future, methods of causal inference can be useful to gain further insights 
on the direction of the associations. Mendelian Randomization (MR) is a pragmatic 
method of causal inference which uses genetic variants in non-experimental data.66,67 
This approach is based on the principle that genetic variants are generally not as-
sociated with confounders owing to the random independent assortment of DNA at 
meiotic segregation of alleles.68 Given that genetic variants are immune to reverse 
causation, MR can be useful to clarify the direction of an association. However, the 
following considerations need to be taken into account. First, MR studies are based 
on the critical assumption that the genetic variants should be associated with the 
exposure. To satisfy this assumption, a large proportion of TSH and FT4 heritability 
needs to be explored and explained by future research. Second, genetic variants 
in MR can sometimes have multiple phenotypic effects, also known as pleiotropic 
effects.69 Third, the effects of genetic variants may be buffered by compensatory de-
velopmental processes. Fourth, MR studies require very large sample sizes in order 
to obtain sufficient statistical power.
Randomized clinical trials (RCTs) can provide important evidence on the effects 
of treatment and can help overcome some limitations of the observational studies.70 
One of the major strengths of RCTs is randomization, which addresses the issue 
of confounding. However, the randomization of individuals to specific interven-
tions can be unethical. Besides, RCTs are expensive and require a long time to be 
completed. Therefore, before designing new RCTs, data from previous RCTs and 
observational studies need to be carefully evaluated.71 To date, guidelines for the 
treatment of subclinical thyroid dysfunction72,73 are mainly based on the results of 
observational research and short-term small RCTs.74-78 The long-term risks related 
to the treatment of subclinical thyroid dysfunction have not been comprehensively 
explored. Moreover, it remains unclear whether the optimal treatment thresholds 
for TSH and FT4 levels are similar to the TSH and FT4 reference ranges. As a result, 
thyroid patients often carry the risk of being overtreated or undertreated. In order 
to minimize this risk, adequately powered RCTs are warranted to explore the risks 
and benefits of the thyroid disease treatment and eventually establish the optimal 
treatment targets for the TSH and FT4 levels.
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mechanisms
The mediation analyses in Chapters 2.1, 2.4, 2.5 of this thesis provide some novel 
insights on the pathways through which thyroid hormones affect cardiometabolic 
health. Specifically, our results in Chapter 2.1 suggest that even slight reductions in 
circulating thyroid hormone levels can increase the risk of NAFLD via affecting the 
metabolism of triglycerides and fat. Furthermore, our results in Chapter 2.4 indicate 
that high and high-normal thyroid hormones may increase the risk of cardiovascular 
diseases via altering the activity of circulating coagulation factors, such as VWF, AD-
AMTS13, and fibrinogen. Future observational studies are needed to replicate the 
results of our mediation analyses in other populations. In addition, in vitro and in 
vivo experimental studies are also needed to explore the exact mechanisms that can 
explain the role of thyroid function on cardiometabolic health and general health. 
Once identified, the modifiable mediators can be further targeted to eventually 
reduce the burden of the clinical implications of thyroid dysfunction.
circulating thyroxine, a potential predictive marker?
Observational studies provide evidence for either the presence or absence of an 
association. Once an association is reported, additional research may further head 
towards new avenues regarding causation and underlying mechanisms. Regardless 
of whether an association is causal or not, it can still be very useful to make predic-
tions.
The studies included in this thesis showed that variations in thyroid function 
are associated with specific aspects of cardiometabolic health (Chapter 2) and 
with several measures of general health (Chapter 3), independently of traditional 
cardiovascular risk factors. Remarkably, our observed associations among euthyroid 
participants were similar and sometimes even stronger than in the general popula-
tion, indicating the robust consistency of our findings. Overall, our results suggest 
that thyroid function measurements among middle-aged and older adults can be 
considered as potential predictive markers for cardiometabolic health and general 
health.
FT4 measurements may even represent a better predictive marker than TSH 
measurements. In line with other studies among middle-aged and older adults, we 
consistently showed that the association between FT4 and clinical outcomes is gen-
erally stronger compared with the association between TSH and clinical outcomes 
(Table 1).12,55,79 One potential explanation for these results is that the direct effects 
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of thyroid hormones on various organs may be independent from the effects of 
thyroid hormones on the pituitary gland. Another potential explanation is related 
to the ageing process, which may modify the TSH-FT4 set point of the negative 
feedback mechanism.80 In order to maintain the same FT4 levels, older persons (such 
as the Rotterdam Study participants) may need different TSH levels compared with 
the younger persons.
Risk prediction modelling can become a new line of thyroid-related research. 
Presumably, the discrimination abilities of some current predictive models can be 
improved after adding FT4 measurement as a potential predictor. Hence, future 
studies may aim to assess the potential role of FT4 in predicting the risk of adverse 
outcomes. Besides, future studies may aim to identify potential subgroups at high 
risk for developing adverse outcomes. Once identified, subgroups at risk may fur-
ther receive additional testing and care.
reference ranges of TSh and FT4 levels
Previous population-based studies have reported that variations in thyroid function 
within the reference range are associated with several diseases such as AF, stroke, 
and diabetes.26,54,79 Studies included in this thesis extend the previous literature by 
showing that variations in thyroid function within the reference range are also 
associated with other clinical outcomes, such as NAFLD and atherosclerosis. These 
data, taken together, suggest that the effects of thyroid dysfunction are extended 
even within the reference ranges of TSH and FT4 levels. Based on this evidence, 
future studies may need to perform a reevaluation of the current reference ranges 
of thyroid function.
The reevaluation of TSH and FT4 reference ranges may have important clinical 
implications on the diagnosis and treatment of thyroid disease. Therefore, the 
criteria of reevaluation need to be carefully established. One approach of reevalu-
ation can redefine the reference ranges of TSH and FT4 levels based on the risk 
of developing adverse outcomes. This approach has two main challenges. First, an 
expert group will need to specify the relevant adverse outcomes that are related 
to thyroid function. To achieve this, inconsistent literature reports on the effects of 
thyroid function will need to be reconciliated. Second, risk estimates of all relevant 
adverse outcomes will need to be further combined into an integrated risk estimate. 
This is complex, because the beneficial effects of specific TSH and FT4 levels on one 
system can be counterbalanced by their harmful effects on another system. Previ-
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ous prospective population-based studies have reported that high-normal thyroid 
function constitutes a decreased risk of metabolic diseases (eg, diabetes), but an 
increased risk of cardiovascular diseases (eg, AF).54,79 Additionally, we report that 
high-normal thyroid function constitutes a decreased risk of NAFLD, but an in-
creased risk of ASCV events.12,55 It is therefore challenging to determine the balance 
of overall benefits and risks for specific cutoffs of TSH and FT4 levels. Moreover, the 
observed associations of thyroid function with various adverse events are generally 
linear, thus making it difficult to propose specific cutoffs.
Another approach for reevaluating the thyroid function reference ranges could 
be based on the measures of general health that reflect the pleiotropic effects of 
thyroid hormones. The major challenge of this approach is that a “golden standard” 
measure of general health does not exist. In these circumstances, future research 
can take into consideration our results in Chapters 3.3 and 3.4, which imply the 
possibility of a downward shift of FT4 reference ranges.
identification of novel thyroid hormone agonists
In line with previous studies,54,79 our findings suggest that thyroid hormones exert 
either beneficial or harmful effects depending on the targeted organs (eg, Chapters 
2.1, 2.3). Given the complexity of thyroid hormone action, researchers over the last 
years have been intrigued by the possibility of discovering novel thyroid hormone 
analogues that can maximize the beneficial effects of thyroid hormones and mini-
mize their deleterious effects. Several interventional studies to date have suggested 
potential beneficial effects of thyroid hormone analogues in reducing the risk of 
metabolic diseases as hepatic steatosis, diabetes, hyperlipidemia, and obesity.81-84 
Unfortunately, detrimental effects of thyroid hormone analogues in various systems, 
including the cardiovascular system, have been reported.85 The most promising thy-
roid hormone analogue, eprotirome, was not approved for clinical use in humans 
due to its adverse effects on the cartilage of animals.85 In this context, one of the 
major challenges for future research remains the identification of novel effective 
thyroid hormone analogues. In particular, future studies may need to identify the 
thyroid hormone receptor genes that are responsible for the specific beneficial and 
deleterious effects of thyroid hormones.
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additional measurements
The Rotterdam Study is characterized by extensive and detailed information regard-
ing the measurements of exposures, outcomes, potential confounders and media-
tors. Future studies may consider performing several additional measurements. First, 
repeated measurements of TSH and FT4 levels could provide additional information 
on the strength and consistency of the associations. However, studies using only one 
measurement of TSH and FT4 can underestimate the association of thyroid function 
with morbidity and mortality by approximately one third, due to the regression 
dilution bias.86 Hence, repeated measurements of thyroid function would be ex-
pected to strengthen even more our risk estimates. Second, although TSH and FT4 
concentrations are currently considered as the most relevant measurements of thy-
roid function in clinical practice, measurements of free triiodothyronine (FT3) levels 
could provide more comprehensive information on the action and bioavailability of 
thyroid hormones. Available FT3 measurements allow the calculation of the FT3/FT4 
ratio, which is a marker of peripheral thyroxine deiodination. Third, longitudinal 
measurements of EAT, coagulation factors and gait patterns would be expected 
to minimize the possibility of reverse causation that derives from cross-sectional 
designs.
concluSionS
This thesis extends the current knowledge on the association of thyroid function 
with specific aspects of cardiometabolic health. Adopting a broader perspective, we 
further present novel insights on the association of thyroid function with markers 
of general health. Our results suggest that the clinical consequences of thyroid dys-
function are extended even within the reference ranges of TSH and FT4 levels, thus 
providing supporting evidence for a reevaluation of the current reference ranges 
of thyroid function. Further studies may consider incorporating thyroid function 
measurements in models for predicting the risk of adverse outcomes. Moreover, 
future research is needed to replicate our results, establish causality, and explore 
additional underlying mechanisms.
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Summary
In chapter 1 of this thesis, we provide a general background on the pleiotropic 
effects of thyroid hormones, with a particular focus on cardiometabolic health. 
Furthermore, we describe the objectives, rationale and outline of this thesis. One 
study in this thesis is a systematic review. The other studies of this thesis are embed-
ded within the Rotterdam Study, a large prospective population-based cohort study 
among middle-aged and older adults.
In chapter 2, we aim to expand the current knowledge about the specific effects of 
thyroid function on cardiometabolic health. We therefore investigate the associa-
tion of thyroid function with several aspects of cardiometabolic health, including 
nonalcoholic fatty liver disease (NAFLD), atherosclerosis, coagulation, and EAT 
(epicardial adipose tissue). In addition, we provide some novel mechanistic insights 
about the effects of thyroid hormones on cardiovascular system. In Chapter 2.1, we 
prospectively investigate the association of thyroid function with the risk of NAFLD 
and liver fibrosis. We show that low and low-normal thyroid function are associated 
with an increased risk of NAFLD and liver fibrosis. In Chapter 2.2, we systematically 
appraise the evidence regarding the role of thyroid function on fibrosis of the liver, 
lung, and heart in humans. The systematic review suggests that low thyroid func-
tion is consistently associated with an increased risk of fibrotic diseases in the liver, 
lung and heart. In Chapter 2.3, we examine the association of thyroid function with 
atherosclerosis throughout its spectrum, spanning from subclinical atherosclerosis 
(measured by coronary artery calcification) to clinical atherosclerotic cardiovascular 
events to atherosclerotic cardiovascular mortality. We show that FT4 levels, even 
within the normal reference range, are positively and linearly associated with high 
coronary artery calcification score, and increased risk of atherosclerotic cardiovascu-
lar morbidity and mortality. Interestingly, these results are independent of traditional 
cardiovascular risk factors. In Chapter 2.4, we investigate the association of thyroid 
function with several coagulation factors, including procoagulant (ie, fibrinogen 
and von Willebrand factor antigen) and anticoagulant (ie, ADAMTS13 activity) fac-
tors. We show that higher FT4 levels are associated with higher fibrinogen, higher 
von Willebrand factor antigen and lower ADAMTS13 activity, which indicate a pro-
coagulant state. Fibrinogen and von Willebrand factor antigen (but not ADAMTS13) 
are further identified as partial mediators linking FT4 to cardiovascular disease. In 
Chapter 2.5, we examine the association of thyroid function with EAT measured by 
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computed tomography. We show that higher FT4 levels among participants with a 
large waist circumference are associated with larger EAT volumes. Furthermore, we 
investigate the potential mediating role of EAT in the association of thyroid func-
tion with atrial fibrillation. We do not find a mediating effect of EAT, though our 
results suggest that the synergic effects of thyroid hormones and EAT may increase 
the risk of atrial fibrillation.
In chapter 3, we aim to yield novel insights on the qualitative and quantitative 
impact of thyroid function on health. We therefore investigate the association of 
thyroid function with general health, using several multidimensional measures that 
can reflect the pleiotropic effects of thyroid hormones, such as frailty index, gait 
patterns, total life expectancy, and disease-specific life expectancy. In Chapter 3.1, 
we investigate the association of thyroid function with frailty index. We show that 
higher FT4 levels are associated with increasing scores of frailty index, thus indicat-
ing an increased risk of health deterioration over time. In Chapter 3.2, we present 
the association of thyroid function with gait patterns. Tandem and base of support 
are identified as novel gait domains related to thyroid function. In view of the 
ongoing debate on redefining the reference ranges of TSH and FT4 levels, Chapters 
3.3 and 3.4 investigate potential differences in total and disease-specific life expec-
tancy, within the reference range of thyroid function. We show that subjects with 
low-normal thyroid function live longer overall, and also live more years with and 
without non-communicable diseases than those with high-normal thyroid function.
In chapter 4, we provide a reflection on the main findings of this thesis and highlight 
several methodological considerations in epidemiological research. Moreover, we 
describe the potential clinical implications of our findings and future perspectives.
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SamenvaTTinG
In hoofdstuk 1 van dit proefschrift beschrijven wij de pleiotrope effecten van schild-
klierhormonen, met bijzondere aandacht voor de effecten op de cardiometabole 
gezondheid. Verder beschrijven we de doelstellingen, beweegredenen en de hoofd-
lijnen van dit proefschrift. Eén onderzoek in dit proefschrift is een systematische 
review. De andere studies van dit proefschrift zijn onderdeel van de Rotterdam 
Study, een grote prospectieve populatie-gebaseerde cohortstudievan middelbare 
en oudere volwassenen.
In hoofdstuk 2 proberen we de huidige kennis over de specifieke effecten van de 
schildklierfunctie op cardiometabole gezondheid uit te breiden. We onderzoeken 
daarom de associatie van de schildklierfunctie met verschillende aspecten van de 
cardiometabole gezondheid, waaronder niet-alcoholische leververvetting (NAFLD), 
atherosclerose, coagulatie en epicardiaal vetweefsel. Daarnaast bieden we enkele 
nieuwe mechanistische inzichten over de effecten van schildklierhormonen op het 
cardiovasculaire systeem. In hoofdstuk 2.1 onderzoeken we prospectief de associ-
atie van de schildklierfunctie met het risico op NAFLD en leverfibrose. We laten 
zien dat lage en laag-normale schildklierfunctie geassocieerd zijn met een verhoogd 
risico op NAFLD en leverfibrose. In hoofdstuk 2.2 beoordelen we systematisch het 
bewijsmateriaal met betrekking tot de rol van de schildklierfunctie op fibrose van 
de lever, de longen en het hart in de mens. De resultaten van de systematische 
review suggereren dat een lage schildklierfunctie gepaard gaat met een verhoogd 
risico op fibrotische aandoeningen van de lever, de longen en het hart. In Hoofdstuk 
2.3 onderzoeken we de associatie van de schildklierfunctie met atherosclerose over 
het gehele spectrum, van subklinische atherosclerose (gemeten door coronaire 
arteriële calcificatie) tot klinische atherosclerotische cardiovasculaire uitkomsten 
tot atherosclerotische cardiovasculaire mortaliteit. We laten zien dat FT4waarden, 
zelfs binnen het normale referentiegebied, positief en lineair geassocieerd zijn 
met een hoge score op de coronaire aderverkalking, en een verhoogd risico op 
atherosclerotische cardiovasculaire morbiditeit en mortaliteit. Interessant is dat 
deze resultaten onafhankelijk zijn van de traditionele cardiovasculaire risicofacto-
ren. In hoofdstuk 2.4 onderzoeken we de associatie van de schildklierfunctie met 
verschillende stollingsfactoren, waaronder procoagulant (dwz fibrinogeen en von 
Willebrand factorantigeen) en anticoagulant (ie ADAMTS13-activiteit) factoren. 
We laten zien dat hogere FT4-niveaus geassocieerd zijn met een hoger fibrinogeen, 
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hoger von Willebrand-factorantigeen en lagere ADAMTS13-activiteit, wat wijst op 
een procoagulante toestand. Fibrinogeen en von Willebrand factorantigeen (maar 
niet ADAMTS13) worden verder geïdentificeerd als gedeeltelijke bemiddelaars die 
FT4 koppelen aan cardiovasculaire ziekte. In hoofdstuk 2.5 onderzoeken we de 
associatie van de schildklierfunctie met EAT gemeten met computertomografie. 
We laten zien dat hogere FT4-niveaus bij deelnemers met een grote middelomtrek 
worden geassocieerd met grotere epicardiaal vetweefsel volumes. We vinden echter 
geen bemiddelend effect van epicardiaal vetweefsel in de asscociatie tussen schild-
klierfunctie en atrium fibrilleren.Wel suggereert onze studie dat de synergetische 
effecten van schildklierhormonen en epicardiaal vetweefsel het risico op atrium 
fibrilleren kunnen verhogen.
In hoofdstuk 3 verschaffen we nieuwe inzichten over de kwalitatieve en kwantita-
tieve impact van de schildklierfunctie op de gezondheid. We onderzoeken daarom 
de associatie van de schildklierfunctie met de algemene gezondheid, met behulp van 
verschillende multidimensionale maten die de pleiotrope effecten van schildklierhor-
monen kunnen weerspiegelen, zoals de frailty index (ie, kwetsbaarheidindex), loop-
patronen, de totale levensverwachting en de ziekte-specifieke levensverwachting. In 
hoofdstuk 3.1 onderzoeken we de associatie van de schildklierfunctie met de frailty 
index. We laten zien dat hogere FT4-niveaus geassocieerd zijn met toenemende sco-
res van de frailty index, wat dus wijst op een verhoogd risico op verslechtering van de 
gezondheid in de loop van de tijd. In hoofdstuk 3.2 presenteren we de associatie van 
de schildklierfunctie met looppatronen. Tandem en basis van ondersteuning worden 
geïdentificeerd als nieuwe loopdomeinen gerelateerd aan de schildklierfunctie. Met 
het oog op het lopende debat betreft het herdefiniëren van de referentiewaarden 
van TSH- en FT4-waardes, onderzoeken de hoofdstukken 3.3 en 3.4 mogelijke verschil-
len in totale en ziekte-specifieke levensverwachting, binnen het referentiegebied 
van de schildklierfunctie. We laten zien dat personen met een laag-normale schild-
klierfunctie langer leven en ook meer jaren leven zowel met als zonder chronische 
aandoeningen dan mensen met een hoog-normale schildklierfunctie.
In hoofdstuk 4 geven we een reflectie op de belangrijkste bevindingen van dit 
proefschrift en benadrukken we verschillende methodologische overwegingen 
in epidemiologisch onderzoek. Bovendien beschrijven we de potentiële klinische 
implicaties van onze bevindingen en toekomstperspectieven.
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leTTer To The ediTor
reSPonSe reGardinG arTicle:“Thyroid FuncTion and The riSk oF 
aTheroScleroTic cardiovaScular morbidiTy and morTaliTy: The 
roTTerdam STudy”
Arjola Bano, Robin P. Peeters, Maryam Kavousi 
Adapted from Circ Res. 2018;122(3):e18
We appreciate the comments by Drs. Zhao and Schooling regarding our recent 
publication.1 In this study, we showed that higher circulating free thyroxine levels 
are associated with an increased risk of atherosclerosis throughout its full spectrum.
Zhao and Schooling argue that our observed associations are not supported by 
a Mendelian Randomization (MR) study, which found no evidence of an association 
between thyroid function and ischemic heart disease.2 The following considerations 
need to be taken into account with regard to this study. First, the MR study focused 
on coronary artery disease. However, there are no MR studies, to our knowledge, 
on thyroid function and atherosclerotic cardiovascular disease. Second, the MR ap-
proach assumes that genetic variants determine the exposure. Still, only a limited 
number of genetic variants for free thyroxine have been identified, while a large 
proportion of thyroid function heritability remains unexplained. Third, the possi-
bility of developmental compensation (ie, canalization) and pleiotropic effects of 
genetic variants cannot be excluded. Taken together, the current lack of genetic 
evidence does not rule out a potential effect of thyroid function on atherosclerotic 
cardiovascular disease.
We agree with the authors that we cannot prove a causal relationship due to 
the observational character of our study. However, the biological plausibility of our 
findings, the temporal relationship of the exposure with atherosclerotic events, and 
the various sensitivity analyses accounting for reverse causation strongly suggest an 
effect of thyroid function on atherosclerotic cardiovascular morbidity and mortality.1 
Moreover, our findings are consistent with the results of the randomized controlled 
trial cited by Zhao and Schooling.3 This trial investigated the effects of dextrothyrox-
ine treatment in patients with a history of myocardial infarction. The proportions 
of all-cause deaths, deaths from cardiovascular disease, deaths from coronary heart 
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disease and non-fatal recurrent myocardial infarctions were higher in the treatment 
arm than in the placebo arm of the trial, leading to a discontinuation of the trial 
after 36 months. In line, our study shows that higher free thyroxine levels are associ-
ated with an increased risk of atherosclerotic cardiovascular mortality, particularly 
among subjects with preexisting atherosclerotic cardiovascular disease.
Furthermore, Zhao and Schooling hypothesize that androgens can confound 
or mediate the association of thyroid function with atherosclerotic cardiovascular 
outcomes. This is an intriguing hypothesis, though the association of testosterone 
with atherosclerotic cardiovascular outcomes remains largely unclear.4 To date, 
randomized controlled trials investigating the effects of testosterone treatment on 
major cardiovascular events have yielded conflicting results.4 We had data available 
on testosterone concentrations in more than 99% of participants. After adding 
testosterone to our models, the association of thyroid function with atherosclerotic 
cardiovascular outcomes remained unchanged or became slightly stronger. Sex-spe-
cific analyses provided consistent findings before and after additional adjustments 
for testosterone. These data suggest that the association of thyroid function with 
atherosclerosis is independent of testosterone concentrations.
In the future, large MR studies are warranted to examine the association of ge-
netically predicted thyroid function with atherosclerotic cardiovascular outcomes. 
Further investigations are also needed to elucidate the exact mechanisms linking 
thyroid function to atherosclerosis.
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leTTer To The ediTor
liFe-exPecTancy oF loW-normal Thyroid FuncTion: rePly
Arjola Bano, Robin P. Peeters, Oscar H. Franco 
Adapted from JAMA Intern Med. 2018;178(3):437-438
We would like to thank Dr. Inoue and colleagues for their interest in our recent 
publication.1 As suggested by Inoue and colleagues, we now provide some addi-
tional information about our analyses. Our life expectancy calculations utilized age-
adjusted hazards and age-specific mortality rates, based on the data of individuals 
at different ages and different health states. In the third transition (ie, mortality 
among those with cardiovascular disease [CVD]), stratified analyses among partici-
pants who acquired CVD during the study period and participants who already had 
a history of CVD at baseline consistently showed that high-normal thyroid function 
is linked to a higher mortality risk than low-normal thyroid function. In addition, 
sensitivity analyses restricting the follow-up time to different lengths (ie, 6, 8, 10 
years of follow-up) yielded similar results. These data point towards a persistent 
effect of thyroid hormones on mortality risk across time.
Both the first and the second transition included participants who were free of 
CVD at baseline. Participants in the first transition (ie, incident CVD) were followed 
up until the occurrence of CVD events, whereas those in the second transition (ie, 
mortality among those without CVD) were followed up until they died. As a conse-
quence, person years at risk were different between the two transitions.
We agree with Dr. Inoue and colleagues that low thyroid function has a nega-
tive impact on cardiovascular health. According to a large meta-analysis from the 
Thyroid Studies Collaboration, patients with subclinical hypothyroidism and thy-
rotropin levels above 10 mIU/L have an increased risk of coronary heart disease.2 
However, it is unclear to what extent these deleterious effects can be extended 
to lower thyrotropin levels. Future studies aiming to define the optimal reference 
ranges of thyrotropin and free thyroxine are warranted. Also, adequately powered 
randomized clinical trials focusing on the treatment of subclinical hypothyroidism in 
relation to CVD need to provide more robust evidence.
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Our study showed that at the age of 50 years, individuals with low-normal thy-
roid function live longer than those with high-normal thyroid function. This is in line 
with other studies performed in middle-aged and older adults, suggesting that the 
risk of CVD and mortality increases from low-normal to high-normal thyroid func-
tion.3,4 Such findings, however, may not be generalizable to younger populations.
We concur with Dr. Inoue and colleagues that low-normal thyroid function has 
been linked to metabolic syndrome. Our results, however, did not materially change 
after accounting for metabolic syndrome components, including diabetes mellitus, 
blood pressure, body mass index and lipid levels. Other factors beyond metabolic 
syndrome and its components therefore likely explain our findings. Within the 
reference range of thyroid function, differences in longevity can reflect differences 
in the risk of adverse outcomes. So far, lower thyrotropin and higher free thyroxine 
levels within the euthyroid range have been prospectively linked to an increased 
risk of atrial fibrillation, atherosclerotic CVD, heart failure and dementia, which are 
all associated with an increased risk of mortality.4-6
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